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The phenotypic effects of a novel X-chromosome linked 
mutation were studied in the offspring of male mice 
treated with the mutagen ethyl nitrosourea (ENU). Studies 
of X-chromosome inactivation patterns in females hetero- 
zygous for the mutation (ENU/+) has delineated four 
distinct cell lineages affected by the mutation, namely, 
B, pre-B and T lymphocytes, erythrocytes and skeletal 
myocytes. The penetrance of the mutation depended on the 
age of mice, the cell lineage affected by the mutation and 
the stage of maturation of the cell lineage. Studies of B 
cells in females heterozygous for the mutation and the X- 
linked mutation, xid that affects B but not pre-B cells, 
indicated that the two mutations were not allelic. Factors 
influencing differences in X-chromosome inactivation 
between cells and hybrids and their relationship to 
alleles of the X-chromosome controlling element (Xce) in 
the ENU-mutant and parental strains were studied. It was 
not possible to identify the effects of the mutation on 
the immune system in functional terms either by flow 
cytometric analysis of leukocytes or after sensitisation 
to oxazolone. Results imply the mutation renders the 
affected cell lineages susceptible to competition with 
normal cells in the heterozygote, rather than there being 
any fundamental defect in cell function and that the 
mutation may be in a gene encoding a component of the cell 



































= ethylene-diamine tetra-acetic acid






tetrazolium bromide: thiazolyl blue
= nicotin amide adenine dinucleotide
= nicotin amide adenine dinucleotide, 
reduced form
= neutral density filter 
= phosphate-buffered saline
= polyethylene-imine, thin layer 
chromatography
= phosphoglycerate kinase-1 (enzyme) 
= phosphoglycerate kinase-1 (gene) 
= phenazine methosulphate 
= triethanolamine hydrochloride 
= X-chromosome controlling element 
= maternally-derived X chromosome 
= paternally-derived X chromosome
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KEY TO ABBREVIATIONS USED IN TABLES AND GRAPHS 
BM = bone marrow
HS = subpopulation of high scattering cells
1C = subpopulation of inner cortical thymocytes
M = subpopulation of medullary thymocytes
NL = neonatal liver
OC = subpopulation of outer cortical thymocytes
WBC = leukocytes (de-blooded extract)
WHOLE = unpurified tissue extract
STAINING FOR SPECIFIC ANTIGENS
(+ and - means staining positively and negatively,
respectively for a specific antigen)
B = B220+ve (B cells)
Bb = cells staining brightly for B220
Bd = cells staining dully for B220 (pre-B cells)
(B/T)+ = B220+ve and Thyl.2+ve cells, pooled
(B/T)- = B220-ve and Thyl.2-ve cells, pooled
L1+ = Lyl+ve cells (subset of T and B cells)
Lib = cells staining brightly for Lyl
Lid = cells staining dully for Lyl
L2+ = Lyt2+ve cells (cytolytic T cells)
L2b = cells staining brightly for Lyt2
L2d = cells staining dully for Lyt2
L4+ = L3T4+ve cells (helper T cells)
L4b = cells staining brightly for L3T4
L4d = cells staining dully for L3T4
T = Thyl.2+ cells (thymocytes/ T lymphocytes)
Tb = cells staining brightly for Thyl.2
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This chapter introduces several topics that are relevant 
to the study of a novel X-linked mutation which affects 
the haematopoietic and muscular systems in mutagen- 
treated mice.
The topics haematopoiesis in which some general points 
are discussed and lymphocyte differentiation which 
includes characterisation of B and T cell subpopulations, 
lymphopoiesis and immunopoiesis are followed by an 
overview of the haematopoietic and muscular X-linked 
defects in humans and mice and the techniques used in 
analysis of the X-linked defects. Finally, the aims of 
this study are presented.
Haematopoiesis
In this study, the term haematopoietic is used in the 
general sense and means relating to and the formation of 
blood cells.
In higher vertebrates haematopoietic stem cells originate 
from yolk sac mesoderm and are subsequently found in 
intraembryonic tissues (Metcalf and Moore, 1971) . Whether 
intraembryonic stem cells arise independently or as a 
result of migration from the yolk sac is controversial. 
Some evidence suggests that lymphocytes in the avian 
embryo are derived de novo from intraembryonic tissues
(Moore and Owen, 1966; Dieterlen-Lievre, 1975; Dieterlen- 
Lievre and Martin, 1981) .
In the mouse, haematopoietic stem cells (HSCs) are 
detectable in blood islands of the yolk sac by 8-9 days 
of gestation and have also been detected in the embryo 
(Cumano et al. 1993; Godin et al. 1993; Medvinsky et al. 
1993). By day 8, these stem cells or colony-forming cells 
(CPUs) are capable of forming erythroid, megakaryocytic, 
granulocytic and mixed colonies. From day 10, CPUs are 
detectable in the fetal liver and are no longer 
detectable in the yolk sac at day 12 (Moore and Metcalf, 
1970; van Rees et al, 1990).
Precursor B cells (Owen et al. 1974) and T cells are 
detectable (Williams et al. 1977) in the 11-day fetal 
liver. Within a few days of birth, the liver ceases to 
generate lymphocytes (Melchers et al. 1975; Rosenberg and 
Cunningham, 1975).
Sites of haematopoiesis are also found subsequently in 
the spleen and towards birth the bone marrow. Bone marrow 
stroma appears to be mesenchymal in origin and is formed 
prior to macrophage and lymphoid invasion. Lymphoid 
precursors are found associated with macrophages prior to 
birth (Tavassoli and Crosby, 1970; Heinen and Tsunoda, 
1987) .
Stem cells persist throughout adult life seeding either 
myeloid (Till and McCulloch, 1961; Fowler et al.1967;
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Kitamura et al. 1981) or lymphoid cell lineages (Trentin 
fit al, 1967; Nowell e_t al, 1970; Abramson et al, 1977; 
van Rees et al. 1990). It has been speculated that 
lymphoid stem cells exist as an intermediate stage, 
between multipotential stem cells and lymphocytes 
(Kincade and Phillips, 1985).
For effective haematopoiesis to occur, stem cells have to 
be supported by a functional stroma or haematopoietic 
inductive micro-environment (HIM) (Trentin, 1971; Dexter 
et al. 1977; Tavassoli and Friedens, 1983; Alien and 
Dexter, 1984). Several culture methods have been used to 
study the factors involved in haematopoiesis including 
long-term marrow culture systems for lymphopoiesis 
(Whitlock and Witte, 1982; Whitlock et al. 1984; 1985), 
megakaryopoiesis (Metcalf et al. 1975; Nakeff and 
Daniels-McQueen, 1976), erythropoiesis (Stephenson et al. 
1971) and mixed colony formation (Johnson and Metcalf, 
1978; Metcalf and Johnson, 1978; Fauser and Messner, 
1979) .
Long-term bone marrow cultures involve the formation of a 
multi-cellular layer and can be used to study the factors 
involved in haematopoiesis such as cell-cell interaction 
and production of soluble factors (Dexter and Lajtha, 
1974; Dexter et al. 1977).
Soluble factors, stimulators and inhibitors of stem 
cells, have been detected in bone marrow (Lord et al. 
1976, 1977) and bone marrow cultures (Tokzoz e_t al, 1980;
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Cronkite et al. 1983). Some molecular factors have been 
shown to have co-stimulatory activities with stromal 
cells. Examples of these include interleukins, colony- 
stimulating factors, insulin-like growth factor (IGF- 
1) and stem cell factor which is the ligand for the 
tyrosine kinase receptor c-kit expressed on various 
haematopoietic cells (Zsebo et al. 1990; McNiece et al. 
1991; Ogawa et al, 1991; Relink et al, 1991a; Hirayama et 
al. 1992; Ikutu et al, 1992; Kodama et al, 1992; Landreth 
et al, 1992). Cytokines exhibit pleiotropy and redundancy 
(Paul, 1989). Specificity to particular differentiation 
events may involve regulation of autocrine production of 
progenitor cells by stromal cells as well as paracrine 
production by stromal cells (Nakayama et al. 1989).
Lymphocyte Pifferentiation
Lymphocyte differentiation can be divided into two 
stages. Firstly, lymphopoiesis whereby lymphocytes 
develop from haematopoietic stem cells, discussed above. 
Secondly, immunopoiesis whereby resting lymphocytes are 
activated following exposure to antigen and interactions 
with various cell types and cytokines.
The various stages of lymphocyte differentiation can be 
defined by flow cyometric analysis of cell populations on 
the basis of cell surface antigen expression and cell 
size and by markers defining nuclear and cytoplasmic 
events. For the purposes of this study, characterisation 
of the various stages of differentiation relates to
analysis of cell surface markers in defining lymphocyte 
subpopulations.
B Cell Differentiation 
B Cell Subpopulations
Hardy et al. 1991 used multiparameter flow cytometry 
analysis to study the cell surface markers differentially 
expressed during B lymphopoiesis to define various B- 
lineage subsets within the bone marrow by identifying
B220 (CD45) found on B-lineage cells in addition to other
lo + 
cell surface markers. Cells defined as B220 and CD43 ,
+ 
or S7 the murine homologue, are named pro-B cells and
can be subdivided into three fractions, named A, B, C 
and C ? according to the differential expression of the 
markers BP-1 and HSA such that the earliest pro-B cell 
fraction A does not express BP-1 and HSA; cells in 
fraction B express HSA but not BP-1; cells in fraction C 
express both BP-1 and HSA; and cells in fraction C' 
differ from those in fraction C by expressing higher 
levels of HSA. Pro-B cells subsequently give rise to pre- 
B cells, named fraction D, a process that is marked by 
the loss of CD43 expression with greater expression of 
HSA. In turn, pre-B cells which do not express surface 
IgM and IgD give rise to immature B cells, named fraction 
E, expressing surface IgM which become mature B cells, 
named fraction F, expressing IgM and IgD.
Other work demonstrated that c-kit, a receptor tyrosine
kinase and IL-7R, the IL-7 receptor are differentially 
expressed by the pro-B cell fractions defined above. It 
was shown that cells in fraction A did not express c-kit 
or IL-7R; cells in fraction B and C expressed both c-kit 
and IL-7R; and cells in fraction C 1 expressed IL-7R but 
c-kit expression is down-regulated. IL-7R expression 
remained until expression of surface IgM. It was 
discussed that the decrease in c-kit expression between 
the pro-B stages C to C' might be related to the 
expression of the JU.-chain molecule and the decrease in 
expression of IL-7R between stage D to E might be related 
to the expression of surface IgM (Era et al. 1994). The 
observed differential expression of c-kit and IL-7R is 
related to the factors affecting B lymphopoiesis namely, 
stem cell factor which is the ligand for c-kit and IL-7, 
discussed below. It should be noted that various studies 
discussed below refer to c-kit expression on pre-B cells 
which belong to fraction D according to the model of 
Hardy et al. 1991. However, this discrepancy can be 
related to a variation in the nomenclature that defines 
the B-lineage compartments used by various laboratories.
The earliest stages of B cell differentiation are 
characterised by Ig heavy-chain rearrangement. Recent 
studies of the rearrangement of the Ig heavy chain genes 
at various stages of differentiation within the bone 
marrow have shown that the Ig genes of the earliest pro-B 
cell fraction A, were in germline configuration, whereas 
pro-B cells within fractions B-C showed increasing D-J
rearrangement but no V-D-J rearrangement. Complete V-D-J 
rearrangement was seen in pre-B and B cell fractions 
(Hardy fit al, 1991; Ehlich fit al, 1993; Li fit al, 1993) . 
Following light-chain V-J rearrangement, an intact 
immunoglobulin molecule is produced and expressed as IgM 
on the cell surface (Yancopoulos and Alt, 1986). Cells 
expressing membrane IgG and IgA are only detectable after 
birth (Abney et al, 1978); IgD is detectable 10-15 days 
after birth, its concentration increasing until it is the 
predominant surface immunoglobulin by 3 months of age 
(Vitetta et al, 1975; Vitetta and Uhr, 1977).
Characterisation of peripheral B cell subpopulations 
by cell surface phenotype has defined distinct subsets of 
splenic B cells according to the density of membrane 
immunoglobulin isotype such that population I has high 
levels of IgD and low levels of IgM; population II has 
high levels of IgD and IgM; and population III has low 
IgD, high IgM and population IV expressed neither IgD nor 
IgM (Hardy fit al, 1982, 1984).
Similarly, B cell subpopulations have been defined by the
level of cell surface expression of IgM and the Fc
+ 
receptor whereby B cells that are IgM , FcR ; IgM , FcR
+ + 
and IgM , FcR represent distinct maturation stages (Chan
and Osmond, 1979). B cells have been defined that have 
higher expression of B220 (Forster et al, 1989), 
expression of CD23 and IgD and lower levels of HSA 
expression (Hardy e_t aJL, 1991; Tarlinton, 1993) . It has
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been shown that differential la expression can define 
recirculating B cells which have higher levels of la 
expression from pre-B and immature B cells of adult bone 
marrow. It was also shown that pre-B cells expressed la 
and pro-B cells did not express la within the adult bone 
marrow (Tarlinton, 1993).
Other B cell subpopulations defined by their cell surface 
phenotype include B-l cells, which were formerly Ly-1 B 
cells, and B-2 or conventional B cells. B-l cells are 
identified by their distinctive expression of IgM, IgD 
and CDS (Ly-1), where IgM levels are higher and IgD 
levels are lower than levels in B-2 cells, including them 
in population III, as defined above (Herzenberg et al. 
1986).
Other markers have been used to further define B-l and
B-2 cells. For example, in the peritoneal cavity B-l
+ 
cells are CD11 (Mac 1) and CD23 whereas B-2 cells are
+ 
CD11 and CD23 . Also, CD11 is expressed on peritoneal
and pleural cavity B-l cells but is not expressed on 
splenic B-l cells or B-2 cells; CD23 is expressed on 
peritoneal B-2 cells and on the splenic B-2 cell 
population expressing high levels of IgD but it is not 
expressed on B-l cells (Waldschmidt et al. 1991; Stall et 
al. 1992) . It has been shown that B-l cells express 
higher levels of MHC class II than B-2 cells and also 
that B-l cells express the activation antigen CD44 (pgp- 
1) (Murphy eJt al, 1990) .
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In addition to cell surface phenotype, B cell sub- 
populations can be defined on the basis of anatomical 
localisation. For example, in contrast to B-2 cells, B-l 
cells predominate in neonatal spleen, peritoneal and 
pleural cavities but are rarely found in lymph nodes, 
Peyer's patches or peripheral blood and represent a small 
percentage of total B cells in the adult spleen (Hardy et 
al. 1984; Hayakawa et al. 1985; Antin et al. 1986; Marcos 
et al, 1989; Kroese et al. 1992).
Furthermore, cell subpopulations have been identified on 
the basis of the developmental lineage to which they
belong. On this basis, three distinct B cell lineages
+ 
have been defined. B-la cells that are CDS are derived
from progenitors present in fetal omentum and fetal liver 
but not adult bone marrow ; B-lb cells that are CDS are 
derived from progenitors present in fetal omentum, fetal 
liver and adult bone marrow and, B-2 or conventional B 
cells are derived from progenitors present in fetal 
liver, adult bone marrow but not fetal omentum (Solvason 
et al. 1991; Kantor et al. 1992a, b; Solvason et al. 
1992; Kantor and Herzenberg, 1993).
Other evidence suggests B-l and B-2 cells are derived 
from independent lineages as irradiated recipients of 
neonatal or embryonic haematopoietic cells generate both 
B-l and B-2 cells but recipients of adult bone marrow 
rarely generate B-l cells (Hayakawa et al. 1985; Hardy 
and Hayakawa, 1986; Herzenberg et al, 1986). In fact,
depletion of B-l cells, early in development, produces 
permanent B-l cell loss (Lalor et al, 1989a, b). Other 
studies confirm independent progenitor origins of B-la 
and B-lb cells (Lalor et al. 1989a, b; Stall et al, 
1992) .
B Lymphopoiesis
B lymphopoiesis is the ordered progression of a stem cell 
through various stages of differentiation from pro-B, to 
pre-B , to immature B cell resulting in the production of 
a mature B cell. The process occurs in the fetal liver 
and subsequently in the neonatal and adult bone marrow. 
Within the fetal liver, pre-B cells can be detected by 
day 11. By day 12, Ig heavy chains are being synthesised. 
Following light chain synthesis, immature B cells 
expressing IgM are detectable by day 16-17. Within a few 
days of birth, the liver stops generating lymphocytes 
(Spear et al. 1973; Owen et al. 1974; Melchers et al. 
1975; Rosenberg and Cunningham, 1975; Raff et al. 1976; 
Cooper, 1981) .
Cell surface components which can be used to define the 
various stages of differentiation, as discussed above, 
may be important in cell-cell interactions or may 
function as receptors for signals from the micro- 
environment resulting in the activation or inactivation 
of genes that regulate cell differentiation (Witte et al. 
1987) .
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Culture systems have enabled studies of B lymphopoiesis 
(Whitlock and Witte, 1982; Kincade e_t aJL, 1989; 
Dorshkind, 1990; Relink and Melchers, 1991). It has been 
shown that the proliferation and differentiation of pro- 
and pre-B cells require cell contact with a micro- 
environment of stromal cells. During B lymphopoiesis in 
fetal liver there is a stromal cell-dependent phase at 
13-16 days of gestation, followed by a stromal cell- 
independent phase at 17-19 days of gestation. Cells 
expressing surface Ig appear at 16-17 days of gestation 
and cells become reactive to antigen at 18-19 days of 
gestation (Strasser et al. 1989) . This suggests that gene 
rearrangements of the Ig heavy and light chain loci occur 
at the early stromal cell-dependent phase and that B 
cells expressing surface Ig become antigen-reactive cells 
at the later stromal cell-independent phase.
Stromal cells derived from fetal liver and bone marrow 
can support long-term proliferation of defined sub- 
populations of pro- and pre-B cells. The stromal cell- 
derived factor, IL-7 has been identified as a co- 
stimulator of proliferation of these cells (Namen et al. 
1988) .
Studies have defined three stages of pro- and pre-B cell 
development namely, a first stage requiring stromal cells 
for proliferation to occur, a subsequent stage which 
requires both stromal cells and IL-7 for proliferation to 
occur and a late stage which requires only IL-7 for
11
proliferation to occur (Nishikawa et al. 1988; Hayashi et 
al, 1990). Sudo et al. 1989 suggested that in the 
intermediate stage, the stromal cell contact with pro- 
and pre-B cells may induce IL-7 production by stromal 
cells.
Relink and Melchers, 1993 discussed that pre-B cells may 
be sub-divided into a pre-BI stage followed by a 
transitory pre-BII stage and that the former remain at 
their given stage of differentiation in the presence of 
stromal cells and IL-7 and the latter remain at their 
given stage in the presence of IL-7 alone. It was 
shown that removal of IL-7 from cultures of pre-BI cells 
results in differentiation with unproductive rearrange- 
ments of Ig gene loci, down-regulation of CD43 and c-kit,
leading to a loss of stromal cell with IL-7 reactivity
+ 
and apoptosis of surface Ig and Ig cells (Relink et al.
1991b). Rolink and Melchers, 1993 discussed whether 
crowding within the marrow can result in some pre-B cells 
being removed from contact with stromal cells and the 
site of IL-7 production resulting in differentiation of 
these cells.
Other molecular factors, introduced in the section on 
haematopoiesis above, that are likely to have co- 
stimulatory activities possibly with different types of 
stromal cells and on different stages and subpopulations 
of differentiating B cells include IL-6, IL-11, GM-CSF, 
IGF-1 and stem cell factor or KL, the ligand for the
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c-kit tyrosine kinase receptor expressed on pro- and pre- 
B cells (Zsebo et al. 1990; McNiece et al. 1991; Hirayama 
et al, 1992; Landreth et al. 1992) . Stem cell factor has 
been shown to synergise with 11-7 in inducing pre-B cell 
proliferation (Billips et al. 1992). It was indicated 
that pro-B cells also required the presence of both 
factors for proliferation and that each factor had 
differing effects (Era et al. 1994).
Various adhesion systems have been shown to be important 
in forming interactions between stromal cells and the 
developing B cell. These include fibronectin, CD44 and 
its ligand hyaluronate, also the integrin molecule VLA-4 
and its ligand VCAM-1, N-cadherin and N-CAM, and the 
surface proteoglycan syndecan (Bernard! et al. 1987; 
Thomas et al. 1988; Miyake et al, 1990a, b; Miyake et al, 
1991a,b; Sanderson et al. 1992).
B-cell formation can be limited by the action of negative 
regulators. For example, transforming growth factor 
(TGF-p ) can inhibit processes at the pre-B cell stage 
(Lee et al. 1987, 1989). There are also examples of 
cytokines that are positive and negative regulators of B 
lymphopoiesis. For example, IL-4 can stimulate pre-B cell 
growth (Peschel et al. 1989) and promote differentiation 
of pre-B cells to B cells (King et al. 1988) and as a 
negative regulator, IL-4 can inhibit pre-B cell 
proliferation (Fanslow e_t al, 1993) . Other cytokines 
include IL-1 which can stimulate pre-B lymphoma
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development (Giri et al, 1984) and act as a negative 
regulator of B lymphopoiesis in culture (Billips et al. 
1990). # IFN can stimulate Ig expression of pre-B cells 
(Weeks and Sibley, 1988), can arrest proliferation and 
can induce apoptosis of pre-B cells in culture (Gimble et 
al, 1993; Grawunder et al, 1993) .
During B lymphopoiesis, cell migration within the marrow 
occurs from the subendosteal region towards the centrally 
located sinuses. It has been suggested that compartment- 
alisation of the bone marrow is important in providing 
distinct stromal cells that produce different signals 
such that the subendosteal cells provide factors that 
support the early lymphopoietic stages and the central 
regions provide factors that support the later 
lymphopoietic stages (Jacobsen and Osmond, 1990; Relink 
and Melchers, 1991).
Following gene rearrangement, the resulting Ig heavy and 
light chain repertoire expressed on the B cell surface is 
exposed to selective processes. As a result of negative 
selection against self antigens, self-reactive B cells 
are either deleted or anergised (Goodnow et al. 1989; 
Nemazee and Burki, 1989). Immature B cells leave the 
bone marrow and a small fraction enter the peripheral 
B-cell pool. This is a selective process and may 
depend on exposure to antigen (MacLennan and Gray, 
1986; Forster and Rajewsky, 1990; Gu e_t al/ 1991) . 
Within the spleen, B lymphocytes migrate from the
red pulp to the white pulp (Brahim and Osmond, 1970; 
1976). It has been suggested that newly-formed B 
lymphocytes become immunologically responsive after 1-4 
days within the periphery (Osmond, 1986).
B Immunopoiesis
The process of immunopoiesis occurs mainly in secondary 
lymphoid organs such as the spleen, lymph nodes Peyer's 
patches and tonsils. The first 3-4 days of a primary 
antibody response involves the rapid conversion of virgin 
B cells into relatively short-lived plasma cells 
secreting mostly IgM of low affinity. For T-dependent 
antigens, a second phase of antibody response after 4-5 
days results in the production of relatively long-lived 
plasma cells secreting high-affinity, mostly IgG or IgA 
with some IgE antibody and also memory cells that 
differentiate into plasma cells following subsequent 
exposures to antigen (Siekevitz et al. 1987; van Rooijen, 
1990; Berek, 1992; MacLennan et al. 1992).
B cell activation follows cross-linking of cell surface 
receptors or surface immunoglobulin receptors for 
antigen. The following discussion relates to B cell 
activation following antigen invasion resulting in cross- 
linking of (1) B cell surface CD40 by its ligand in a T 
cell-dependent response to antigen and (2) surface 
immunoglobulin triggered by antigen.
Dendritic cells from skin or mucosa trigger a specific
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immune response by trapping antigen and migrating into 
the T cell-rich paracortical areas of the secondary 
lymphoid organs such as the spleen or lymph nodes 
(MacLennan and Gray, 1986; Kroese et al. 1990; MacLennan 
et ai, 1990; Liu et al, 1992; Gray, 1993). In the T cell- 
rich areas the antigen-derived peptides bound to MHC 
class II antigens are presented by the inter-digitating 
dendritic cells to virgin or memory antigen-specific T 
cells triggering the extrafollicular reaction and 
adhesion molecules maintain the interaction between the 
dendritic and T cells. Cross-linking of surface CD40 on 
dendritic cells by its ligand on T cells enhances 
production of cytokines by dendritic cells which triggers 
activation, proliferation and differentiation of T cells. 
Similarly, the cross-linking of surface CD28 on T cells 
by its ligand on dendritic cells stimulates increased T 
cell cytokine production which may function as T cell 
growth and differentiation factors, in an autocrine 
manner or may in turn activate the dendritic cells or may 
induce the proliferation and differentiation of antigen- 
specific B cells. T cells interact with the antigen- 
activated B cells through surface molecules. For example,
cross-linking of surface CD40 on B cells by the CD40
+ 
ligand on activated CD4 T cells switches on activation
and differentiation and may act as a signal for the 
migration of B cells into primary follicles composed of 
follicular dendritic cells (Tew et al. 1990; Armitage et 
al. 1992; Noelle et al, 1992; Schriever and Nadler,
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1992) .
A massive proliferation of B cells initiates the germinal 
centre reaction (Kroese et al. 1987; Liu et al. 1991) and 
once a germinal centre has formed, proliferating centre- 
blasts are identifiable within the dark zone where high- 
rate somatic mutations within the variable regions of Ig 
genes of B cells occur (Tonegawa, 1983; Berek et al. 
1991; Jacob et al, 1991) .
Subsequently, centroblasts mature into centrocytes that 
are non-proliferating in the light zone. Within the light 
zone, centrocytes are selected for their ability to bind 
to antigen deposited on follicular dendritic cells as 
immune complexes. Survival of these cells depends on 
positive selection by antigen receptor triggering. The 
antigen presented on follicular dendritic cells is 
processed by selected B cells and presented to activated 
antigen-specific T cells that produce IL-2, IL-4 and IL- 
10. Subsequently, as a result of interactions with 
surface CD40 on B cells and its ligand, proliferation of 
selected B cells occurs. Isotype switching within B cells 
takes place and selected B cells are induced to 
differentiate into recirculating memory cells or plasma 
blasts that migrate from the germinal centres to the bone 
marrow or to the mucosal lamina propria forming plasma 
cells (Gray et al, 1991; Howard et al. 1992; Butch et al. 
1993; Lebecque et al. 1993). Plasma cells produce 
immunoglobulins the isotypes of which have specific
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effector functions such as binding to Fc receptors which 
results in an array of activities (Ravetch and Kinet, 
1991) .
Cross-linking of CD40 on B lymphocytes induces tyrosine 
phosphorylation of four substrates. Activation of protein 
kinases is important for the transduction of CD40 
signals. Cross-linking of CD40 results in phosphorylation 
of a subunit of PI3K (phosphatidyl inositol 3 kinase) 
resulting in increased PI3K activity which catalyses 
phosphoinositol phosphorylation. Ligation of CD40 induces 
phosholipase C phosphorylation (Kansas and Tedder, 1991; 
Uckun e£ £l, 1991; Banchereau et al, 1994) .
CD40 cross -linking has been shown to induce B cells to 
produce IL-6 and IL-10 and the presence of IL-4 with the 
CD40 ligand enhances the proliferation of B cells. Other 
factors such as IL-1, 11-2, IL-10 and IFN % , in 
combination with CD40 cross -linking, enhance B cell 
proliferation. CD40 cross-linking activates immuno- 
globulin isotype switching, the specificity of which is 
dependent on the type of cytokine involved. IL-4 and IL- 
10, in combination with CD40 cross-linking induce B cell 
differentiation with the production of immunoglobulins of 
various isotypes (Clark and Shu, 1990; Banchereau et al . 
1991; Rousset e£ al, 1991, 1992; Spriggs et al, 1992; 
Armitage e_£ al, 1993; Burdin gt ai, 1993) .
The importance of the ligand for CD40 has been 
demonstrated in studies of patients with X-linked hyper-
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IgM syndrome, discussed below in the section X-linked 
defects. B cells produce IgM but almost no IgG or IgA and 
secondary antibody responses to T-dependent antigens are 
defective in these patients (Ochs et al. 1971; Alien e_t 
al, 1993; Aruffo e_£ al, 1993; DiSanto et al, 1993; 
Korthauer £t al, 1993) .
Following antigen invasion resting B cells are activated 
by cross-linking of surface Ig. Although antigens are 
recognised by surface IgM and IgD, transmembrane 
signalling induced by interaction of antigen with surface 
Ig is mediated by other associated molecules. The B cell 
antigen receptor complex appears to be composed of 
surface Ig molecules which are associated with the 
molecules Ig-°^ and Ig- p which may be responsible for 
generating the signals that mediate activation (Campell 
et al . 1991; Reth, 1992) . The activation process involves 
calcium mobilisation and activation of protein kinase C
(PKC) following PIP (phosphatidylinositol 4,5-bis-
2 
phosphate) breakdown into IP (inositol-1, 4, 5-tris-
3 2 + 
phosphate) and DG (diacylglycerol) where IP causes Ca
3 
release and DG causes PKC activation (Berridge and
Irvine, 1984; Nishizuka, 1984). The combined effect of 
two signals, namely cross -linking of Ig receptors and 
helper factors leads to growth factor receptor expression 
and hence activation. Cross-linking of Ig receptors 
activates B cells and induces the formation of receptors 
for IL-4 or IL-5 which are B cell growth factors.
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Subsequently, IL-4 induces early activation of resting B 
cells and IL-5 stimulates the proliferation of these 
activated cells. Finally, IL-6 which is a B cell 
differentiation factor, brings about the final 
differentiation of B cells, to form Ig-secreting cells. 
IL-4, IL-5 and IL-6 have other roles in B cell 
differentiation. IL-4 induces expression of FcR, MHC 
class II antigens and production of IgE and IgGl. IL-5 
induces expression of the IL-2 receptor, IgM, IgG and 
IgA; and IL-6 stimulates IL-2 production and cell growth 
(Paul and Ohara, 1987; Takatsu et al. 1988; Van Snick, 
1990). IFN o6and IFN |3 have both positive effects on B 
cell proliferation (Defranee et al. 1986; Peters et al. 
1986) and negative effects on differentiation (Rabin et 
al, 1986; Kashiwa et al. 1987).
+ 
Cytokines are produced from different CD4 helper T
cells. Studies of murine T cell clones have shown that 
IL-4, IL-5, IL-6 and IL-10 are produced by TH2 clones 
whereas IL-2 and IFN ^are produced by TH1 clones 
(Banchereau and Rousset, 1992) . As a result of the 
different cytokines produced, TH2 cells induce IgGl and 
IgE secretion and TH1 cells induce IgG2a secretion 
(Coffman et al. 1988). The combination and the relative 
concentrations of cytokines produced can determine the Ig 
isotype secreted (Croft and Swain, 1991).
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T Cell Differentiation 
T Cell Subpopulations
The process of thymocyte differentiation can be studied
by analysis of cell surface markers that define distinct
subpopulations of T cells.
T cell markers have been identified on bone marrow cells 
which have been shown to have the capacity to form T cell 
clones in culture. These include, the early T cell 
marker, CD7 and co-expression of the stem cell marker, 
CD34 with various T-lineage restricted markers such as 
CD7, CD2 and cytoplasmic CD3. Flow cytometric analysis of 
three cell surface markers on bone marrow cells has 
identified a cell subpopulation that reconstitutes T cell 
development following transfer into immunodeficient SCID 
mice (Benveniste et al, 1990; Bertho et al. 1990; 
Palacios et al. 1990; Terstappen et al. 1992) . The extent 
to which commitment to the T-cell lineage occurs in the 
bone marrow is controversial. Although the above evidence 
suggests some degree of commitment to the T-cell lineage 
in the bone marrow, other studies have demonstrated the 
ability of HSCs to colonise an irradiated thymus and that 
cells from the thymus can produce cells of the B- and 
myeloerythroid-lineage under certain conditions which may 
imply that HSCs seeding the thymus are multipotential 
(Spangrude ££ al, 1988; Kurtzberg ejt al, 1989; Spangrude 
and Johnson, 1990; Spangrude and Scollay, 1990).
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The earliest thymocytes are blast cells expressing 
low level Thy-1, receptors for 11-3, IL-4 but no 
expression of CD4 (murine L3T4), CDS (Lyt2) nor TCR. 
Expression of low level CDS (Lyl) follows, with the 
receptor for IL-2 and a loss of the receptor for IL-3 
(Lobach e_t al, 1985; Adkins et al. 1987; Bluestone et al, 
1987; Campana et al, 1989; Fowlkes and Pardoll, 1989; 
Terstappen et al. 1992).
At this CD4 CDS or double-negative stage there is 
rearrangement of the TCR gene the nature of which 
determines the T cell pathway followed. Thus, cells 
eventually differentiate into either TCROC//CD3 T cells
at day 14-15 that remain double-negative or later acquire
+ 
CDS only or TCR°^(VcD3 T cells that are single-positive,
+ + 
CD4 or CDS , 2-3 days later following a transient
+ - + 
CD4 CDS or CD4 CDS stage and then a double-positive
+ +
CD4 CDS stage. In the transition from the double- 
positive to single-positive stage, cells increase their 
surface expression of CD3 and TCR and alter their 
expression of homing receptors to that seen on virgin 
peripheral T cells (Pardoll et al. 1987; Palacios and 
Pelkonen, 1988; Fowlkes and Pardoll, 1989; Terstappen et 
al, 1992) .
Single-positive thymocytes appear during the medullary 
stage following positive selection for single-positive 
cells with productive TCR gene rearrangements and the 
expression of TCR marks the end of the proliferative
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phase by day 18-19 of gestation (Kinnon et al, 1986; 
Kronenberg et al, 1986; Jenkinson et al. 1987; Sprent et 
al, 1988; Guides et al, 1989).
Thymocytes can be further defined by their differential
expression of RO and RA isoforms of CD45 or T-200
antigen, a protein tyrosine phosphatase. For example,
expression of isoforms that stain with CD45R antibodies
is higher for thymocytes of the medulla than the cortex
- +
and CD4 CDS thymocytes have been shown to be CD45RO
CD45RA (Pulido et al, 1988; Janossy e_t al, 1989; 
Gillitzer and Pilarski, 1990; Okumura et al. 1992).
+ + 
Both CD4 and CDS T cells can be subdivided by CD45
isoform expression (de Jong et al. 1991; Inoue et al, 
1993; Okumura e^t al, 1993) . In humans, peripheral T cells 
can be divided into subsets according to the reciprocal
expression of the RA and RO isoforms of CD45 such that
+ - to lo
virgin T cells are defined as CD45RA /RO and
hi 
effector/memory T cells are defined as CD45RA /RO
(Sanders et al. 1988; Picker et al, 1993). These two cell 
populations can be further defined by their differential 
expression of adhesion molecules that facilitate cellular
interactions with target cells, accessory cells and
hi 
endothelium. For example, the CD45RA /RO subset
displays increased expression of ^2- and fl-integrins, 
ICAM-1 (CD54), CD2, LFA-3 (CD58) and HCAM (CD44) (Sanders 
et al. 1988; Buckle and Hogg, 1990; Picker et al. 1990; 
Shimizu ej; al, 1990, 1991) .
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It has also been shown that CD4 memory/effector T cells 
can be divided into TH1 and TH2 subsets which differ in 
the type of cytokine produced and these cells arise from 
a common precursor population, THO (Abbas et al. 1991; 
Mosmann et al. 1991; Romagnani, 1991; Swain et al. 1991).
T Lymphopoiesis
Stem cells from the fetal yolk sac, fetal liver and 
adult bone marrow colonise the developing thymus at 11 
days of gestation in the mouse (Moore and Owen, 1967; 
Owen and Raff, 1970; Stutman and Good, 1971). The extent 
to which commitment to the T-cell lineage occurs in the 
bone marrow is controversial, as discussed above. In 
vitro studies have shown that the chemotactic peptide, 
thymotaxin which is produced by thymic epithelial cells 
is involved in migration of stem cells to the thymus 
(Champion et al. 1986) .
T lymphopoiesis involves interactions between lymphoid 
progenitors and cells within the microenvironments of the 
thymus. The cortex makes up to 90% of the thymus and the 
medulla comprises 10-15% (Scollay, 1983). Prothymocytes 
have been located in the thymic cortex and during 
development they migrate to the cortico-medullary 
junction and then to the medulla (Owen and Raff, 1970). 
During the cortical stage, immense proliferation of 
prothymocytes occurs as a result of interaction with 
thymic epithelial cells or marrow-derived accessory
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cells. Phagocytic cells of the thymic reticulum regulate 
proliferation by producing IL-1, prostaglandins and 
deoxynucleosides which stimulate blast proliferation and 
protect prothymocytes from deoxyguanosine activity and 
hence, cell death (Papiernik et al. 1983; El Rouby et 
al, 1985; Penit and Papiernik, 1986).
It has been shown that phagocytic cells of the thymic 
reticulum induce prothymocyte proliferation in 
combination with IL-2 (Papiernik et al. 1987). It has 
been suggested that at 12-15 days of gestation 
proliferation and differentiation of prothymocytes is 
induced by IL-4 (Palacios and Pelkonen, 1988) and at 15- 
16 days IL-2 is used as cells capable of producing IL-4 
are found at the former stage (Sideras et al. 1988) and 
IL-2 activity appears to be at the latter stage (Lugo et 
al. 1986; Ceredig et al, 1987). It has been suggested 
that early on in the cortical proliferative phase, IL-2 
is important for cell surface expression of CD4 and CDS 
(Tentori et al. 1988) .
The thymic epithelium has been shown to produce IL-1, IL- 
3, IL-6, IL-7 and LIF and GM-CSF which affect the 
differentiation of thymocytes (Fujiwara et al,1990; Le et 
al. 1990; Carding et al, 1991; Dalloul et al. 1991). 
Thymic epithelial cells express surface adhesion 
molecules which may form adhesive associations with 
thymocytes and may function in the transduction of 
activation signals (Singer e_t al/ 1990) . Thymic
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epithelial cells also produce peptide hormones and 
chemotactic peptides which are involved in induction of 
stem cell differentiation, induction of surface markers 
on thymocytes and activation of effector activity 
(Dardenne and Bach, 1988; Dargemont et ai f 1989).
Developing thymocytes, with varying affinity levels for 
MHC, interact with MHC molecules on the cortical epi- 
thelium (Benoist and Mathis, 1989; Blackman et al. 1989) 
Cells are subsequently screened for low-intermediate 
affinity levels (MHC-restricted cells), are positively 
selected, or protected and the remaining cells die. 
Transgenic studies have shown that mature T cells 
expressing a particular MHC class-restricted TCR, only
develop in mice of the appropriate MHC haplotype such
+ 
that class I-restricted TCRs are found on CDS cells and
+ 
class II-restricted TCRs are found on CD4 cells, in
general (Kisielow et al. 1988; Sha et al. 1988; Teh et 
al. 1988; Berg et al. 1989); this was also demonstrated 
in normal mice (MacDonald et al. 1988).
Other studies show that self-peptides, presented on the 
thymic epithelium along with class I MHC molecules, are 
involved in positive selection of T cells that are class 
I MHC-restricted (Nikolic-Zugic and Bevan, 1990). It has 
been shown that an unidentified minor antigen, in 
addition to MHC class II molecule is required for clonal 
deletion and its effect can be mimicked by bacterial 
enterotoxins (Janeway e_t al, 1989; White et al. 1989) . T
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cell migration to the cortico-medullary junction occurs 
where further screening or negative selection for high 
affinity (auto-MHC reactivity) levels for MHC by 
macrophage and dendritic cells takes place (Lo et al. 
1986 ; Lo and Sprent, 1986). This appears to be specific 
to the medulla (Hengartner et al. 1988; MacDonald, 1989) . 
It has been shown that T cells bearing an auto-reactive 
TCR die in culture and this cell death can be prevented 
by inhibitors of RNA and protein synthesis (MacDonald and 
Lees, 1990) .
It has been suggested that positive signals from the 
cortical epithelium occur because TCR density of immature 
thymocytes is too low for high-affinity MHC binding and 
as medullary thymocytes have increased TCR levels and 
therefore higher affinity levels for MHC, negative 
signals from the medullary dendritic cells results in 
clonal deletion. Furthermore, remaining cells receive
positive signals, are protected and survive to become
+ + 
mature CD4 or CDS T cells (Sprent et al, 1988).
Other results have shown that cortical epithelial cells 
present molecules which differ from medullary molecules 
(Marrack et al. 1989). A monoclonal antibody detecting 
an MHC class II epitope has been described which stains 
the medulla but not the cortex (Murphy et al. 1989).
Quackenbush and Shields, 1988 suggested that those cells 
which fail positive selection do not die within the 
thymus, are exported and fail to survive outside. Some
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evidence suggests this cell death takes place in the 
intestine (Joel et al. 1971) and this view is in keeping 
with a lack of histological evidence of intra-thymic cell 
death (Rothenberg, 1990).
Lymphocyte fibronectin receptors may be involved in 
the migration of T cells from the thymus (Cardarelli et 
al, 1988) . Once lymphocytes are in circulation, their 
homing receptors or points of adhesion interact with 
ligands of high endothelial venules (HEV). The nature of 
directed migration depends on the lymphocyte involved, 
their developmental stage, state of activation and 
history of antigenic stimulation and may involve 
haptotactic and chemotactic gradients (Yednock and Rosen, 
1989) .
Evidence suggests that T cell maturation is not confined 
to the thymus and that post-thymic factors are involved 
(Stutman, 1978; Piguet et al. 1981) . It has been shown 
that recent emigrants are larger than peripheral T cells 
(Kelly and Scollay, 1990) and express different antigens 
(Scollay et al, 1984).
T Immunopoiesis
Antigenic stimulation of T cells results in clonal 
expansion, generation of memory T cells and maturation 
into regulatory or effector cells. T cells require 
activation signals from the antigen presenting cell (APC) 
in the form of cell surface molecules which provide co-
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stimulatory signals. The level of expression by APC may 
depend on the state of cell activation and the presence 
of cytokines. For example, CD28 on T cells is a receptor 
for co-stimulatory signals provided by the B7 molecule on 
APCs (Jenkins e_t al, 1988; Mueller et al, 1989; Geppert 
ejt ai, 1990; Linsley e£ a_l, 1991a, b; Liu e£ al, 1992) 
and studies have shown that activation of T cells with 
anti-CD28 mAb and anti-CD2 leads to the production of 
various cytokines (Thompson et al, 1989; Ledbetter et al, 
1990; Cerdan et al. 1991) . Adhesion receptors such as CD2 
on T cells which interact with LFA-3 on the APC are 
important in stabilising interactions between these cells 
(Springer, 1990).
+ + 
In general, CD4 cells are termed helper T cells and CDS
cells are termed cytolytic T cells and the cell surface 
glycoproteins CD4 and CDS on T lymphocytes have 
specificity for class II or class I MHC proteins, 
respectively. These proteins are involved in the 
differentiation of thymocytes resulting in the production 
of a mature T cell repertoire and have a role in the 
activation and effector functions of mature peripheral T 
cells (Swain, 1983; Parnes, 1989).
+ 
CD4 T cells recognise antigen bound to MHC class II
+ 
molecules and CDS T cells recognise antigen bound to MHC
class I molecules (Swain, 1983) . In accordance with the 
co-receptor model, the association between antigen- 
bearing APCs and T cells leads to the co-receptor CD4 or
29
CDS binding the same MHC ligand as the TCR/CD3 complex
which involves transmembrane signal transduction by
Ick 
association with the tyrosine kinase p56 (Kupfer et al.
1987; Kupfer and Singer, 1989; Veillette et al, 1988; 
Shaw e_t al, 1989, 1990; Turner et al. 1990) . Combinations 
of cell surface molecules can modulate the signalling 
events induced via the TCR/CD3 complex. A role for CD45 
in T-cell signal transduction has been implicated (Pingel 
and Thomas, 1989; Koretzky et al, 1990, 1991; Weaver et
al. 1992). It was suggested that CD45 may regulate
Ick 
tyrosine phosphorylation of p56 associated with CD4 or
CDS (Janeway, 1992).
Activated or memory subsets of T cells expressing 
distinct CD45 isoforms associating with the TCR/CD3 
complex and CD4 or CDS on different subsets of T cells 
have been described (Volarevic et al. 1990; Dianzani et 
al. 1992) . Furthermore, T cells that express different 
CD45 isoforms release different cytokines (Bottomly et 
al. 1989) . Hence, distinct subsets of T cells appear 
to differ in the organisation of CD45 with other cell 
surface structures which may relate to differences in 
their activation characteristics and expression of 
different CD45 isoforms may induce different signals that 
result in the differentiation of cells that produce 
different cytokines (Janeway, 1992).
Stimulation of the TCR/CD3 complex results in hydrolysis
of PIP to produce diacylglycerol which activates protein 
2
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kinase C and IP which causes an increase in intra-
2+ 3 
cellular Ca (Iraboden et al. 1985) . These events occur in
some but not all T cell subsets where it appears that 
there is utilisation of different TCR-associated signal 
transduction pathways by TH1 and TH2 clones. For example,
stimulation of TH1 clones with concanavalin A or anti-TCR
2 + 
mAb results in an increase in intracellular Ca and in
inositol phosphate production. However, following 
stimulation of TH2 clones, these secondary messengers are 
not detectable. (Gajewski et al. 1990; Williams et al. 
1991). Furthermore, TH2 clones can be induced to produce 
IL-4 following treatment with ionomycin while similar 
treatment induces anergy in TH1 clones (Mueller et al. 
1989; Abbas et al, 1991) . It has also been shown that 
CDS clones utilise similar signal transduction pathways 
to those of TH1 clones (Schell and Fitch, 1989).
Other factors have been described that determine the 
specificity of the T cell subset activated. For example, 
TH1 and TH2 clones respond differently to different types 
of APC possibly by utilising different cell surface 
receptors and ligands (Magilavy et al, 1989; Gajewski et 
al. 1991; Liu and Janeway, 1991).
Furthermore, the nature of the cytokines produced can 
determine the specificity of the T cell subset activated.
For example, TH1 CD4 cells secrete IL-2 and IFN^but not
+
IL-4, IL-5, IL-6 or IL-10 and TH2 CD4 cells secrete 
IL-4, IL-5 and IL-10 but not IL-2 or IFN tf. These cells
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arise from a common precursor population, THO which has 
the potential to produce a variety of cytokines. Hence, 
the functions of TH1 and TH2 cells differ due to the 
varying patterns of cytokine secretion. TH1 cells are 
mainly responsible for production of delayed-type hyper- 
sensitivity through the release of IFN J( which activates 
macrophages and TH1 cells also lyse virus-infected cells 
and induce destruction of extra- and intra-cellular 
pathogens by macrophages. Through the secretion of IL-4 
and IL-5 which are B cell growth and differentiation 
factors, TH2 cells act as helper cells in interactions 
between T and B cells. Secretion of some cytokines by TH1 
and TH2 cells can have an inhibitory effect on the other 
subset. IL-4 and IL-10 secretion by TH2 cells can
suppress TH1 cell function and IFN X secretion by TH1
+ 
cells is an inhibitor of TH2 cells. CDS cells have been
shown to have a THl-like phenotype in secreting IFN Xbut 
not IL-4 or IL-5 and under certain conditions a TH2-like
phenotype in secreting IL-4 but not IFN tfand the TH2-like
+ +
CDS cells can behave like TH2-like CD4 cells in being
inhibitory for TH1 cells (Mosmann and Coffman, 1989; 
Abbas et al, 1991; Kelso et al, 1991; Mosmann et al, 
1991; Romagnani, 1991; Scott and Kaufman, 1991; Swain et 
al. 1991; Bloom et al, 1992; Sher and Coffman, 1992).
Also, antigen concentration can determine which T cell 
subset is stimulated in an immune response (Gajewski et 
ai, 1989) .
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Following stimulation, T cells release IL-2 initially ana 
IL-4, IL-5, IL-6 and IFN tfappear several days later 
(Swain et, al, 1991) . The combination and the relative 
concentrations of the cytokines released determines the 
effect on B cells. For example, T cells that release high 
levels of IL-4, IL-5, IL-6 but low levels of IL-2 and IFN 6 
induce B cells to produce all isotypes. However, T cells 
that release IL-2, IL-6 and IFNo induce B cells to 
produce lower levels of Ig which is mainly IgM (Croft and 
Swain, 1991).
In general, the generation of cytolytic T cell responses
requires help from helper T cells. It has been shown that
+ 
TH1 clones secrete IL-2 which induces CDS cytolytic
+ 
clones to proliferate and IL-4 allows CDS cytolytic T
cells to develop from resting T cells. 11-6 and IL-10
+ 
enhance CDS cytolytic T cell proliferation (Glasebrook
and Fitch, 1979; Nabholz and MacDonald, 1983; Trenn et
al, 1988; Vink et al, 1990; Chen and Zlotnik, 1991).
+ 
However, some CDS T cells have been identified as
helper-independent which can be cultured without added 
growth factors (Widmer and Bach, 1981) .
Mechanisms exist that inhibit an immune response. Results 
of various studies have revealed several negative 
immunoregulatory mechanisms. These include various models 
of T suppressor cells that inhibit the responses of 
either other T suppressor cells (Germain and Benacerraf, 
1981) or helper T cells (Bloom et al. 1992) by producing
soluble factors. It has also been suggested that immune 
responses can be suppressed through elimination of APCs 
by cytolytic T cells (Simpson, 1988; Lanzavecchia, 1989). 
A third mechanism involves suppression by inducing anergy 
or antigen-specific unresponsiveness without deletion of 
the cells (Jenkins and Schwartz, 1987). Suppression can 
also be mediated by cytokines. For example, TH1 clones 
can be rendered unresponsive to stimulation with antigen 
and the APC and fail to produce cytokines following 
exposure to IL-2 (Wilde et al. 1984; Otten et al. 1986).
X-linked Defg<-t-R
Alleles of human and murine genes encoding a variety of 
defects or mutations have been mapped to the X chromosome. 
X-linked defects, relevant to this study, include 
immunodeficiency syndromes, haematopoietic disorders and 
muscular disorders. In this section, an overview of 
relevant human and murine X-linked defects or mutations is 
given. This is followed by a discussion of the 
characterisation of the X-linked defects using studies 
of X-chromosome inactivation patterns, gene mapping and 
flow cytometry. Finally, the aims of the present study are 
presented. A comparative human and mouse X-chromosome map, 
Fig. 1 is given at the end of Chapter 1.
X-linked Human Imnuinodeficiency Syndromes 
X-linked Severe Combined Immunodeficiency (XSCID)
X-linked severe combined immunodeficiency is characterised 
by hypo- or agammaglobulinaemia in affected males, atrophy 
of the thymus and absent or depressed T lymphocytes 
without the severe form of lymphopenia, characteristic of 
autosomal SCID. Patients are susceptible to bacterial, 
fungal and viral infection and lack delayed hyper- 
sensitivity reactions (Rosen et al, 1966, 1968; Dooren et 
al. 1968; Yount e_t al, 1978) . B lymphocytes are present in 
normal or increased numbers and are capable of normal 
antibody production in the presence of normal T cells. B 
cells have been shown to express p!20 antigen, a cell
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surface protein normally expressed only on pre-B cells 
(Gougeon e_t al, 1990; Conley, 1992) . It appears that bone 
marrow-derived T cells are primarily affected by the 
genetic lesion since the T cell deficiency can be 
corrected by bone marrow transplantation and the thymus 
of XSCID recipients can support donor T cell development 
(Rosen et al. 1962; Gitlin and Craig, 1963; Cooper et al. 
1973; Buckley e£ al, 1976, 1986; Seeger e_t al, 1976; 
Griscelli et al. 1978; Pahwa et al. 1980; Reisner et al. 
1983; Friedrich et al. 1985; de Villartay et al, 1986).
Studies of X-chromosome inactivation patterns in XSCID 
carrier females can be used to identify cells affected by 
the genetic defect where non-random expression of the X 
chromosome in cells identifies those cells carrying the 
mutant gene which are at a selective disadvantage, as 
discussed in detail below. Cell types affected include T 
and B cells and in some cases granulocytes and natural 
killer cells. Studies have shown non-random expression of 
the X chromosome for T cells (Puck and Conley, 1987; 
Conley, 1992; Puck, 1993), random X-chromosome expression 
for immature surface IgM B cells and non-random X- 
chromosome expression for more mature surface IgM B cells 
(Conley et al. 1988) . Wengler et al. 1993 showed non- 
random expression of the X chromosome for B cells, CD4 
and CDS T cells and natural killer cells but random X- 
chromosome expression for neutrophils and monocytes. 
Goodship et al. 1991 demonstrated non-random X-chromosome
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expression for B and T cells and granulocytes. Hendriks et 
al, 1992 suggested the existence of two XSCID defects as 
random expression of the X chromosome for granulocytes was 
seen in two pedigrees studied but in a third pedigree 
there was non-random X-chromosome expression.
XSCID has been described as being phenotypically 
heterogeneous (Mensink and Schuurman, 1987). One form of 
X-linked combined immunodeficiency, similar to but less 
severe than XSCID, termed thymic dysplasia with normo- 
gammaglobulinaemia, has been described by several workers 
(Nezelof et al. 1964; Fulginiti et al. 1966; Miller and 
Schieken, 1967; Cooper et al. 1973; Lawlor et al. 1974). 
It is characterised by T and B lymphocyte dysfunction, 
with normal or slightly low lymphocyte levels and presence 
of plasma cells and immunoglobulins.
There is also evidence of human XSCID due to a membrane 
defect (Kersey et al. 1977; Yount et al, 1978). Affected 
individuals have normal levels of B cells, T cells and 
immunoglobulins but they have abnormal responses to 
concanavalin A, which is characterised by an inability to 
"membrane cap" membrane glycoproteins (Gelfand et al. 
1979) .
Brooks et al. 1990 described a form of X-linked combined 
immunodeficiency which differed from XSCID. Susceptibility 
to infection differed and patients survived into 
adulthood. In contrast to XSCID, serum concentrations of
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iinmunoglobulin isotypes were normal and the deficiencies 
in specific serum antibody responses were most pronounced 
for igG. The deficiencies in the numbers of T cells were 
less marked than in XSCID.
Another X-linked combined immunodeficiency, suggested as 
being either an attenuated form of XSCID or corresponding 
to a separate X-linked locus has been described (de Saint- 
Basile et al, 1992) . Patients had T and B cell dysfunction 
and X-chromosome inactivation patterns were identical to 
those in XSCID. However, unlike XSCID, patients had normal 
numbers of T cells.
XSCID was mapped to Xqll-ql3 (de Saint-Basile et al. 1987) 
and then to Xql2-q21.3 by Puck et al. 1988 who suggested 
that heterogeneity might exist as the exact localisation 
remained uncertain. Mensink and Schuurman, 1987 indicated 
that there may be more than one genetic locus for XSCID 
because there is immunological heterogeneity. XSCID was 
further mapped to Xql3.1-q21.1 (Puck et al, 1989).
The cell surface protein, interleukin-2 receptor )( chain 
(IL-2R$ ) has been shown to be encoded by the gene which 
when mutated results in XSCID. Genetic linkage analysis 
indicated the colocalisation of the I1-2R o gene and the 
XSCID locus to Xql3 (Noguchi et al, 1993a).
It has been shown that IL-2R 0 is an essential component 
of the IL-2, IL-4 and IL-7 receptor systems (Kondo et al. 
1993; Noguchi et al, 1993b; Russell et al, 1993) and it
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has been suggested that as a component of these receptor 
systems can affect B and T cells in XSCID. T cells are 
induced to synthesise and secrete IL-2 when activated by 
antigens (Smith, 1989; Waldmann, 1989; Taniguchi and 
Minami, 1993). 11-4 is a B cell growth factor (Boulay and 
Paul, 1992; Puri and Siegel, 1993) and IL-7 is also a 
growth factor for pre-B cells (Namen et al, 1988a, 1988b), 
a growth factor for thymocytes (Murray et al. 1989; Watson 
et al. 1989; Uckun et al. 1991) and a growth factor for T 
cells (Chazen et al. 1989; Morrisey et al. 1989; Londei et 
al, 1990) .
Other forms of SCID, which are not X-linked, include 
Swiss type agammaglobulinaemia, characterised by cellular 
and humoral immunodeficiencies (Conley et al. 1990). Also, 
SCID due to ADA (adenosine deaminase) deficiency, where 
lymphocyte numbers and immunoglobulin levels may be normal 
to very low (Giblett et al. 1972). ADA is an important 
enzyme in the purine catabolic pathway. In ADA deficiency, 
the normal catabolism of purines is inhibited resulting in 
accumulation of metabolic substrates which are toxic to 
the cell. ADA deficiency is due to either point mutations 
or deletions of the ADA gene (Bonithron et al. 1985; 
Markert et al. 1987) . Also, SCID due to PNP (purine 
nucleoside phosphorylase) deficiency, where T 
lymphocyte numbers are very low but B lymphocyte and 
immunoglobulin levels are usually normal. PNP catalyses 
the conversion of inosine to hypoxanthine and guanosine to
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juanine. In PNP deficiency, intracellular accumulation of 
netabolic substrates results in inhibition of DNA 
synthesis (Markert, 1991). Point mutations in the PNP gene 
have been identified that result in PNP deficiency 
(Andrews and Markert, 1992).
Other cases of SCID, due to functional T cell deficiencies 
include a disorder described as a familial defect in 
expression of the TCR/CD3 complex where a defective CDS 
subunit prevents transfer of the TCR/CD3 complex to the 
cell membrane. One sibling died of acute autoimmune 
haemolytic anaemia whereas the other was apparently 
healthy (Alarcon et al. 1988). Defective signal 
transduction of T lymphocytes has been described with 
failure in induction of IL-2 production where the disease 
is characterised by severe recurrent infections (Doi et 
al. 1988; Weinberg and Parkman, 1990). Also, SCID with II- 
1 receptor deficiency of T cells (Chu et al, 1984) and IL- 
1 deficiency (Sahdev et al. 1989) .
X-linked Agammaglobulinaemia (XLA)
Bruton's X-linked agammaglobulinaemia (XLA) is usually 
characterised by recurrent bacterial infections and 
paucity of lymph node tissue. Patients have very low 
numbers of circulating B cells and normal levels of T 
cells (Bruton, 1952; Geha et al f 1973; Lederman and 
Winkelstein, 1985; Conley and Puck, 1988) and immuno- 
globulin levels are low but not absent (Ochs and
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Wedgewood, 1989) . The numbers of pre-B cells in the bone 
marrow is normal indicating a defect in the transition 
from pre-B to B cell (Pearl e_t al, 1978) . Conley, 1985 
showed that the small numbers of peripheral blood B 
cells present in XLA patients exhibit an immature 
phenotype and appear arrested at an early stage of 
development. A major and minor XLA phenotype depending on 
the stage at which B cell maturation is arrested has been 
described by Schwaber and Chen, 1988. The major phenotype 
is arrested at the stage of pre-B cells and the minor 
phenotype is arrested at the stage of immature B cells. 
The defect for both is due to a failure of rearrangement 
of the Ig heavy chain variable region. Kwan et al. 1990 
and Schwaber, 1992 also demonstrated that the arrest in 
the transition from pre-B to B cell was due to a failure 
of rearrangement of the Ig heavy chain (V(D)J) region and 
that this arrest was incomplete, as some B cells were 
identified in peripheral blood.
From studies of X-chromosome inactivation patterns, the 
defect was shown to be intrinsic to B cells as there was 
non-random expression of the X chromosome for B cells 
(Conley et al. 1986; Fearon et al. 1987; Conley and Puck, 
1988; Hendriks et al, 1989) .
The XLA gene was originally mapped to Xq21.3-Xq22 (Kwan 
et al. 1986) and the locus refined to Xq22 (Kwan et al. 
1990; Lovering et al. 1993; Parolini et al, 1993).
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Vetrie et al, 1993 identified a gene, now known as 
Bruton's tyrosine kinase, BTK which encodes protein 
tyrosine kinases, is expressed in B cells, is found to be 
mutated in XLA patients and is tightly linked to the XLA 
locus. This was also demonstrated by Tsukada et al, 1993 
and it was also shown that the gene encoded a cytoplasmic 
tyrosine kinase and its mRNA, protein expression and 
kinase activity were all reduced or absent in pre-B and B 
cells of XLA patients.
Studies have shown that cytoplasmic tyrosine kinases when 
coupled with lymphocyte surface receptors act as signal 
transducers following specific ligand binding (Bolen, 
1993; Weiss, 1993). In addition, cytoplasmic tyrosine 
kinases have been shown to modify the activity of other 
tyrosine kinases and down-regulate the signal trans- 
duction pathways in which they participate (Nada et al. 
1991) .
It is possible that deficient expression of BTK may affect 
pre-B cell development by modulating the processes of 
apoptosis or selection in XLA. Identification of molecules 
that interact with BTK might provide clues about the 
regulatory properties of BTK in the signalling pathways of 
B cells (Tsukada et al, 1993).
X-linked Immunodeficiency with Hyper-IgM (HICM1)
X-linked immunodeficiency with hyper-IgM (HIGM1) is 
characterised by recurrent bacterial infections with low
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or absent IgG, IgA and IgE and normal to increased IgM and 
IgD serum levels. HIGM1 patients often have neutropenia 
and are susceptible to opportunistic infections 
characteristic of a T cell defect. B cells expressing 
surface IgM and IgD are present in normal numbers but IgG- 
and IgA-bearing B cells are undetectable (Rosen et al 
1961; Levitt et al, 1983; Notarangelo et al. 1992). 
An inability to switch from IgM/IgD to other Ig 
isotypes has been demonstrated (Geha et al. 1979; Brahmi 
et al. 1983) .
There have been conflicting results from studies of X- 
chromosome inactivation patterns to identify the defective 
cells in HIGM1. Although random expression of the X 
chromosome was found for T and B cells (Hendriks et al. 
1990), non-random expression of the X chromosome was 
described for B and T cells and neutrophils reflecting the 
involvement of several cell lineages in the defect 
(Notarangelo et al. 1991) . Hendriks et al. 1990 proposed 
that the defect in isotype switching may lie in a factor 
produced by T cells and transferred to B cells.
A primary T cell defect has been suggested as the basis 
for HIGMl following studies in which B cells are induced 
to produce IgG and IgA in the presence of T lymphoblasts 
from patients with Sezary Syndrome (Mayer et al. 1986).
HIGMl was first mapped to Xq24-q27 (Mensink et al. 1987) 
and the locus further refined to Xq26 (Padayachee et al,
1992, 1993). It has been suggested that a defective gene 
which maps to Xq26 and encodes the T cell ligand, CD40 is 
the gene in HIGM1 (Lane et al. 1992; Noelle et al. 1992; 
Alien et al. 1993; Aruffo et al, 1993; Fuleihan et al, 
1993) .
Deletions or point mutations of the CD40 ligand, also 
named gp39, have been identified in HIGM1 (DiSanto et al. 
1993). Point mutations of the TRAP gene which encodes a 
TNF-related activation protein or CD40 ligand on T cells 
resulting in defective expression of TRAP on the T cell 
surface were identified. It was suggested that the 
failure of TRAP to interact with CD40 on B cells is 
responsible for the defect in Ig switching in HIGM1. The 
mutation which produces defective expression of TRAP has 
been shown to vary in HIGM1 patients (Korthauer et al. 
1993) .
It was shown that HIGM1 B cells express functional CD40 
but T cells do not express detectable levels of 
functional CD40 ligand on the cell surface and suggested 
that activation signals from T cells to B cells cannot be 
delivered using the CD40 ligand-receptor pair (Aruffo et 
al. 1993) . Durandy et al. 1993 confirmed that HIGM1 B 
cells have an intact Ig isotype switch mechanism as B 
cells could be induced to differentiate into IgG-, IgA- 
and IgE-producing cells in the presence of CD40 monoclonal 
antibody, IL-4 and IL-10. Using this method, an intact 
isotype switch mechanism in HIGM1 B cells was also
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demonstrated by Fuleihan et al. 1993. It was also shown 
that HIGM1 T cells failed to induce IgE synthesis in B 
cells and are unable to express the CD40 ligand although 
the mRNA for the ligand is expressed normally.
Results of studies suggest that the defective expression 
of the CD40 ligand on T cells underlies the failure of 
isotype switching in HIGM1 B cells
Wiskott-Aldrich Syndrome (WAS)
Wiskott-Aldrich syndrome (WAS) is an X-linked condition 
in which patients are susceptible to infection, eczema 
and thrombocytopenia due to a platelet abnormality. 
Immunological abnormalities are low serum IgM, elevated 
IgA and IgE and failure to make antibodies to carbo- 
hydrate antigens (Aldrich et al, 1954; Cooper et al. 1968; 
Spitler et al. 1975; Remold-O'Donnell and Rosen, 1990). T 
cell function is variable and tends to decline with age; 
there may be decreased proliferative responses to mitogens 
and poor production of cytotoxic T cells (Ochs et al. 
1980) .
Studies of WAS have demonstrated imbalances in X- 
chromosome inactivation patterns for several haemato- 
poietic cell lines. Non-random X-chromosome expression 
was seen for B and T cells and monocytes (Fearon et al. 
1988; Greer et al, 1989) . Other studies revealed that the 
defect was more profound for T cells and platelets, less 
profound for granulocytes and B cells and there was
random expression of the X chromosome for erythrocytes 
and neutrophils (Gealy et al. 1980) . Notarangelo et al. 
1991 showed that T cells had non-random X-chromosome 
expression but the X-chromosome inactivation patterns 
were balanced for granulocytes.
A lymphocyte surface glycoprotein, CD43, gpllS or 
sialophorin which is expressed in various haematopoietic 
cell lines (Carlsson et al. 1986) has been shown to be 
absent or abnormally glycosylated in WAS lymphocytes and 
platelets (Remold-O'Donnell et al. 1984; Reisinger and 
Parkman, 1987; Higgins et al, 1991; Filler et al. 1991).
The gene for CD43 has been mapped to chromosome 16 
(Pallant et al. 1989) which is not the primary locus for 
the gene in WAS. This was mapped to a marker in Xpll.3- 
pll (Kwan et al. 1988) and the locus was further refined 
to Xpll.2 (Kwan et al, 1991; Greer et al, 1989).
It has been suggested that WAS is associated with a 
defect in the coupling of surface Ig on B cells resulting 
in impaired signal transduction pathways (Simon et al. 
1992) .
X-linked Lymphoproliferative Disease (XLP)
X-linked lymphoproliterative disease (XLP) is 
characterised as a combined, variable, progressive 
immunodeficiency disorder with an inadequate immune 
response to infection with Epstein Barr Virus (Purtilo et
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, 1974, 1975; Hamilton et al, 1980; Grierson et al, 
1991) .
Studies of X-chromosome inactivation patterns in XLP 
carriers revealed random X-chromosome expression for T 
cells, B cells and neutrophils which suggests that the 
defect either resides in a subset of haematopoietic cells 
or that the defect is not detrimental to cell survival or 
proliferation (Conley et al, 1990).
Linkage analysis mapped XLP to Xq24-q27 (Skare et al. 
1987) and to Xq25-q26 (Sylla et al, 1989) . A deletion 
involving Xq25 in XLP patients (Sanger et al. 1990) and 
males with deletions which result in XLP (Skare et al, 
1993) have been documented.
Miscellaneous X-linked Human Haematopoietic Disorders
In chronic granulomatous disease, CGD, defects in the 
cytochrome b complex result in the failure of NADPH 
oxidase in phagocytic leukocytes to generate superoxide 
needed for the killing of micro-organisms (Baehner, 
1990). The gene for CGD, CYBB has been mapped to Xp21.2- 
p21.1 (Baehner et al. 1986) . Various mutations in CYBB 
and deletions in Xp21 have been described (De Saint- 
Basile et al. 1988; Dinauer et al. 1989; Francke et al, 
1990; Bolscher et al, 1991; De Boer et al, 1992).
Other deficiencies include the properdin deficiency which 
involves fatal bacterial infection due to impairment of
complement activation via the alternative pathway. The 
properdin locus, PFD has been mapped to Xpll.23-p21.1 
(Goundis et al. 1989) . Alpha galactosidase deficiency of 
leukocytes, which is found in patients with Fabry disease 
The locus GLA has been mapped to Xq22-qter (Shows et al. 
1978). Various glucose-6-phosphate dehydrogenase 
deficiencies affecting the haematopoietic system are 
characterised by erythrocyte and leukocyte dysfunction. 
The G6PD locus has been mapped to Xq28 (Pai et al. 1980). 
GPL-115 deficiency (115,000 Dalton surface glycoprotein) 
which is characterised by immature T lymphocytes and T 
lymphocyte dysfunction (see McKusick, 1994). Glycerol 
kinase-1 deficiency, of leukocytes, which is associated 
with muscular dystrophy. GK has been mapped to Xp21.3- 
p21.2 (Hartley et al. 1986). Phosphoglycerate kinase-1 
deficiency which gives rise to haemolytic anaemias and 
deficiency in leukocytes (Valentine et al. 1969). PGK has 
been mapped to Xql3 (Willard et al, 1985).
Other disorders include haemophilia, with type A and B, 
which results from defects of clotting factors VIII and 
IX with loci HEMA or F8C at Xq28 and HEMB or F9 at Xq27 
(Tantravahi et al, 1986; Chance et al, 1983). Sidero- 
blastic anaemia with locus ANH1 or ALAS mapped to Xp21- 
q21 (Cox et al. 1990) . Proliferating defect of haemato- 
poietic cells; acute leukaemia; thrombocytopenia; 
malignant reticuloendotheliosis. Finally,
localisation of gene GF-1 to Xp21-ll (Zon et al. 1990), 
a transcriptional regulator, has important implications 
for hereditary persistence of fetal haemoglobin 
syndromes.
X-linked Human Muscular Disorders
There are several different types of X-linked muscular 
dystrophy in man: Duchenne; Decker; McLeod; Emery- 
Dreifuss; scapuloperoneal myopathy and myotubular 
myopathy (Swash and Schwartz, 1988). The Duchenne gene 
(DMD) has been mapped to Xp21-p22.3 (Murray et al. 1982) 
and the Becker gene (BMD) to the same region (Kingston et 
al, 1983, 1984; Brown et al, 1985; Fadda et al, 1985); 
the Emery-Dreifuss locus (EMD) and the myotubular myo- 
pathy locus (MTM1) are at Xq28 (Boswinkel et al, 1985; 
Thomas et al. 1987); the McLeod locus (XK) is at Xp21.2- 
p21.1 (Frey et al. 1988) which is close to the Duchenne/ 
Becker locus.
Linkage analyses have lead to the suggestion that the 
Duchenne and Becker genes may be allelic (Murray et al. 
1982; Kingston et al, 1983, 1984; Bakker, 1985; Brown et 
al. 1985; Fadda et al, 1985; Wilcox et al, 1985). Both DMD 
and BMD have been shown to result from mutations or 
deletions of the gene encoding dystrophin (Lindlof et al. 
1988; 1989; Read et al, 1988; den Dunnen et al, 1989; 
England et al. 1990; Nordenskjold et al. 1990; Norman et 
al. 1990; Kilimann et al, 1992; Lenk et al, 1993).
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The dystrophin gene product is absent in muscle of 
patients with Duchenne muscular dystrophy (Bulfield et a_l, 
1984; Hoffman et al, 1987a; Koenig et al. 1987) and, in 
the Becker form, the dystrophin molecule is truncated 
(Hoffman et al. 1987b). The concentration of a glyco- 
protein, which is an integral component of the dystrophin 
complex, has been shown to be greatly reduced in DMD 
patients. It is suggested that the absence of dystrophin 
may lead to the loss of this dystrophin-associated 
glycoprotein which, in turn, leads to molecular 
pathogenesis of muscle (Ervasti et al. 1990).
X-linked Murine Loci
Animals with mutations affecting normal function and 
developmental processes can be used to study the factors 
controlling development and as models for the study of 
genetic disease in man. Comparison of the genetic maps in 
man and mouse may indicate chromosome regions where the 
genetic order is conserved and may identify mouse genetic 
loci which may be homologous to human mutations causing 
disease (see the comparative human and mouse X-chromosome 
map, Fig. 1 given at the end of Chapter 1).
Only a few X-linked immunodeficiency syndromes have been 
identified in mice. The xid mutation in CBA/N mice has 
been related to XLA in humans (see below). More recently, 
the murine gene for the I12r o chain was mapped to a locus 
on the X chromosome consistent with the human IL2R 0 locus
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at Xql3 (Noguchi et al. 1993a) and it was shown that the 
defect in the gene is not responsible for the xid mutation 
(Cao ejt al. 1993) . The murine X-linked scurfy mutant, sf 
resembles WAS in humans although sf differs from WAS in 
that sf males are hypogonadal. The human and murine loci 
lie in homologous segments of the X chromosome although in 
different positions relative to other gene loci (Lyon et 
al, 1990) .
Studies of the xid mutation allow analysis of the genetic 
factors affecting B lymphopoiesis and B cell function. Xid 
is characterised by a deficiency in responsiveness to 
type III pneumococcal polysaccharide antigens (Amsbaugh 
e_t al, 1972) and some type II thymus-independent antigens 
(Scher et al. 1975). It is also characterised by hypo- 
and unresponsiveness to different B cell mitogens (Scher 
et al. 1975; Goodman et al. 1978) and defects in B cell 
colony production, following antigenic stimulation 
(Kincade, 1977) .
Particular B cell subpopulations are absent. These are
+ 
BLA-1 cells which are normally detectable from two weeks
+ 
of age (Hardy et al, 1983), BLA1 , BLA-2 cells (Hardy et
+ 
al. 1984) and Lyb-5 cells which are normally detectable
2-3 weeks after birth (Ahmed and Scher, 1976). Other 
absent B cell subpopulations include those cells that 
belong to Population I with high IgD, low IgM (Hardy 
et al. 1982) and members of Population III with low IgD,
\>
high IgM (Hardy et al. 1984) and also, those cells 
expressing minor lymphocyte-activating determinants 
(Ahmed and Scher, 1976).
Studies of X-chromosome inactivation patterns have 
revealed that the defect in xid is intrinsic to B cells 
and that T cells, pre-B cells, ocher haematopoietic cells 
and non-haematopoietic cells are unaffected by the xid 
mutation (Nahm et al, 1983; Forrester, 1986).
Although xid. like XLA, is characterised by a B cell 
lesion, the defect is less severe than that seen in XLA 
patients. In contrast to XLA, xid mice do have peripheral 
B cells and immunoglobulins of different isotypes (Scher, 
1982) .
The xid locus has been mapped to the Fl region of the X 
chromosome which shares homology with the human XLA locus 
at Xq22 (Copeland and Jenkins, 1991; Hillyard et al, 
1992). The murine Btk has been mapped to the xid locus 
and sequencing of the Btk gene identified a missense 
mutation which altered a single amino acid residue in the 
Btk protein (Rawlings et al. 1993; Thomas et al. 1993) 
indicating that xid and XLA share a similar molecular 
lesion despite exhibiting different disease phenotypes. 
In contrast to XLA, Btk mRNA expression and protein 
kinase activity in vitro were shown to be unaltered in 
the B cells of xid mice (Rawlings et al. 1993) which may
relate to the variation in phenotype of XLA and xid.
Several murine lymphoid loci, with no known human 
homologues have been characterised. These include the X- 
1 inked lymphocyte regulated sequence family, XLR which 
was originally identified from a lymphocyte- specif ic cDNA 
library (Cohen et al, 1985a) . A cDNA was found to encode 
a protein expressed exclusively in the nucleus of B and T 
cells (Garchon and Davis, 1989) .
Mapping studies have revealed that XLR sequences, Xlr-1 
and Xlr-2 localise to two separate positions in region XA 
and that these loci do not map to the xid locus (Mullins 
et al. 1990) although it had been demonstrated 
previously that some members of the XLR gene family 
are closely linked to xid (Cohen et al. 1985a) and 
that the xid mutation disrupts XLR gene expression (Cohen 
et al, 1985b) .
Other murine lymphoid loci include the lymphocyte 
membrane antigens, Lyx-1. Lyx-2 . Lyx-3 which are 
controlled by immune response (Ir) genes and are found to 
be antigenically distinct such that Lyt-X relates to T 
cells and Lyb-X relates B cells (Lyon and Searle, 1989) .
Murine loci which are homologous to haematopoietic loci in 
man have been mapped to the short arm of the X chromosome . 
These include the cytochrome b-245 beta polypeptide locus, 
Cybb located in the region XA (Mullins et al . 1990) . The 
loci for clotting factors VIII and IX, cf-8 and cf -9
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located in the region XB and XA6, respectively (Mullins et 
al, 1988) . The locus for glucose-6-phosphate 
dehydrogenase, G6pd. located in the region XA6-A7 or XB 
(Mullins et al. 1988). The locus for phosphoglycerate 
kinase-1, Pgk-1 located in the XD region (Cavanna et al. 
1988) and the alpha-galactosidase A locus, Ags located in 
the XF region (Paigen, 1979; Mullins et al. 1988); Gf-1 
also named Gatal (Chapman e_t al, 1991) involved in 
regulation of transcription of erythroid cells.
An homologous murine locus (mdx) has been noted for the 
Duchenne, Becker and Emery-Dreifuss dystrophies (Searle 
et al. 1987; Cavanna et al, 1988) . The murine model for 
muscular dystrophy resulted from a spontaneous mutation
(mdx) in C57BL/10 mice (Bulfield et al, 1984). Unlike 
human dystrophies, mdx is characterised by limb and 
cardiac muscle lesions without obvious dysfunction
(Emery, 1980; Dangain and Vrbova, 1984; Bridges, 1986).
Mdx has been mapped to the region homologous to the DMD 
locus on the mouse X chromosome (Brockdorff et al. 1987; 
Chamberlain et al. 1987; Heilig et al, 1987), between the 
loci Hprt (hypoxanthine phosphoribosyltransferase) and 
pgk-1. in the mouse (Chapman et al, 1985; Peters et al, 
1988). Evans et al. 1990 showed that the mouse dystrophin
locus is positioned in the XC band of the X chromosome.
2cv 3cv 4cv
Three alleles of mdx (mdx .mdx , mdx ) were ident- 
ified in mice treated with the mutagen N-ethylnitrosourea 
and it was also shown that reduced dystrophin levels are
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a consequence of mutations at the dystrophin locus 
(Chapman et al, 1989). A point mutation in the dystrophin 
gene of mdx mice which results in the premature 
termination of translation of the dystrophin polypeptide 
has been identified (Sicinski et al, 1989).
2 + 
It has also been shown that intracellular Ca is
elevated in mdx muscle and it is suggested that ion
2 + 
channels in mdx myotubes provide Ca -leakage into the
cell (Franco and Lansman, 1990).
Characterisation of X-linked Defects
Techniques to Evaluate X-chromosome Inactivation Patterns
X-Chromosome Inactivation
During female embryogenesis one of the two X chromosomes 
is inactivated resulting in dosage equivalence between 
females who have two X chromosomes and males who have one 
X chromosome (Lyon, 1961; Russell, 1961) and the inactive 
status is inherited by descendents within a somatic cell 
lineage (Chapman, 1987) . X-chromosome inactivation is 
generally random such that tissues are composed of a
mosaic mixture of equal numbers of cells expressing the
M P
maternal (X ) and paternal (X ) chromosome (West, 1982;
Gartler and Riggs, 1983; Chapman, 1987).
Non-random X-chromosome inactivation or selection for 
cells expressing either the maternal or paternal X 
chromosome results in unequal numbers of cells and
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greater expression of one kind of X chromosome. In
P 
studies on murine extraembryonic membranes, the X has
been shown to be preferentially inactivated (Takagi and 
Sasaki, 1975; West et al. 1977). It is suggested that this 
differential expression is due to an imprinting process,
probably by DNA modification such as methylation, prior to
M P 
X inactivation, making X and X intrinsically different
(Mohandas et al, 1981; Chapman et al. 1982; Monk, 1986) . 
The fact that normally hypomethylated CpG-rich islands 
become methylated on the inactive X chromosome suggests a 
role for methylation in the maintenance of the inactive 
state (Bird, 1986; Norris et al. 1991).
Both human and murine X-chromosome inactivation is 
thought to proceed from an inactivation centre (XlC/Xic) 
Russell, 1963; Cattanach, 1975). Therman, 1974 
hypothesised the existence of an X-inactivation 
centre in relation to a Barr body condensation centre.
The human XIC was initially located between Xqll.2 and 
Xq21.1 (Mattei, 1981). A visible bend at Xql3.3-q21.1 was 
suggested as being representative of the condensation 
process (Flejter et al. 1984) and was also expressed in 
other primates at a band homologous to human Xql3-q21 
(Flejter et al. 1986). Brown and Willard, 1989 located 
the human XIC to Xql3. The gene XIST (X-inactivation 
specific transcript) from the region of the human XIC was 
found to be expressed on the inactive chromosome and was
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suggested as being involved or influenced by the 
inactivation process (Brown et al. 1991a). XIST was 
further localised to XIC at Xql3 (Brown e£ al, 1991b). 
XIST RNA was shown to be localised within the nucleus at 
the position of the X-inactivation associated Barr body 
(Brown et al. 1992) .
The mouse Xic was mapped to band XD (Rastan, 1983; Rastan 
and Robertson, 1985) . Similarly to humans, murine Xist 
was shown to map to the region of Xic (Borsani et al. 
1991), was shown to be exclusively expressed by the X 
chromosome and was suggested as being involved in X- 
chromosome inactivation (Brockdorff et, al, 1991) .
X-chromosome controlling elements have been shown to 
produce non-random inactivation of the X chromosome 
(Cattanach and Williams, 1972; West and Chapman, 1978). 
The murine locus (Xce) was mapped to the XD region, 
between mdx and Pgk-1 (Cattanach, 1970; Cattanach et al. 
1970). Allelic variants of this locus influence X-
chromosome inactivation such that an X chromosome
a 
expressing the Xce allele has a greater chance of being
b 
inactivated than an X chromosome carrying the Xce allele
which, in turn, is more likely to be inactivated than an
c 
X chromosome carrying the Xce allele (Cattanach, 1972;
Johnston and Cattanach, 1981). It has also been shown 
that the parental source of the Xce allele determines 
which X chromosome is inactivated (Rastan and Cattanach, 
1983) . For example, in females heterozygous for Xce (b/c),
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M C 
the X chromosome bearing the Xce allele is less likely
P 
to be inactivated than the X chromosome carrying the same
allele (Forrester and Ansell, 1985). Further evidence of 
parental effects on expression of the X chromosome, in 
addition to the possible existence of a fourth Xce allele 
have been demonstrated (Fowlis, 1988; Fowlis et al. 1991).
Analysis of Electrophoretic Alloenzymes
In addition to X-chromosome controlling elements, X- 
linked mutations may also result in non-random expression 
of the X chromosome. Detailed examples of these are given 
above in the overview of X-linked defects. In the 
heterozygote, the relative expression of the maternal or 
paternal X chromosome can be quantified by measuring the 
relative amounts of allelic X-linked enzyme which is used 
as a cell marker and can be separated by electrophoresis. 
Electrophoretic variants for enzymes HPRT, PGK-1 and G6PD 
are examples of such a marker. For example, female 
carriers of WAS who are heterozygous both for the WAS 
locus and for the G6PD locus which encodes for the 
enzyme G6PD with A/B polymorphism have expression of the 
B alloenzyme in T cells and platelets and equal 
expression of A and B alloenzymes in other cell types. 
Hence, non-random expression of the X chromosome 
demonstrates selection against those cells affected by 
the WAS defect. (Gealy et al. 1980). Also, female carriers 
of XLA who are heterozygous both for the XLA locus and for
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the G6PD locus have expression of the A alloenzyme in B 
cells and equal expression of both alloenzymes in other 
cell types. Hence, non-random expression of the X 
chromosome demonstrates selection against those cells 
affected by XLA (Conley e£ al, 1986).
Similarly, in mice heterozygous for the Pgk-1 locus where 
cells express either the normal (PGK-1B) or the variant 
(PGK-1A) form of the enzyme, cells carrying the maternal 
or paternal X chromosome can be traced and quantified. For 
example, females heterozygous for both the xid mutation 
and the Pgk-1 locus demonstrate non-random expression of 
the X chromosome for B cells (Nahm et al. 1983; Forrester 
e_t al, 1987) .
Analysis of Methylation Patterns
This method of analysis of X-chromosome inactivation 
patterns takes advantage of differences in methylation of 
specific cytosine bases in the DNA of active versus 
inactive X chromosomes (reviewed by Winkelston and Fearon, 
1990) .
Two X-chromosome encoded genes that vary in their pattern 
of methylation on the active and inactive X chromosome, 
HPRT and PGK, are also the sites of restriction fragment 
length polymorphisms (RFLPs) with restriction sites that 
bracket sequences that are variably methylated. To use 
the methylation technique (Vogelstein et al, 1987), DNA 
from females heterozygous for one of the RFLPs is sub-
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jected to double digestion with restriction enzymes such 
that one enzyme reveals the RFLP allele and the other, a 
methylation-sensitive enzyme cuts the DNA derived from 
the non-methylated chromosome.
The inactive X chromosome is methylated at the PGK locus 
while the active X chromosome is methylated at the HPRT 
locus. Using a Southern blot, the DNA is analysed using a 
labelled probe from a sequence that flanks the PGK or HPRT 
gene.
If the cells examined have normal random X-chromosome 
inactivation, the DNA digested with both enzymes will show 
diminished intensity of both the bands seen in the lane 
containing DNA digested only with the RFLP-revealing 
enzyme because some of the DNA in each of the two bands 
has been digested by the methylation-sensitive enzyme. 
However, when DNA is derived from cells with non-random 
X-chromosome inactivation, then one of the bands will 
disappear in the lane digested with both enzymes as the 
DNA from that allele is nonmethylated.
Somatic Cell Hybrid Technique
A subsequent method to determine the X-chromosome 
inactivation pattern in cell lineages from women is based 
on forming hybrids between the human lymphocytes of 
interest and a hamster cell line deficient in the X- 
encoded enzyme, HPRT (Puck e_t al, 1987) . Hybrids grown in 
selective media retain the human active X chromosome
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resulting in HPRT activity. This X chromosome is 
identifiable using analysis for any X-linked polymorphic 
marker for which the donor woman was heterozygous. A 
normal random X-chromosome pattern demonstrates that some 
of the hybrids have retained the paternally-derived 
allele and some have retained the maternally-derived 
allele. A non-random X-chromosome inactivation pattern 
shows the hybrids have retained the same X chromosome.
Hence, analysis of electrophoretic alloenzymes, 
methylation patterns and somatic cell hybrids have been 
used to assess the X-chromosome inactivation patterns in 
female carriers of XLA (Conley et al. 1986; Fearon et al. 
1987; Conley and Puck, 1988; Hendriks et al, 1989); XSCID 
(Puck and Conley 1987; Conley e_t al, 1988; Goodship et 
al, 1991; Conley, 1992; Hendriks et al, 1992; Puck, 1993; 
Wengler et al, 1993) and WAS (Fearon et al. 1988; Greer 
et al. 1989; Notarangelo et al, 1991) . Defective cell 
lineages include B cells in XLA, B and T cells and in 
some cases granulocytes and natural killer cells in XSCID 
and B and T cells, monocytes and platelets in WAS.
Interpreting results of X-chromosome inactivation studies 
requires taking into account the degree to which random 
X-chromosome inactivation can result in variation from 
the expected mean of 50% of cells with the maternally- 
derived X chromosome active and 50% of cells with the 
paternally-derived X chromosome active. X-chromosome 
inactivation studies using the X-linked enzyme G6PD as a
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cell marker and studies using the hybrid technique have 
shown that, in approximately 10% of normal females, 
random X-chromosome inactivation results in the 
expression of one X chromosome as the active X chromosome 
in 80% of the cells with the remaining 20% of cells 
expressing the other X chromosome (Fialkow, 1973; Stewart 
g£ al, 1989) . This indicates a wide variation in normal 
random patterns of X-chromosome inactivation. Hence, 
the importance of evaluating the X-chromosome inactiv- 
ation pattern in a cell lineage unaffected by an X-linked 
mutation from an individual in which there are cell 
lineages that are affected by the mutation. In normal 
women, the pattern of X-chromosome inactivation in all 
tissues tends to be similar (Fialkow, 1973).
Thus, studies of X-chromosome inactivation patterns can 
be used to identify specific cell types affected by an X- 
linked defect or mutation. In males, hemizygous for X- 
linked genes, cell types expressing the mutation are not 
detectable using the enzyme marker system since there is 
no selection against those cells.
Studies of X-chromosome inactivation patterns can also be 
used to indicate the stage in differentiation at which 
the cell type is affected by the the X-linked mutation. 
For example, in obligate carriers of XSCID, surface 
IgM B cells, committed to IgG- and IgA-expression, 
exhibited preferential use of the non-mutant X chromosome 
whereas balanced X-chromosome expression was seen for
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+ 
less mature surface IgM B cells. This indicated that the
defective gene product of XSCID is expressed throughout B 
cell differentiation and its activity results in a 
relative rather than an absolute block in differentiation 
with progressively more skewing of X-chromosome 
inactivation patterns as B cells proliferate and 
differentiate (Conley et al. 1988).
Studies of X-chromosome inactivation patterns have been 
used in cell-lineage analyses and to determine 
contributing cell numbers of developing tissues by 
estimating the proportions of the genetically distinct 
cell populations. For example, variants of the X-linked 
enzyme G6PD have been used to study clonality of tumours 
to determine founder cell numbers of different tissues in 
man (Fialkow, 1973, 1983) .
Mapping of Genetic Defects
A new marker for a locus can be located using a genetic 
or linkage map which contains the order and approximate 
recombinational distance between genetic markers on a 
chromosome and a physical map which describes the 
physical features of a chromosome.
Linkage mapping to map loci in relation to each other 
utilises the process of recombination which is the 
rearrangement of genetic material at crossover points or 
chiasmata on nonsister chromatids of homologous
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chromosomes during meiosis (Morgan, 1910; Tease and 
Jones, 1978) . This results in the formation of different 
arrangements of genes in the gametes such that the 
original arrangements of alleles on the two chromosomes 
are called the parental combinations and two new 
combinations are called recombinants. Sturtevant, 1913 
suggested that the percentage of recombinants is a 
quantitative index of the linear distance between two 
genes such that the greater the distance between genes on 
a chromosome the greater the chance that nonsister 
chromatids cross over in the region between the genes and 
hence the greater the proportion of recombinants that 
would be produced. Thus, analysis of the meiotic 
recombinational frequency can determine the map distance 
between genes on a chromosome such that 1 map unit or 
centimorgan (cM) is defined as a recombinant frequency of 
1%.
The greater the interval between genes on a chromosome 
the greater the probability that multiple crossovers 
occur. Therefore, to take account of multiple crossovers 
between loci, the mapping function (Haldane, 1919) is 
used to relate distance along a chromosome and recomb- 
inational frequency.
Linkage analysis maps loci for genetic defects by 
determining which region of the chromosome is inherited 
with the locus for the defect. For the mouse, it is 
possible to establish the relative levels of error
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associated with intergenic distances by altering the 
number of mice analysed in a cross. Gene orders can be 
determined by minimising the number of multiple crossover 
events for a given set of loci (Mullins et al, 1990).
Physical mapping can be used to trace loci of genetic 
defects by analysing the region of the chromosome 
containing such loci. Closely linked polymorphic loci are 
used as markers of loci for genetic defects. For example, 
the loci for Duchenne (Murray et al. 1982) and Becker 
(Kingston et al, 1983) muscular dystrophies have been 
linked with DNA markers. DNA sequence polymorphisms can 
be detected using restriction enzymes (Botstein et al. 
1980). Restriction fragment length polymorphisms (RFLPs) 
can be detected using Southern transfers (Owerbach et al. 
1980; Naylor et al. 1984) . RFLPs can result from an 
insertion, a deletion or a difference in the number of 
repeats of a short sequence between two restriction 
enzyme cleavage sites. For example, genetic studies of 
CYBB the gene whose deficiency causes X-linked CGD, have 
detected RFLPs in the DNA of carriers (Francke et al. 
1990).
The polymerase chain reaction (PCR) (Saiki et al. 1985) 
can be used to map genetic markers whereby PCR amplifies 
a region of DNA containing variable numbers of inserts. 
The size of a fragment synthesised by PCR identifies the 
size of the insert. Microsatellite markers can be 
analysed by PCR (Luty ££ £l, 1990).
65
Fluorescence in situ hybridisation can be used to map 
regions of the chromosome by hybridising a radiolabelled 
RNA or DNA probe to fixed metaphase chromosomes. For 
example, the human gene encoding the CD40 ligand was 
biotin-labelled and shown to hybridise to the X 
chromosome at band Xq26 (Aruffo et al. 1993).
The development of yeast artificial chromosomes(YACs) as 
cloning vectors for large segments of DNA has made 
cloning of chromosome regions possible and permits the 
analysis of candidate genes in a targeted region of the 
chromosome. For example, using this method the region 
Xq24-Xq28 containing the XLP locus has been cloned 
(Schlessinger et al. 1991).
Flow Cytometric Analysis
The effect of an X-linked immunological defect in 
leukocytes can be studied by flow cytometric analysis in 
which leukocyte subpopulations are identified by 
analysing the relative size of cells (Loken and Stall, 
1982), the integral structure and granularity of cells 
(Ritchie et al. 1983) and analysis of the relative 
proportion of leukocyte subpopulations by quantifying 
fluorescence-labelled cells to assess the distribution of 
surface antigen. Defined subpopulations of cells can be 
isolated (Herzenberg et al. 1976) for further study, 
namely electrophoretic alloenzyme analysis in the present 
study to evaluate the X-chromosome inactivation patterns
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within a subpopulation of cells 
Aims Of This?
Animals with genetic mutations can be used to study the 
factors controlling normal development and function and 
as models for the study of genetic disease in man. 
Comparison of human and murine genetic maps can indicate 
the chromosome regions where the genetic order is 
conserved and can identify mouse genetic loci which may 
be homologous to human mutations causing disease. Genetic 
defects can be mapped to the chromosome using linkage and 
physical mapping. In humans and mice, loci controlling 
the haematopoietic and muscular systems have been mapped 
to the X chromosome {see the comparative human and mouse 
X- chromosome map, Fig.l) .
The aim of this study was to characterise the phenotypic 
effect of a novel X-linked mutation in offspring of male 
mice treated with the mutagen N-ethylnitrosourea (ENU) 
which has been shown to transmit mutations via the germ 
line at a frequency of 1 mutation per 700 loci tested 
(Johnson and Lewis, 1981; Russell et al. 1982a, 1982b; 
Justice and Bode, 1986) . It has been demonstrated that 
treatment with ENU can produce X-linked mutations 
affecting the haematopoietic and muscular systems (Chapman 
e_t al, 1988, 1989) .
Studies of X-chromosome inactivation patterns in 
heterozygous females using electrophoretic alloenzyme
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analysis were used to characterise the phenotypic effect 
of the X-linked ENU mutation by delineating the cell 
lineages affected by the mutation, the stage at which the 
mutation acts and the penetrance of the mutation in the 
affected cells.
In the heterozygote, the relative expression of the 
maternal or paternal X chromosome was quantified by 
measuring the relative amounts of allelic X-linked 
alloenzyme (PGK-1) which is used as a cell marker and is 
separated by electrophoresis. Non-random expression of 
of the X chromosome in cells demonstrates selection 
against the cells affected by the mutation.
The phenotypic effect of the ENU mutation was studied by 
analysis of cells of brain, haematopoietic and muscular 
systems from female carriers of ENU that were heterozygous 
for the ENU mutation (ENU/+) such that the presence of 
cells carrying the + locus on the X chromosome was 
detected by visualisation of the alloenzyme, PGK-1B and 
the presence of cells carrying the ENU mutation was 
detected by visualisation of the PGK-1A alloenzyme.
Attempts to relate the ENU mutation to a candidate gene 
were made by assessing whether the ENU mutation was an 
allele of xid by assessing the X-chromosome inactivation 
patterns in cells of females which were heterozygous for 
the ENU mutation and xid (ENU/xid) such that the presence 
of cells carrying the xid locus on the X chromosome was
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detected by the marker PGK-1B alloenzyme.
Studies of X-chromosome inactivation patterns in normal 
cells of heterozygous females using alloenzyme electro- 
phoretic analysis were also used to assess possible 
factors influencing X-chromosome inactivation in various 
strains, including the parental strain from which ENU- 
mutant mice were derived. Genetic factors such as the 
mouse X-chromosome controlling element, Xce have been 
shown to affect X-chromosome inactivation (Cattanach and 
Williams, 1972; West and Chapman, 1978) and allelic 
variants of the Xce can influence X-chromosome 
inactivation patterns (Cattanach, 1972; Johnston and 
Cattanach, 1981). Parental factors such as the parental 
source of the Xce allele can also determine which X 
chromosome is inactivated (Rastan and Cattanach 1983; 
Forrester and Ansell, 1985; Fowlis, 1988; Fowlis et al. 
1991) .
Various heterozygous females were produced from crosses 
between different strains and evaluated to examine 
variation in X-chromosome inactivation patterns. Studies 
were made of various normal cell types, that is cells 
unaffected by either the ENU or the xid mutation. Results 
were related to possible genetic and parental factors in 
the various strains studied that might influence X- 
chromosome inactivation.
Flow cytometric analysis was used to study the phenotypic
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effect of the ENU mutation on leukocyte subpopulations to 
assess whether the mutation affects relative leukocyte 
numbers in haematopoietic tissues of ENU-mutant males and 
their hybrids which were produced from crosses with either 
normal or xid mice. Leukocyte subpopulations were 
classified according to various cell properties such as 
relative size, integral structure and granularity. The 
relative proportion of leukocyte subpopulations was 
analysed by quantifying fluorescence-labelled cells to 
assess the distribution of cell surface antigen.
Furthermore, defined subpopulations of cells were 
isolated and the X-chromosome inactivation patterns of 
the defined cell subpopulations from the heterozygous 
females were evaluated to characterise which leukocyte 
subpopulations were affected by the ENU mutation.
A preliminary study to characterise the effects of the 
ENU mutation on the immune system in functional terms 
was made. Leukocyte responses in ENU-mutant mice and 
their hybrids which were produced from crosses with 
either normal or xid mice were assessed following 
sensitisation to the skin-sensitising agent oxazolone. 
Leukocyte responses were assessed using flow cytometric 
analysis and by making cell counts. Electrophoretic 
alloenzyme analysis of leukocytes from heterozygous 
females was used to study X-chromosome inactivation 
patterns following sensitisation to oxazolone.
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Finally, it is discussed whether the phenotypic effects 
of the novel X-linked mutation, in ENU-mutant mice might 
be compared to known disorders in humans or mice. Studies 
of the X-linked mutation in ENU-mutant mice may prove to 
be useful as a model for human X-linked disorders of the 
haematopoietic and muscular systems, and in assessing the 























































































Fiq.l Comparative X-chromosome Map showing the location of 
murine loci given in the text in terms of recombinational 
distance in centimorgans from the centromere and the known 
homologies to human chromosomes given as loci in bold and 
lines for conserved segments on the left; slanted lines on 
the X chromosome represent excluded regions that are not 






Strains of mice, with abbreviations in brackets, used in 
this study were CBA/Ca (CBA), CBA/Ca-Pgk-la (CBA-Pgk-la), 
CBA/N, C3H x C57BL/6 sublines (AT29, see below for 
genotype) and AT29xC57BL/10 .mdx (female 556-derived) 
(AT29-ENU.556). AT29 and AT29-ENU.556 mice were obtained 
from V.M Chapman, Molecular and Cellular Biology 
Department, Roswell Park Memorial Institute, Buffalo, 
N.Y. 14263.
Phosphoglycerate kinase-1 (PGK-1) is an X-chromosome 
encoded enzyme marker present in all cells. Two Pgk-1 
alleles exist in mice: CBA, CBA/N and C57BL/10.mdx are 
homozygous for the Pgk-lb allele and CBA/Pgk-la, AT29 and 
AT29-ENU.556 are homozygous for the Pgk-la allele (Fig. 
2i). Alloenzymes of HPRT and PGK-1 (see below) can be 
separated and quantified by electrophoresis such that the 
relative amounts of the alloenzyme in tissue homogenates 
represents a relative measure of cells expressing either 
the maternal or paternal X chromosome and can be used to 
screen for mutations that result in unbalanced expression 
of the X chromosome, as discussed in the Introduction.
The techniques of mutagenesis and screening for X-linked 



















































































































































fit al, 1988). 
(i) formation of the AT29-ENU.556 line
The AT29 (allelic transfer stock 29) line was produced by 
transferring a recombinant X chromosome carrying both the 
M. musculus Pgk-la allele from the congenic strain 
C3H/HeHa Hprta, Pgk-la and the M. castaneus Hprta allele 
to the C57BL/6JRos inbred strain.
The AT29-ENU.556 line was produced by treating male AT29 
mice with ethyl nitrosourea (ENU/NEU, 200-250 jug/gm) and, 
following their return to fertility, mating treated mice 
to females of the C57BL/10.mdx which were homozygous for 
alleles Hprtb and Pgk-lb to produce the Fl heterozygous 
female, 556 which had unbalanced expression of both 
markers in tissues (see screening, below). AT29-ENU.556 
mice were selected for being hemi/homozygous for alleles 
Hprta and Pgk-la and were produced by mating siblings 
derived from the original C57BL/10.mdx x 556 cross (Fig. 
21) .
(ii) screening for X-linked mutations
1762 Fl heterozygous females were tested for deviations 
from balanced mosaic expression of HPRT and PGK-1 in 
blood and tail tissue. By measuring both PGK-1 and HPRT 
levels, mutations specific to the indicator loci were 
distinguished from less specific mutations which affect 
normal balanced mosaicism.
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9 of these Fl females had an unbalanced pattern of 
expression in blood for both markers such that only the 
maternally-derived alloenzyme was expressed. Female 556, 
also had unbalanced expression of both markers in tissues 
of tail and skeletal muscle. 7 female progeny of the cross 
between female 556 and male C57BL/10.m^x (Fig. 2i) were 
heterozygous for both indicator loci and 3 of these 
females had unbalanced mosaicism in blood. This shows 
that the mutation present on the Pgk-la. Hprta X 
chromosome of the ENU-treated male alters the mosaic 
expression of the X chromosome and is heritable to 
heterozygous female offspring. Variation of non-mosaic 
expression of the X chromosome in blood of heterozygous 
females suggests that either the mutation has variable 
penetrance or its map position is distant from the Pgk-la 
and Hprta marker loci. Furthermore, the sex ratio of mice 
receiving the X chromosome bearing the mutation did not 
differ from the expected 1:1 ratio indicating that the 
mutation is not a cell autonomous lethal condition.
Descendants of the cross between female 556 and male 
C57BL/10.m^x (Fig. 2i) were selected for the presence of 
the ENU mutation and used in the present study: females, 
homozygous for Pgk-la. Hprta were mice: 1708, 1709, 1710, 
1998, 1821, 2115 and males, hemizygous for Pgk-la and 
Hprta were mice: 687, 1010, 1706, 1937, 2140, 1818, 2203, 
2261, 1843, 1842, 1703, 1752, 1756, 1758, 2199, 2121. 
In the present study, an AT29-ENU.556 homozygous line and
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hybrids between this line and CBA and CBA/N mice and CBA 
and CBA-Pgk-la were formed. The male parent in any hybrid 
is written first. For example, in AT29-ENU.556 x CBA mice, 
the father is AT29-ENU.556 and the mother, CBA.
The mice in this study were maintained on a diet of Rat 
and Mouse No. 1 stock breeding pellets (Special Diet 
Services, Essex, England) and chlorinated water ad 
libitum. Offspring were transferred to stock cages after 
being weaned 21 days post partum.
Flow cytometry
(i) preparation of cell samples
Mice were sacrificed by ether anaesthesia and cells were 
suspended in FACS medium (Appendix 1) for both FACScan 
analysis and FACSIV sorting (Chapter 6, 7).
cell suspensions
Sub-cutaneous lymph nodes (2 brachial, 2 axillary, 2 
inguinal), thymus, spleen and neonatal liver were placed 
in a petri dish containing FACS medium and tissues were 
dissociated by squeezing gently between two ground glass 
slides. Cell suspensions were produced by sieving (O.llmm 
mesh) the material into a test tube on ice.
Bone marrow cell suspensions were produced by flushing 
femora with FACS medium in a petri dish using a 25g 
needle and syringe and dissociating the marrow plug by
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aspirating through the needle several times in a test 
tube on ice.
10 drops of blood were removed from the retro-orbital 
sinus of etherised mice using a heparinised capillary 
tube (Hawksley, Sussex, England). The blood was collected 
into a test tube on ice which contained FACS medium, and 
100 units of Heparin solution (25,000 units/ml, diluted 
1:25 in 0.9% saline, Evans Medical Ltd., Middlesex, 
England). The supernatant was removed following centrif- 
ugation at 550g for 10 minutes and 9ml of distilled water 
was added for 12 seconds to lyse the erythrocytes during 
resuspension of the pellet (Chandler et al. 1979) . The 
distilled water shock was terminated by the addition of 
1ml lOx concentrated Minimum Essential Medium-Eagle 
(Gibco) and, following centrifugation at 200g for 7 
minutes and removal of the supernatant, the final pellet 
of white blood cells was resuspended in 0.3ml FACS medium.
(ii) cell counts
lOjil of acridine orange/ethidium bromide solution 
(Appendix 1) was added to lO^ul of each cell suspension. 
Cell counts were made using a fluorescent microscope on 
the basis that live cells appear green due to the uptake 
of acridine orange. Viability was routinely >90%. Cells
from each tissue were washed and resuspended in FACS
7 
medium at a concentration of 1 x 10 cells/ml.
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Table 2A: Antibodies used for FACS analysis of surface 
antigens
ANTIGEN ANTIBODY REFERENCE SOURCE VOLUME
(monoclonal and 5
raised in rat /(2xlO
unless stated) cells)
B220 RA36B2 Coffman and
Weissman, 1981a,b la 20jil
Reif and
Alien, 1964 la 20jml
Thyl.2 30-H12 Micklem et al, 1980 Ib 4jil
Abehsira et al, 1981
Lyl 53-7.3 Cantor and
Boyse, 1975 la 20jil
Ledbetter and
Herzenberg, 1979 Ib 4jjl
Lyt2 53-6.7 Boyse et al, 1968 la 20jal
Ledbetter and 
Seaman, 1982 Ib 4jul
L3T4 GK 1.5 Dialynas et aJL, 1983 la 20jul
Ib 4jal
mlgM PE conjugated, Vitetta et £1,1971,1972 2 0.28jul 
Goat-anti-mouse-IgM 
polycl.
mlgD FITC conjugated, 3 0.28jal 
Sheep-ant i-mouse-igD 
polycl.
second Goat-anti-rat-IgG 4 0. 3ul 
step (H+L chain specificity 
FITC mouse adsorbed) 
conjugated polycl.
PE = Phycoerythrin 
FITC = Fluorescein Isothiocynate 
la: made in author's laboratory
Ib: Sera-Lab. Ltd. Crawley Down, Sussex, England (1/100 
dilution)
2 : Caltag Labs., S.O., San Francisco, C.A.
3 : Nordic Immunology, Tilburg, The Netherlands




For analysis of cell surface antigens, 2 x 10 viable
cells suspended in FACS medium were placed in the wells 
(20ul/well) of a round-bottomed microtitre plate 
(Sterilin, Middlesex, England) and the appropriate amount 
of antibody added (Table 2A). Wells adjacent to filled 
wells were left empty to minimise the risk of 
contamination by splashing. The plate was shaken on a 
micro-shaker (Dynatech, England) and incubated on melting 
ice for 40 minutes. FACS medium was then added to each 
well and the plate was centrifuged at 350g for 15 
seconds. The supernatant was discarded and the pellets 
resuspended by shaking after refilling the wells with 
FACS medium. The cells were then centrifuged and 
resuspended again. If an indirect staining procedure was 
adopted, the primary antibody was revealed by incubating 
the washed cells for a further 40 minutes with a FITC-
conjugated goat anti-rat IgG antibody (Tago Inc., CA,
5 
USA), used at O.Sjil per 2 x 10 cells. If the primary
antibody had a conjugated fluorescent tag (direct 
staining), no further staining was necessary. All cells 
were again washed twice, and resuspended in FACS 
medium.
There were both positive and negative controls for 
analysis. Negative controls were unstained cells, while 
positive controls were stained with second step antibody 
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For cell sorting, 5 x 10 cells were stained with an
appropriately scaled up volume of antibody (the volume of
primary and secondary antibody was increased by a factor
6 5 
of 25, i.e. 5 x 10 /2 x 10 ). The staining procedure was
similar to that above, but in FACS tubes (Falcon, Becton
Dickinson Immunocytometry Systems, Mountain View, CA,
USA) and cells were centrifuged at 400g for 7 minutes.
Analysis was performed on the FACScan and cell sorting 
was carried out using the FACSIV (Becton Dickinson 
Immunocytometry Systems, Mountain View, CA, USA). 
(See Fig. 2ii for a general illustration of a FACS 
machine).
(iii) analysis
The FACS machine was fitted with an Argon laser 
(excitation wavelength 488nm) and logarithmic amplifiers 
(four decades per 255 channels) for the fluorescence 
channels.
Information resulting from analysis was stored in Consort 
30 list mode data files. Analysis of data was carried out 
on hardware from Hewlett Packard, Belgium using the Lysys 
software package (Becton Dickinson Immunocytometry 
Systems, Mountain View, CA, USA); data was displayed 
using dotplots, histograms and contour plots.
For FACS analysis (Fig. 2iii), the suspension of cells was
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conveyed through a sensing region by a fluid flow system. 
Cells were directed through the nozzle assembly and were 
centred in a cell-free sheath which formed a liquid jet 
that intersects the laser beam. As cells passed through 
the laser beam, light was scattered and fluorescent 
molecules (fluorescein isothiocyanate, FITC was mainly 
used in this study) became excited and fluoresced.
Excitation of fluorescent molecules on the cell surface 
resulted in emission of light of different wavelengths 
which was divided into different ranges by reflector 
filters and directed to a fluorescent detector for 
measurement. The emission spectra for the dyes FITC and 
PE overlap; this was compensated for electronically.
Light scatter gives a relative determination of cell- 
sized particles and describes the granularity and size of 
cells passing through the laser beam. Light is collected 
by detectors and converted into electronic signals, the 
magnitude of which is proportional to the light intensity.
Light scattered forwards (FSC) is collected at small
o 
angles of 3-12 (Parks et al, 1986). Forward light
scatter measurements are used to initiate analysis, to 
permit gating out of dead cells or erythrocytes by 
demonstrating their low scatter profile (Loken and 
Herzenberg, 1975) and to determine relative cell sizes in 
mixed populations (Loken and Stall, 1982).
Light scattered at right angles or side scatter (SSC)
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o 
is collected within the range 70-110 (Parks et al,
1986) . Side scatter measurements reflect integral 
structure and granularity of cells and thus permits 
identification or gating out of granulocytes which have 
granular cytoplasm (Ritchie et al. 1983) . For example, in 
mixed populations of leukocytes, lymphocytes can be 
distinguished from cells with a relatively higher right 
angle scatter being structurally more complex. Such high 
scattering cells are a heterogeneous population that 
include monocytes and granulocytes. Forrester, 1986 
defined a cell population with a relatively higher right 
angle scatter than lymphocytes as granulocytes for 
peripheral blood and bone marrow.
The ability to analyse forward and side gated populations 
means that fluorescence distributions can be obtained for 
a specific subpopulation of cells. Similarly, using two 
fluorescence parameters, gated analysis can distinguish 
cells which bear different levels of one surface antigen 
among a subpopulation of cells bearing a second antigen 
(Herzenberg et al. 1976) .
Cell subpopulations were defined by quantifying
fluorescence-labelled cells to assess the distribution of
+ 
cell surface antigen (Table 2A). These included B (B220 )
cells and their subsets, population I with high IgD, low 
IgM; population II with high IgD, high IgM and population 
III with low IgD, high IgM which were classified according
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to the density of membrane immunoglobulin isotype and
+ 
also, T (Thyl.2 ) cells and the T cell and thymocyte
+ + + + 
subsets, CD4 (L3T4 ) helper cells, CDS (Lyt2 ) cytolytic
+ + 
cells, CDS (Lyl ) cells, discussed in Chapter 3, 6 and 7.
Hence, cells in mixed cell populations were categorised 
according to a combination of cell properties such as the 
relative size of cells from forward light scatter 
measurements, the integral structure and granularity of 
cells from right angle scatter measurements and the 
expression of surface antigen quantified by fluorescence 
which is a measure of the density of surface antigen per 
cell.
(iv) cell sorting
For cell sorting, any combination of the above properties 
can be employed. During sorting, the nozzle assembly was 
vibrated vertically at 37,000 cycles per second which 
resulted in the stream of cells dividing into droplets at 
a fixed point after intersection with the laser beam. The 
conditions were set such that a droplet containing more 
than one cell is discarded. The fluorescent properties of 
the cell within the droplet were recorded as each droplet 
passed through the laser beam. Fluorescence and scatter 
criteria were established using a dotplot before formation 
of the droplet. Cells which fulfilled the requirement for 
sorting were charged before droplet formation and, upon 
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charged droplets were collected separately from positively 
charged droplets, and both separated from the uncharged 
jet containing cells which did not meet the given criteria 
and were discarded.
Hence, defined subpopulations of cells were isolated for 
further study, namely electrophoretic alloenzyme analysis, 
in this study, to determine cell origin, discussed in 
Chapter 3.
Alloenzyme Analysis
Phosphoglycerate kinase-1 (PGK-1) is an enzyme found in 
all tissues and existing in two forms, the alloenzymes 
PGK-1A and PGK-1B which are separable by electrophoresis 
and can be measured relative to one another. The locus for 
Pgk-1 is on the X chromosome and the strains of mice used 
in this project were homozygous for either alloenzyme. The 
overall levels of each alloenzyme in any tissue of mice 
heterozygous for Pgk-1 depends on genetic factors and on 
X-chromosome inactivation patterns in the tissue 
progenitors which is discussed in the Chapter 1 (McLaren, 
1972; West, 1975; Fialkow, 1973; Pappaioannou et al. 1981; 
McMahon et al, 1983) .
PGK-1 is an enzyme of the glycolytic pathway, catalysing 
the conversion of 1,3-diphosphoglyceric acid to 3- 
phosphoglyceric acid with the production of ATP. The 
enzyme assay for PGK-1 is illustrated in Fig. 2iv. 
Electrophoresis is carried out on cellulose acetate
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membranes and PGK can be visualised either by autoradio-
14 
graphy following incorporation of a C-labelled substrate
or by using MTT staining following reduction of a 
tetrazolium salt to formazan. The substrate for PGK-1, 
1,3-diphospoglycerate, is unstable and is generated in 
situ on the electrophoresis membrane. Following the 
production of ATP, resulting from PGK-1 action, ATP is 
used in the production of glucose 6.phosphate and 6- 
phosphogluconolactone which is catalysed by hexokinase and 
glucose 6-phosphate dehydrogenase along with NADPH 
production. The system described was based on the work by 
Bucher et al. 1980 and modified by Ansell & Micklem, 
1986.
(i) preparation of cell samples for electrophoresis
Sorted cells and homogenised pieces of the following 
tissues were frozen in sample buffer after washing in 
FACS medium (Appendix 1) soon after sacrifice: spleen, 
lymph node, thymus, brain, bone marrow, a drop of whole 
blood, neonatal liver and skeletal muscle of the leg.
Analysis of the leukocytes of spleen and blood required 
removal of erythrocytes by lysis using distilled water 
shock (see above) and analysis of blood platelets required 
removal of erythrocytes and other leukocytes: 6 drops of 
blood were collected in a non-heparinised tube containing 
5ul of 38% sodium citrate (38g per 100ml distilled water). 
The tube was inverted and centrifuged at 300g for 5
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minutes. The platelet-rich plasma was removed and 
centrifuged at 800g for 20 minutes. After the supernatant 
was discarded, the pellet was resuspended, washed in FACS 
medium, centrifiged at 300g for a further 5 minutes before 
being frozen in sample buffer.
o 
Samples to be analysed were frozen at -70 then thawed
in sample buffer (Appendix 1) the volume of which was 
dependent on the cell number and the staining system used:
a drop of blood (20jal) required 80ul buffer; samples for
8 
MTT-type electrophoresis required 2 x 10 cells/ml buffer
7 
and sorted samples using autoradiography required 2 x 10
cells/ml buffer. The buffer lyses cells and keeps enzymes 
stable during storage.
(ii) electrophoresis
Titan III cellulose acetate membranes (Helena Laborat- 
ories, Cat. No. 3024, Beamont, Texas, USA) were blotted 
to remove excess buffer after soaking in electrophoresis 
buffer for 20 minutes (Appendix 1). 0.25ul aliquots of 
sample were loaded at the cathodal end of cellulose 
acetate membranes using a "Super Z" applicator (Helena 
Labs). The membranes were positioned sample side down on
a Helena electrophoresis tank containing 12.5 mg
/
adenosine 5 monophosphate (AMP) (Sigma) in 50 ml
electrophoresis buffer in both anodal and cathodal 
chambers. Filter paper wicks (Helena Labs, Cat.No.5081) , 
soaked in the AMP/buffer solution, were applied over the
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bridge sides, maintaining contact with the solution in 
the two chambers. A lOgm weight, positioned on top of 
each membrane ensured contact between the membranes and
the wicks. Electrophoresis ran for 45 minutes at 15mA per
o 
membrane, at 4 C.
PGK-1A, being more negatively charged, migrates closer to 
the anode than PGK-1B.
(iii) staining methods
14 
Staining solutions for MTT and C indicator systems were
prepared 10 minutes before the end of electrophoresis. 
(a) tetrazolium indicator system (MTT)
NADPH, produced from the reaction catalysed by G6PDH, is 
linked through phenazine methosulphate (PMS) to reduce 
dimethyl thiazolyl-diphenyl tetrazolium bromide (MTT). A 
blue colour indicates the presence of PGK-1.
75jiil sample buffer, 400jil assay stock (see Appendix) , 
lOOjal indicator stock (see Appendix) , lOjul aldolase 
(6.5jJ/ml) (Boehringer, W. Germany), 5ul GDH (2000^1/ml) 
(Sigma) , 7.5jil GAPDH (lOmg/ml) (Boehringer), 5jul hexo- 
kinase (6000ju/ml) (Sigma) and lOjul G6PDH (312u/ml (Sigma) 
were added to SOOul electrophoresis buffer.
A mixture of SOOjal MTT (lOmg/ml distilled water ) 
(Sigma), SOOul PMS (2.5mg/ml distilled water) (Sigma) 
and 2500iil 1.2% agar noble (Difco, Michigan, USA)
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o 
was boiled and retained at 56 C seconds before adding
to the staining mixture. The final mixture was poured
evenly over the membranes, allowed to set in darkness as
o 
the dyes are light-sensitive prior to incubation at 37 C
until alloenzyme bands appeared. Membranes or gels were 
then fixed in an aqueous solution of 15% glycerol and 3% 
acetic acid.
14 
(b) autoradiographic indicator system ( C)
14 
Addition of C-labelled glucose as a substrate for the
reaction catalysed by hexokinase results in the
14 14 
incorporation of C into the indicator system. The C-
labelled products of the hexokinase and G6PDH reactions 
(glucose-6-phosphate and 6-phosphoglucono-lactone, 
respectively) bind covalently via their phosphate groups 
to the polyethylene imine (PEI) cellulose chromatography
sheets (Bakerflex, Linton Products, Hysol, England). Any
14 
unconverted C is washed out and PGK-1 visualised by
autoradiography.
PEI sheets were soaked for 20 minutes in distilled water
o 
at 4 C, then blotted. The staining mixture was similar to
that of the MTT system with reduced quantities of electro- 
phoresis buffer (500ul) and sample buffer (30jj.l) and the 
glucose content of indicator stock is reduced to l/10th 
(Appendix 1) such that the relative proportion of labelled 
glucose converted into phosphate products was increased. 
MTT, PMS and agar were ommitted from this system and
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14 
instead, I5jil D-(ji- C) glucose (ImCi/ml) (Amersham) was
added to the stain prior to pouring the final mixture 
evenly over the PEI sheet. The electrophorised gel was 
placed on top, ensuring even contact and excluding air
bubbles at the interface. Following a 15 minute incubation
o 
at 37 C, the PEI sheet was rinsed in 8mM Tris (Sigma) and
washed with stirring for 4 hours in 8mM Tris at room 
temperature. After drying, PEI sheets were exposed to X- 
ray film (Kodak X-OMATS) for at least 3 days, or longer if 
the alloenzyme bands appeared faint. Films were developed 
for 2.5 minutes in a 1:4 solution of Kodak LX24 developer, 
washed in 2% acetic acid and fixed for 2.5 minutes in 1:4 
solution of Kodak FX40 Fixer. Finally, the film was washed 
in distilled water for 20 minutes.
(iv) densitometry of alloenzyme bands
14 
For both MTT and C gels, the proportions of the two
PGK-1 alloenzymes were assessed by a scanning 
densitometer (Chromoscan 3, Joyce Loebl, Vickers 
Instruments, Gateshead, England) using transmitted 
light for autoradiographic gels and reflected light for 
MTT-gels. Data were analysed and stored on a Sirius 
microcomputer. The programme calculated the area under 
each curve by integrating peaks produced by scanning.
(v) technical errors 
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Fig. 2v
Linearity in the electrophoretic measurement of PGK-1A and PGK-1B mixtures 
Figures shown on graph are number of samples per point (adapted from Ansell and 
Micklem, 1986)
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in the author's laboratory (Ansell & Micklem, 1986; H. 
Taylor, pers. comm.) whereby, in artificial mixtures of 
PGK-1A and PGK-1B cell lysates, there is a linear relat- 
ionship between the electrophoretic and volumetric 
measurement of %PGK-1A over the range 20-80%. Minor 
components tend to be overestimated outside this range 
(Fig. 2v). In practice, separations were discarded in 
which the total enzyme activity was too low, too high or 
were faulty for example, trailing, distorted, smearing, 
poorly separated or having lumpy agar. There was not much
difference in the variation due to technical error between
14 
the MTT and C system, although the latter was more
sensitive (Ansell & Micklem, 1986). 
Functional Analysis
Preliminary tests were carried out (Chapter 7) to examine 
the effect of 4-ethoxymethylene-2-phenyl oxazolone (BDH 
chemicals, Ltd.) hereafter named, oxazolone on the 
cellularity of the spleen and lymph nodes of homozygous 
and heterozygous mice which were aged 12 weeks, 
approximately.
(i) sensitisation
10 mg of oxazolone dissolved in 0.1 ml absolute
o 
ethanol at 60 C was applied to a shaved area of the skin,
approximately 2 cm in diameter, on the right side of the
thorax. Control animals received only O.lml of absolute
o 
ethanol at 60 C and were caged separately from treated
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mice for 3 days. 
(id.) assessment of sensitisation
The brachial lymph nodes of experimental and control mice 
were examined by eye for signs of swelling 3 days after 
treatment.
Cell suspensions were prepared for FACS analysis in the 
case of homozygotes or FACS sorting and PGK-1 alloenzyme 
analysis in the case of heterozygotes, as described above. 
Leukocyte counts were made using a Coulter Counter 
(Coulter Electronics Ltd., Luton, England) by gating out 
erythrocytes.
Data Analysis
In this study, a test of significance is applied when 
comparing the means of two different samples to see if 
they differ. When samples contain less than 30 members, 
the sample standard deviation becomes unreliable as an 
estimate of the standard deviation of the population. 
Hence, in significance testing, Student's t-test can be 
used. The t-distribution is similar to the normal 
distribution in being symmetrical about a mean but its 
dispersion varies according to the size of the sample. The 
bigger the sample, the closer the t-distribution 
approaches the normal distribution. The smaller the 
sample size, the greater is the difference between the 
means demanded by the t-test for a significant result.
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There is a limit on the number of t-comparisons that can 
be made in a data set and that is 1 less than the number 
of mean values in the data set.
In this study, for comparisons tests between the means of 
two samples with low sample number, the distribution of 
the sample values was compared with the t-distribution, 
discussed above and Student's t-test was used such that a 
significant difference between the means of two samples 
was taken as P<0.05 when analysed.
In Chapter 3 correlation analysis was performed using the 
Minitab computer system to assess the effect of the ENU 
mutation indicated by the level of PGK-1A expression with 
age for selected tissues. Correlation concerns the 
strength association between the values of two variables 
which, in this case, were the mean %PGK-1A values and age 
in weeks. The mean %PGK-1A values were plotted against the 
age in weeks to produce the correlation coefficient, r and 
a scatter diagram which showed the amount of scatter or 
the strength of the linear association between the two 
variables and the direction of the linear association such 
that positive values implied a direct association and 
negative values implied an indirect association between 
the two variables. A correlation coefficient of + 1 or -1 
implied a perfect linear association and the closer r 
approached +1 or -1, the stronger was the association 
between the mean %PGK-1A values and age. A correlation 
coefficient of 0 implied no linear association and when r
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approached 0 the weaker was the association between the 
mean %PGK-1A values and age. It should be noted that 
correlation analysis only picks up the linear association 
and it may miss more complicated associations where the 
variables are related in a nonlinear fashion (Groeneveld, 
1988; Hogg and Ledolter, 1992)
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CHAPTER 3
The Phenotypic Analysis Of An X-liriked Mutation By X- 
inactivation Studies
X-linked mutations can result in unbalanced expression of 
the X chromosome. If a mutation at an X-linked locus 
directly affects a cell population by being lethal at a 
particular developmental stage or by affecting the 
ability of cells to proliferate there will be unbalanced 
expression of the X chromosome in the cells of females 
heterozygous for the mutation. Studies of X-chromosome 
inactivation patterns can be used to identify specific 
cell types affected by an X-linked mutation and the 
degree of imbalance of X-chromosome expression may 
reflect the extent of the mutation.
Analysis of X-chromosome inactivation patterns involves 
assessing the relative expression of the maternal or 
paternal X chromosome in heterozygotes by quantifying the 
relative amounts of allelic X-linked enzyme which is used 
as a cell marker and can be separated by electrophoresis.
For example, female carriers of XLA who are heterozygous 
both for the XLA and the G6PD locus encoding for the 
enzyme G6PD with A/B polymorphism have balanced 
expression of both alloenzymes in all cell types except B 
cells which are affected by XLA and demonstrate 
unbalanced expression of the A alloenzyme (Conley et al. 
1986). Similarly, in mice heterozygous both for the xid
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mutation and the Pgk-1 locus where cells express variant 
forms of the enzyme PGK-1, unbalanced expression of the X 
chromosome has been demonstrated for B cells (Nahm et aj,, 
1983; Forrester et al. 1987).
The aim of this study was to characterise the phenotypic 
effect of a novel X-linked mutation in various tissues of 
offspring (AT29-ENU.556) of male mice (AT29) treated with 
the mutagen N-ethylnitrosourea (ENU). It has been shown 
that treatment with ENU can produce X-linked mutations 
affecting the haematopoietic and muscular systems 
(Chapman et al. 1988, 1989).
Studies of X-chromosome inactivation patterns in 
mice heterozygous for an ENU mutation using 
electrophoretic alloenzyme analysis were used to 
characterise the phenotypic effect of an X-linked ENU 
mutation by delineating the cell lineages affected by the 
mutation, the differential effect of the ENU mutation in 
various cell types and the effect of the mutation with 
age.
In this study, electrophoretic variants of the X- 
chromosome linked enzyme PGK-1 were used as markers to 
determine the expression of the X chromosome in mice 
heterozygous for the ENU mutation (ENU/+) such that the 
presence of cells carrying the + locus on the X 
chromosome was detected by visualisation of the allo- 
enzyme, PGK-1B and the presence of cells carrying the
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ENU mutation was detected by the alloenzyme, PGK-1A. 
Hence, unbalanced expression of PGK-1A in a cell lineage 
delineates the lineage affected by the ENU mutation.
Interpreting the results of X-chromosome inactivation 
studies requires taking into account the degree to which 
random X-chromosome inactivation can result in variation 
from the expected mean of 50% of cells with the 
maternally-derived X chromosome active and 50% of cells 
with the paternally-derived X chromosome active. As a wide 
variation in normal random patterns of X-chromosome 
inactivation exists it is important to evaluate the X- 
chromosome inactivation patterns in cell lineages of 
heterozygous female controls that are unaffected by an X- 
linked mutation and also in cell lineages unaffected by an 
X-linked mutation from an individual in which there are 
cell lineages that are affected by an X-linked mutation.
Attempts to relate the ENU mutation to a candidate gene 
were made by assessing whether the ENU mutation was an 
allele of xid by assessing the X-chromosome inactivation 
patterns in cells of females which were heterozygous for 
the ENU mutation and xid (ENU/xid) such that the presence 
of cells carrying the xid locus on the X chromosome was 
detected by the PGK-1B alloenzyme.
The phenotypic effect of the ENU mutation was studied by 
analysis of X-chromosome inactivation patterns in tissues 
of females heterozygous for the ENU mutation and results
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were compared with the X-chromosome inactivation patterns 
in tissues of control heterozygous females.
Hence, X-chromosome inactivation patterns were studied in 
heterozygous females produced from the following crosses:
(1) AT29-ENU.556 x CBA (ENU/+)
(2) AT29-ENU.556 x CBA/N (ENU/xid) 
and PGK-1AB controls:
(3) AT29 x CBA
(4) AT29 x CBA/N
(5) CBA x Pgk-la
As all mice referred to in this chapter are heterozygous 
females, to simplify the text, the term mice is used to 
denote heterozygous females. Studies were also made of 
mice derived from the reciprocal crosses of (1) and (3), 
above.
The tissues studied included the non-haematopoietic 
tissues brain, which was a control tissue as it was 
unaffected by the mutation, and skeletal muscle and the 
haematopoietic tissues blood, spleen, thymus, lymph node, 
bone marrow and neonatal liver. X-chromosome inactivation 
studies were extended to defined subpopulations of haemat 
opoietic cells to characterise the leukocyte sub- 
populations affected by the ENU mutation. The leukocyte 
subpopulations studied included platelets isolated from 
peripheral blood, white blood cells isolated from 
peripheral blood and spleen and cell subpopulations
102
leukocytes that were separated from lymphocytes by virtue 
of their relatively high right angle scatter being 
structurally more complex than lymphocytes. In the case of 
neonatal liver, lymphocytes were defined by their 
relatively low right angle scatter profile and not 
according to staining for antigen expression.
In the case of thymus, a combination of forward light 
scatter measurements defining relative cell size and 
intensity of fluorescence measuring the density of the 
antigen Thyl.2 permitted differentiation of thymocyte 
subsets of the inner cortex, outer cortex and medulla.
In the analysis of the effect of the ENU mutation with age 
mice were divided into: adults of >24 days, defined by 
sexual maturity; pre-adults of 15-24 days and young of <15 
days.
phenotypic variation of AT29-ENU.556 heterozygous females
PGK-1 analysis of mice from (1) AT29-ENU.556 x CBA and (2) 
AT29-ENU.556 x CBA/N crosses revealed two distinct 
phenotypic groups for each cross, namely PI, PI I and PHI, 
PIV respectively, the genetic basis of which is discussed 
in Chapter 4.
One phenotypic group from each of (1) and (2), namely PI 
and PHI, respectively had skewed patterns of PGK-1 
expression, in favour of non-ENU-mutant (PGK-1B) cells. 
This was the case for all cell types studied, except
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brain, high scattering leukocytes, possibly platelets and, 
depending on age, B cells of CBA/N mice (PHI) .
The other phenotypic group from each of (1) and (2) , 
named PII and PIV, respectively had PGK-1 patterns which 
reflected random expression of either chromosome. Hence, 
the assumption that PII and PIV mice did not carry the 
ENU-mutant X chromosome. These patterns were similar to 
those observed in normal (CBA-PGK-1AB) mice in all cell 
lineages, of all age groups, except in B cell populations 
in PIV mice where B lymphocytes carrying the xid mutation 
were selected against. The data for PIV mice were similar 
to published data (Forrester et al. 1987).
SECTION I.
Characterisation Of The Cell Lineages Affected By The 
KNU Mutation
%PGK-1A values were determined in adult (>24 day) mice of 
the nine groups discussed above. Results are presented in 
summary tables. The mean %PGK-1A values for whole tissue 
extracts of PI-PIV mice and AT29 control mice were 
compared using Student's t-test and the results are 
presented in the comparisons tables which follow an 
account of the results. Non-AT29 control mice (CBAxCBA- 
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n 4 4 7 8 1












































































With reference to the summary table 3.1 and the 
comparisons table 3.2, there was no significant 
difference between the mean %PGK-1A values for mice of the 
reciprocal AT29 or AT29-ENU.556 crosses. Hence, the mean 
%PGK-1A values for each group were pooled for comparison 
with other crosses. It should be noted that for the AT29 
control mice, the sample number was low which may have 
produced a false result. There was no significant 
difference between the mean %PGK-1A values for PI and AT29 
control mice; for PI and PI I mice; and for PHI and AT29 
control mice and also for PHI and PIV mice.
Table 3.2 BRAIN : Fl COMPARISONS (>24 day mice) showing 











each cell contains values of P and the mean %PGK-1A values 
~=(AT29xCBA)/(CBAxAT29) control pooled mean %PGK-1A values 
#=(AT29-ENU.556xCBA)/(CBAxAT29-ENU.556)PI pooled mean 
%PGK-1A values
Skeletal muscle
With reference to summary table 3.3 and comparisons table 




















































































































































were much broader than for most other tissues. For PI, 
PII and PHI mice the %PGK-1A values did not fit the t- 
distribution. An example of this is shown in Fig.3.1 where 
the distribution of %PGK-1A values is bimodal for (AT29- 
ENU.556xCBA) PI mice, denoted by PI*.
There was no significant difference between the mean %PGK- 
1A values for mice of the reciprocal AT29 crosses. Hence, 
the data were pooled for comparison with other crosses. As 
PI* females had bimodal distribution of %PGK-1A values the 
group was divided into <15% and >15% PGK-1A sample groups, 
with equal numbers of mice in each and the >15% PGK-1A 
sample group was compared separately with other crosses 
(see Fig.3.1). Similarly, PII mice had bimodal 
distribution of %PGK-1A values so the sample was divided 
into <65% and >65% PGK-1A sample groups and the former 
group compared with other crosses.
The >15% PGK-1A sample group of PI* mice with a mean value 
of 26% PGK-1A was significantly lower than the mean value 
for PII mice with 56% PGK-1A and for the AT29 control mice 
with 53% PGK-1A and was significantly higher than the mean 
value for the PI mice of the reciprocal cross with 13% 
PGK-lA. However, if the PI* sample group was not split 
the overall mean of (AT29-ENU.556xCBA) PI mice was 14% 
PGK-lA compared with 13% PGK-lA for (CBAxAT29-ENU.556) PI 
mice of the reciprocal cross. It should be noted that 
there were only 3 PI mice in the reciprocal cross sample 
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n 4 4 7 8 8 4 34 3 4 1





















































































distribution of %PGK-1A values for PI mice of the 
reciprocal cross might have also been bimodal had a 
larger sample been analysed.
Skeletal muscle of PHI mice also had bimodal distribution 
of %PGK-1A values. Hence, the sample was divided into <15% 
and >15% PGK-1A sample groups and the >15% PGK-1A sample 
group was compared separately with other crosses. The mean 
value for PHI mice with 24% PGK-1A was significantly 
lower than the mean value for PIV mice with 63% PGK-1A 
and for the AT29 control mice mice with 56% PGK-1A.
Table 3.4 SKELETAL MUSCLE : Fl COMPARISONS (>24 day mice) 





















each cell contains values of P and the mean %PGK-1A values 
~=(AT29xCBA)/(CBAxAT29) control pooled mean %PGK-1A values 
* denotes bimodal distribution of PI females in Fig.3.1.




With reference to summary table 3.5 and the comparisons 
table 3.6, there was no significant difference between the 
mean %PGK-1A values for mice of the reciprocal AT29 
crosses, although the low sample number may have produced 
a false result. Hence, for simplicity the data were pooled 
for comparison with other crosses. The mean value for 
(AT29-ENU.556xCBA) PI mice with 26% PGK-1A was 
significantly lower than that for PI mice of the 
reciprocal cross with 47% PGK-1A and than that for PII 
mice with 72% PGK-1A and also than the mean value of the 
AT29 control mice with 58% PGK-1A.
The mean value for PHI mice with 26% PGK-1A was 
significantly lower than that for PIV mice with 70% PGK-1A 


























































































































































64 52 71 72 55 42
 
































































































Table 3.6 BLOOD : Fl COMPARISONS (>24 day mice) showing 

















each cell contains values of P and the mean %PGK-1A values 
~=(AT29xCBA)/(CBAxAT29) control pooled mean %PGK-1A values
Blood Leukocytes
With reference to table 3.19 and 3.20 at the end of 
Chapter 3 in >24 day mice, for white blood cells, the mean 
value for PI mice was 17% PGK-1A which was much lower than 
that for PII mice with 74% PGK-1A and the AT29 control 
mice with 38% PGK-1A. Similarly, the mean value for white 
blood cells of PHI mice was 20% PGK-1A which was lower 
than that for PIV mice with 79% PGK-1A and the AT29 
control mice with 57% PGK-1A. The mean %PGK-1A value for 
white blood cells of PII and PIV mice was higher than that 
for the AT29 control mice, given above.
For blood platelets of PI mice, the mean was 33% PGK-1A 
which was lower than that for PII mice with a mean value 
of 70% PGK-1A. PHI mice had a mean value of 24% PGK-1A 
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With reference to summary table 3.7 and the comparisons 
table 3.8, there was no significant difference between the 
mean %PGK-1A values for mice of the reciprocal AT29 
crosses. Hence, the data were pooled for comparison with 
other crosses. The mean value for (AT29-ENU.556xCBA) PI 
mice with 27% PGK-1A was significantly lower than that for 
PI mice of the reciprocal cross with 44% PGK-1A and that 
for PII mice with 73% PGK-1A and the AT29 control mice 
with 57% PGK-1A.
Similarly, for CBA/N Fls, the mean value for PHI mice 
with 34% PGK-1A was significantly lower than that for PIV 
mice with 80% PGK-1A and that for the AT29 control mice 
with 62% PGK-1A.
Table 3.8 SPLEEN: Fl COMPARISONS (>24 day mice) showing 

















each cell contains values of P and the mean %PGK-1A values 
~= (AT29xCBA)/(CBAxAT29) control pooled mean %PGK-1A values
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Splenic Leukocytes
With reference to tables 3.21-3.29 at the end of Chapter 
3 for >24 day mice, the mean value for splenic white blood 
cells of PI mice was 24% PGK-1A which was lower than that 
of PII mice with 74% PGK-1A. The mean value for splenic 
white blood cells of PHI mice was 37% PGK-1A which was 
lower than that of PIV mice with 84% PGK-1A.
Sorted material
Without carrying out comparison tests, there were obvious 
differences between the mean %PGK-1A values for sorted 
splenic cell populations of ENU-mutant and control mice. 
Note that the mean %PGK-1A values for either T or B cells 
were obtained by pooling %PGK-1A values of their subsets. 
For example, the mean %PGK-1A value for splenic B cells
^L -_-i
was derived by pooling %PGK-1A values of B220 and Thyl.2 
cells sorted by flow cytometry (Table 3.21, for >24 day 
mice) .
The mean value for splenic B cells of PI mice was 2% PGK- 
1A which was lower than that of the AT29 control mice with 
51% PGK-1A and than that of PII mice with 68% PGK-1A. 
Similarly, the mean value for splenic T cells of PI mice 
was 2% PGK-1A which was lower than that of the AT29 
control mice with 48% PGK-1A and than that of PII mice 
with 69% PGK-1A. However, high scattering cells of PI 
females had a mean value of 43% PGK-1A.
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The mean value for splenic B cells of PIV mice was 92% 
PGK-1A and that of the AT29 control mice was 78% PGK-1A 
which were both greater than that of PHI mice with 50% 
PGK-1A. Similarly, for splenic T cells, the mean value of 
PIV mice was 72% PGK-1A and that of the AT29 control mice 
was 65% PGK-1A which were both greater than the mean value 
of PHI mice with 21% PGK-1A. The mean value for high 
scattering cells of PHI mice was 48% PGK-1A.
The mean %PGK-1A values for B and T cells of PII and PIV 
mice were higher than those of the AT29 control mice which 




Refer to summary table 3.9 and the comparisons table 3.10. 
There was no significant difference between the mean %PGK- 
1A values for mice of the reciprocal AT29 or AT29-ENU.556 
crosses. Hence, the data for the respective groups were 
pooled for comparison with other crosses. The mean value 
for PI mice with 13% PGK-1A was significantly lower than 
that for PII mice with 68% PGK-1A and the AT29 control 
mice with 59% PGK-1A.
Similarly, the mean value for PHI mice with 14% PGK-1A 
was significantly lower than that for PIV mice with 70% 
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Table 3.10 THYMUS : Fl COMPARISONS (>24 day mice) showing 













each cell contains values of P and the mean %PGK-1A values 
~=(AT29xCBA)/(CBAxAT29) control pooled mean %PGK-1A values 
#=(AT29-ENU.556xCBA)/(CBAxAT29-ENU.556)PI pooled mean 
%PGK-1A values
Sorted material
Refer to tables 3.30-3.38 at the end of Chapter 3, for 
>24 day mice. As for sorted splenic material, the mean 
%PGK-1A value for thymocytes was obtained by pooling the 
%PGK-1A values of the thymocyte subsets sorted by flow 
cytometry. There were obvious differences without 
comparison tests between the mean %PGK-1A values for 
thymocytes of ENU-mutant and control mice.
The mean value for thymocytes of the AT29 control mice was 
53% PGK-1A and that of PII mice was 63% PGK-1A which were 
both greater than that of PI mice which was 4% PGK-1A. 
Similarly, the mean value for thymocytes of the AT29 
control mice was 54% PGK-1A and that of PIV mice was 71% 
PGK-lA which were both higher than that of PHI mice which 
was 4% PGK-lA. The mean %PGK-1A values for thymocytes of 
PII and PIV mice were higher than that for the AT29 
control mice which was also the case for T cells of lymph
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node.
With reference to table 3.30 and 3.31, for >24 day mice, 
there was little variation in the PGK-1 expression between 




With reference to summary table 3.11 and the comparisons 
table 3.12, there was no significant difference between 
the mean %PGK-1A values for mice of the reciprocal AT29 
crosses. Hence, the data of the reciprocal crosses were 
pooled for comparison with other crosses. The mean value 
for (AT29-ENU.556xCBA) PI mice with 13% PGK-1A was 
significantly lower than that for PI mice of its 
reciprocal cross with 33% PGK-1A and than that for both 
PI I mice with 64% PGK-1A and the AT29 control mice with 
62% PGK-1A.
The mean value for PHI mice with 23% PGK-1A was 
significantly lower than that for PIV mice with 77% PGK-1A 
and the AT29 control mice mice with 62% PGK-1A.
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Table 3.12 LYMPH NODE : Fl COMPARISONS (>24 day mice) 


















each cell contains values of P and the mean %PGK-1A values 
~=(AT29xCBA)/(CBAxAT29) control pooled mean %PGK-1A values
Sorted material
With reference to Tables 3.39-3.47 at the end of Chapter 
3 for >24 day mice, the mean %PGK-1A value for either B 
or T cells was obtained by pooling the %PGK-1A values of 
their subsets sorted by flow cytometry, as discussed 
above. There were obvious differences between the mean 
%PGK-1A values for lymph node cell subsets of ENU-mutant 
and control mice, without comparisons tests.
The mean value for B cells of PI mice was 3% PGK-1A which 
was lower than that of PII mice with 60% PGK-1A and also 
that of the AT29 control mice with 52% PGK-1A. Similarly, 
the mean value for T cells of PI mice was 2% PGK-1A which 
was lower than that of PII mice with 62% PGK-1A and than 
that of the AT29 control mice with 50% PGK-1A. 
Similarly, the mean value for B cells of PHI mice was 
32% PGK-1A which was lower than that of PIV mice with 92% 
PGK-1A. The mean value for T cells of PHI mice was 11%
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PGK-1A which was lower than that of PIV mice with 72% PGK- 
1A and also lower than that of the AT29 control mice with 
63% PGK-1A. The mean %PGK-1A value for T cells of PIV mice 
and for B and T cells of PII mice were higher than the 
values of the AT29 control mice, given above.
Bone marrow 
Unsorted material
With reference to summary table 3.13 and comparisons 
table 3.14, there was no significant difference between 
the mean %PGK-1A values for mice of the reciprocal AT29 
and AT29-ENU.556 crosses. Hence, the respective data were 
pooled for comparison with other crosses. The mean value 
for PI mice with 40% PGK-1A was significantly lower than 
that for PII mice with 68% PGK-1A and than the AT29 
control mice with 57% PGK-1A.
The mean value for PHI mice with 40% PGK-1A was 
significantly lower than that for PIV mice with 70% PGK-1A 
and than that for the AT29 control mice with 57% PGK-1A.
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Table 3.14 BONE MARROW : Fl COMPARISONS (>24 day mice) 











each cell contains the values of P and the mean values 
~=(AT29xCBA)/(CBAxAT29) control pooled mean %PGK-1A values 
#=(AT29-ENU.556xCBA)/(CBAxAT29-ENU.556) PI pooled mean 
%PGK-1A values
Sorted material
With reference to Tables 3.48-3.58 at the end of Chapter 
3 in >24 day mice, there were obvious differences without 
comparisons tests between the mean %PGK-1A values for 
sorted bone marrow cells of ENU-mutant and control mice. 
For B cells the mean value of PI mice was 10% PGK-1A 
which was lower than that of the AT29 control mice with a 
value of 47% PGK-1A and than that of PII mice with a 
value of 68% PGK-1A. For non-B (B220 ) cells, the mean 
value for PI mice was 18% PGK-1A which was lower than 
that for the AT29 control mice with 50% PGK-1A and than 
that for PII mice with 50% PGK-1A. However, for high 
scattering cells of PI mice the mean value was 52% PGK-1A, 
that of the AT29 control mice was 59% PGK-1A and that of 
PII mice was 50% PGK-1A.
The mean value for bone marrow B cells of PHI mice was 
22% PGK-1A which was lower than that of the AT29 control
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mice with 62% PGK-1A and than PIV mice with 70% PGK-1A. 
The mean value for non-B (B220 ) cells of PHI mice was 
13% PGK-1A which was lower than that of the AT29 control 
mice with 56% PGK-1A and than PIV mice with 57% PGK-1A. 
However, for high scattering cells of PHI mice the mean 
value was 39% PGK-1A and that of the AT29 control mice was 
52% PGK-1A and that of PIV mice was 73% PGK-1A. The mean 
%PGK-1A value for B cells of PII and PIV mice was higher 
than that for the AT29 control mice which is consistent 
with the data for B cells of other tissues.
The following table 3.15 summarises data presented in 
Section I. It gives the %PGK-1A modal range (mean ± 
standard deviation) and the mean %PGK-1A values for 
unsorted tissues of the mice of the nine crosses. Values 
underlined refer to tissues affected by the ENU mutation. 
It shows the variation of PGK-1A expression between 
tissues and between individual mice within a cross and 
the PGK-1A variation between mice of the nine crosses. 
(CBAxCBA-Pgk-la) mice are included as non-AT29 controls to 




Table 3.15: summary table for Section I showing the %PGK- 
1A modal ranges and the mean %PGK-1A values for>24 day 
mice
%PGK-1A 
BRAIN MUSCLE BLOOD SPLEEN NODE THYMUS MARROW
(AT29XCBA) 59-79 51-79 62-66 57-63 59-77 57-69 53-65
69 61 64 60 68 63 59
(CBAXAT29) 48-62 39-53 45-59 48-60 51-59 50-60 46-62
55 46 52 54 55 55 54
Pla 50-76 0-28 13-39 19-35 3-23 2-25 29-51
63 14 26. 22 1! 13. 40
PIb 58-70 2-24 37-57 37-51 32-34 0-24 36-42
64 11 47 44 33. 9 29.
PII 55-79 58-78 66-78 65-81 52-76 55-81 61-75 
67 68 72 73 64 68 68
(AT29XCBA/N) 57-69 49-63 55-65 56-68 58-66 51-63 47-67
60 56 59 62 62 57 57
PHI 52-76 5-27 13-39 24-44 13-33 6-22 32-48
64 16. 2£ 14 21 14. 40
PIV 50-76 45-81 61-79 74-86 69-85 59-81 60-80
63 63 70 80 77 70 70
(CBAx 62-76 58-70 58-84 62-82 59-79 55-77 53-79 
CBA-Pgk-la) 69 64 71 72 69 66 66
a=(AT29-ENU.556xCBA), b=(CBAxAT29-ENU.556)
tissues affected by the ENU mutation are underlined
Results of comparisons tests revealed no significant 
difference between the mean %PGK-1A values when the AT29 X 
chromosome was maternally-derived (CBAxAT29) than when 
the X chromosome was paternally-derived (AT29xCBA) for 
all tissues.
There was a significant difference between the mean 
%PGK-1A values for PI mice of the reciprocal crosses in 
which the mean %PGK-1A values were lower for blood, spleen
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and lymph node of Pla mice. However, there was no 
significant difference between the mean %PGK-1A values for 
PI mice of the reciprocal crosses for brain, skeletal 
muscle, thymus and bone marrow. Hence, variation between 
Pla and PIb mice of the reciprocal crosses appeared to be 
tissue-specific.
Comparing tissues affected by the ENU-mutation, those 
with the lowest mean %PGK-1A values were skeletal muscle, 
lymph node and thymus of Pla, PIb and PHI mice.
SECTION II
Assessment Of The Effect Of The ENU Mutation With Age
The effect of the ENU mutation with age was assessed in 
various tissues and sorted cell populations by analysis of 
the X-chromosome inactivation patterns in mice derived 
from eight of the crosses discussed above, excluding mice 
of the CBA x CBA-Pgk-la cross. The mean %PGK-1A values 
were plotted against age to produce the developmental 
profiles of the mice studied. Each point on the graph for 
whole tissues is a mean %PGK-1A value of mice of the same 
age. For sorted cell populations, individual %PGK-1A 
values were plotted against age. Profiles provide a crude 
indication of PGK-1 variation with age, complicated by 
individual variation. It should be noted that, for thymus 
and lymph node, the amount of material available for PGK- 
1 analysis decreases with age. Hence, as reflected in the 
data, priority was given to sorted material, rather than
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to whole tissue extracts. Developmental profiles are 
presented at the end of Chapter 3 (Fig. 3.2-3.28) .
With reference to the developmental profiles presented at 
the end of this chapter, the interpretation of the 
variation in the mean %PGK-1A values with age was 
difficult possibly due to variation between individuals 
within a cross. Hence, the effect of the ENU mutation 
with age was assessed in selected tissues of PI and PII 
mice by correlation analysis of PGK-1 expression with age, 
as discussed in Chapter 2.
For brain, skeletal muscle, blood and lymph node of PI 
and PII mice, the correlation coefficient, r is given 
which quantifies the degree of linear association between 
the mean %PGK-1A values and age. The correlation 
coefficient measures the direction and strength of a 
linear association. Positive values imply a direct 
association and negative values imply an indirect 
association. The value of the correlation coefficient 
gives a measure of the strength of the linear association. 
A correlation coefficient of +1 or -1 implies a perfect 
linear association and the closer r approaches +1 or -1, 
the stronger is the association between the mean %PGK-1A 
values and age. A correlation coefficient of 0 implies no 
linear association and when r approaches 0 the weaker is 
the association between the mean %PGK-1A values and age.
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Non Haematopoietic Tissues 
Brain
The mean %PGK-1A values for brain of all crosses was 
variable. Peaks and troughs of each profile were probably 
attributable to variation between individuals within a 
cross and not to differences in age as they occurred 
randomly, at different time points. Despite the variation 
in the mean %PGK-1A values, the level of expression of 
PGK-1A for PI and PHI mice was similar to that for PII, 
PIV and the AT29 control mice (Fig. 3.2 and 3.3).
The correlation between mean %PGK-1A values and age was 
assessed in PI and PII mice of age 0-100 weeks. For PII 
mice r=-0.233 with n=7 and for PI females r=0.051 with 
n=24. Although there was a difference in the correlation 
coefficients of PI and PII mice which may be attributable 
to the small sample size for PII mice, the correlation 
coefficients approached 0 which implies that the 
association between the mean %PGK-1A values and age for 
brain of PI and PII mice was relatively weak (see below). 
This suggests that the mean %PGK-1A values did not change 
with age, as suggested above (Fig 3.2).
Skeletal muscle
There was a decline in the mean %PGK-1A values with age 
for PI and PHI mice. The greatest decrease in these 
values appeared to occur during the first 12 weeks of age,
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after which there appeared to be a relatively gradual 
decline in the mean %PGK-1A values. The variation in PGK- 
1A expression for PII, PIV and the AT29 control mice did 
not appear to alter with age and probably reflected 
individual variation (Fig. 3.4 and 3.5).
The correlation between the mean %PGK-1A values and age 
was assessed in PI and PII mice of age 0-100 weeks and 
also in PI mice of age 0-11 weeks and 14-100 weeks to 
assess whether the greatest decrease in the mean %PGK-1A 
values occurred during the first 12 weeks of age, as 
described above. For PII mice of age 0-100 weeks r=0.032 
and for PI mice of age 0-100 weeks r=-0.264. For PI 
mice of age 0-11 weeks r=-0.694 and for PI mice of age 14 
100 weeks r=0.100.
Comparing the correlation coefficients for skeletal 
muscle of PI and PII mice of age 0-100 weeks revealed 
a relatively strong indirect association between the mean 
%PGK-1A values and age for skeletal muscle of PI mice. 
There was also a relatively strong indirect association 
between the mean %PGK-1A values and age for skeletal 
muscle compared with brain of PI mice of the same age 
group. Hence, the results suggest that for skeletal 
muscle of PI mice the mean %PGK-1A values declined 
with age.
Comparison of the correlation coefficients for the two 
age groups for skeletal muscle of PI mice suggests a
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stronger indirect association between the mean %PGK-1A 
values and age for mice of age O-ll weeks than for mice 
of the 14-100 week age group. This suggests that the 
decline in the mean %PGK-1A values was greater during the 
period 0-11 weeks than during the 14-100 week period which 
relates to the information derived from the developmental 
profile, as discussed above (Fig 3.4).
Haematopoietic tissues 
Blood
The pattern of PGK-1A expression with age for blood (Fig. 
3.6 and 3.7) of PI and PHI mice was similar to that for 
skeletal muscle (Fig. 3.4 and 3.5) where the greatest 
decrease in the mean %PGK-1A values appeared to occur 
during the first 12 weeks of age, followed by a relatively 
gradual decrease with age. The variation in PGK-1A 
expression for PII, PIV and the AT29 control mice did not 
appear to alter with age and was probably due to 
individual variation.
The correlation between the mean %PGK-1A values and age 
was assessed in PI and PII mice of age 0-100 weeks and 
also in PI mice of age 0-11 weeks and 14-100 weeks to 
assess whether the decrease in the mean %PGK-1A values 
was greater during the first 12 weeks as described above. 
For PII mice of age 0-100 weeks r=-0.384 and for PI mice 
of age 0-100 weeks r=-0.668. For PI mice of age 0-11 weeks 
r=-0.571 and for PI mice of age 14-100 weeks r=-0.574.
133
Comparing the correlation coefficients for blood of PI 
and PII mice of age 0-100 weeks revealed that the decline 
in the mean %PGK-1A values with age for PI mice was 
relatively greater than that for PII mice. In fact, this 
decline in the mean %PGK-1A values with age for blood of 
PI mice was rather striking when compared to brain of PI 
mice of the same age group.
Comparing the correlation coefficients for blood of PI 
mice of age 0-11 weeks with PI mice of age 14-100 weeks 
showed that there was little difference in the degree of 
the decline in the mean %PGK-1A values with age. This 
differed from skeletal muscle in which there was a 




The profile for PI mice demonstrated a decline in the 
mean %PGK-1A values with age and that for PHI mice gave 
an inconclusive result. The variation in the mean %PGK-1A 
values for PII, PIV and AT29 control mice probably 
reflected individual variation. Note that lymph node was 
only collected in sufficient quantities for PGK-1 analysis 
from mice of age >15 days that is 2.57 weeks on the 
profiles (Fig 3.18 and 3.19).
The correlation between the mean %PGK-1A values and age
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was assessed in lymph node of PI mice of age 2.57-100 
weeks and also of age 2.57-11 weeks and age 14-100 
weeks to assess whether the level of PGK-1A expression 
altered with age. There was no correlation analysis made 
for lymph node of PII mice as the sample number was low 
(n=4). For the 2.57-100 week period r=-0.403 and for 
the 2.57-11 week period r=0.059 and for the 14-100 week 
period r=-0.403. The results demonstrate a relatively 
strong indirect association between the mean %PGK-1A 
values and age for lymph node of PI mice compared to brain 
of PI mice of age 0-100 weeks, implying that the mean 
%PGK-1A values declined over the 100 week period.
Comparing the correlation coefficients of the period up 
to 11 weeks with that from 14-100 weeks suggests that the 
decline in the mean %PGK-1A values was more pronounced 
after 14 weeks of age. This differs from the correlation 
analysis for skeletal muscle which implied that the 
decline in the mean %PGK-1A values was more pronounced 
during the 0-11 week period.
Sorted material
The profile for lymph node B and T cells of PI mice 
demonstrated a decline in the %PGK-1A values during the 
100 week period. For B and T cells there appeared to be a 
marked decline in the level of PGK-1A expression at around 
12 weeks of age (Fig. 3.20 and 3.21).
For lymph node T cells of PHI mice the %PGK-1A values
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appeared to remain at a constant level from age 12 weeks 
(Fig. 3.23 and 3.24) . The profile for the B cell
populations of Pill mice was more difficult to interpret
+ 
(Fig. 3.22). The profile for B220 cells appeared to
decrease at about 12 weeks of age and increased by 60 
weeks of age. This result is consistent with the profile 
for splenic and bone marrow B cells (Fig. 3.12 and Fig 
3.28). However, it appeared that the %PGK-1A values of 
other lymph node B cell populations of PHI mice were 
at a constant level from 12-60 weeks old.
Spleen
Unsorted material
The mean %PGK-1A values for PI mice appeared to decrease 
gradually with age. The profile for PHI mice demonstrated 
this pattern up to 12 weeks of age, after which there was 
an increase in the mean %PGK-1A values with age. The 
profiles for PII, PIV and the AT29 control mice did not 
demonstrate a decline in the mean %PGK-1A values with age 
but the profiles were variable which was probably due to 
individual variation (Fig. 3.8 and 3.9).
Sorted material
The profiles for splenic B and T cell populations of PI 
mice demonstrated a decline in the %PGK-1A values with 
age, particularly during the first 3 weeks and around 
12 weeks of age (Fig. 3.10 and 3.11) .
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For splenic T cells of PHI mice there was unbalanced 
expression of PGK-1 (Fig. 3.13). However, the level of 
PGK-1A expression for splenic T cells of PI mice was 
generally higher than that for thymocytes (Fig. 3.17) and, 
unlike thymus but similar to lymph node (Fig. 3.23 and 
3.24), appeared to have a constant level of PGK-1A 
expression with age, following a decrease during the first 
3 weeks.
For splenic B cells of PHI mice there was an increase in 
the %PGK-1A values from 12-60 weeks of age (Fig 3.12). 
This is consistent with the profile for B cells of bone 
marrow (Fig. 3.28) and the profile for some B cells of 
lymph node of PHI mice (Fig. 3.22) .
Thymus
Unsorted material
There appeared to be a relatively steep decline in the 
mean %PGK-1A values during the first 12 weeks followed by 
a relatively gradual decline after 12 weeks of age for PI 
and PHI mice but not for Pll, PIV or the AT29 control 
mice where variation in PGK-1A expression appeared to 
reflect individual variation and not variation with age 
(Fig. 3.14 and 3.15) .
Sorted material
The pattern for thymocyte populations of PI and PHI
mice reflected the pattern seen for unsorted thymus, where
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there was a relatively steep decrease in the %PGK-1A 
values during the first 12 weeks of age and a relatively 
gradual decrease after 12 weeks of age. There did not 
appear to be a difference in the level of PGK-1A 
expression between thymocyte subsets. All thymocytes of 
ENU-mutant crosses eventually expressed very low %PGK-1A 
values (Fig. 3.16 and 3.17).
Neonatal liver and Bone marrow 
Unsorted material
Fig. 3.25 and 3.26 shows the developmental profile for 
both neonatal liver in PI and PHI mice up to 3 days old 
and for bone marrow in all mice after 15 days old as it 
was not possible to collect bone marrow material in 
sufficient quantities for PGK-1 analysis from mice younger 
than 15 days old. The mean %PGK-1A values for bone marrow 
of PI and PHI mice were lower than those for PI I, PIV and 
the AT29 control mice and there appeared to be a slight 
decline in the level of PGK-1A expression with age.
Sorted material
Fig. 3.27 and 3.28 shows the developmental profile for 
neonatal liver lymphocytes from mice up to 3 days old and 
for bone marrow lymphocytes from mice of >15 days old. The 
profiles for the sorted cell populations for neonatal 
liver and bone marrow appeared to be consistent with the 
result for unsorted bone marrow. Taking the %PGK-1A values
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for both neonatal liver lymphocytes and bone marrow B and 
non-B (B220 ) lymphocytes of PI mice, there appeared to be 
a relatively steep decline in the profile during the first 
12 weeks after which there was a relatively gradual 
decline up to 100 weeks old (Fig. 3.27) .
Taking the %PGK-1A values for both neonatal liver 
lymphocytes and bone marrow B and non-B (B220 ) 
lymphocytes of PHI mice there appeared to be a relatively 
steep decline in the profile during the first 12 weeks 
after which the %PGK-1A values appeared to increase up to 
60 weeks of age (Fig. 3.28) . This profile is consistent 
with that observed for splenic B cells (Fig. 3.12) and 
some lymph node B cells (Fig.3.22) of PHI mice.
Comparisons Of The Effect Of The ENU Mutation In 
Various Age Groups
In the previous section the effect of the ENU mutation 
with age in all tissues of mice was assessed using the 
developmental profiles given at the end of this chapter 
and correlation analysis for brain, skeletal muscle, blood 
and lymph node of PI and PII mice. This section examines 
these results more closely by making statistical 
comparisons of the effect of the ENU mutation in selected 
tissues from mice of post-natal age: <15 day, 15-24 day 
and >24 day. The level of PGK-1A expression was determined 
in all whole tissues except brain and in sorted cell 
populations of PI mice and also in blood, spleen, lymph
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node and bone marrow and in sorted B cells of PHI mice. 
Differences between the mean %PGK-1A values of the various 
age groups were recognised as significant by Student's t- 
test. Only statistical results that were significant are 
presented in Tables 3.16 and 3.17.
Skeletal muscle
There was a significant difference between the mean values 
for <15 day PI mice with 33% PGK-1A and 15-24 day PI mice 
with 19% PGK-1A. Hence, only <15 day PI mice were compared 
with >24 day PI mice (Table 3.3 and 3.16) .
In the >24 day group there was bimodal distribution of 
%PGK-1A values. Hence, the group was divided into PI mice 
with <15% PGK-1A which had a mean value of 1% PGK-1A and 
>15% PGK-1A which had a mean value of 26% PGK-1A and each 
sample compared separately with <15 day PI mice with a 
mean value of 33% PGK-1A. There was a significant 
difference between the mean value for <15 day PI mice and 
the mean value for each group of the >24 day PI mice, 




There was a significant difference between the mean values 
for <15 day PI mice with 55% PGK-1A and 15-24 day PI mice
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with 42% PGK-1A. Similarly, there was a significant 
difference between the mean values for <15 day PHI 
mice with 59% PGK-1A and 15-24 day PHI mice with 44% PGK- 
1A. Hence, only <15 day PHI mice were compared with >24 
day PHI mice. Both PI and PHI >24 day mice had mean 
values of 26% PGK-1A which were significantly lower than 
the mean values for PI and PHI <15 day mice, given above 
(Table 3.5 and 3.16) .
Spleen
Unsorted material
There was no significant difference between the mean 
values for <15 day PI mice with 41% PGK-1A and 15-24 day 
PI mice with 30% PGK-1A. Similarly, there was no 
significant difference between the mean values for <15 day 
PHI mice with 52% PGK-1A and 15-24 day PHI mice with 45% 
PGK-1A. Hence, values of all <24 day PI or PHI mice were 
pooled and compared with >24 day PI or PHI mice. The mean 
values for PI and PHI >24 day mice of 27% and 34% PGK-1A, 
respectively were significantly lower than those for PI 
and PHI <24 day mice of 36% and 51% PGK-1A, respectively 
(Table 3.16, 3.21, 3.22) .
Sorted material
For splenic high scattering cells of <24 day PI mice, 
there was a mean value of 46% PGK-1A compared to >24 day 
PI mice with a single value of 43% PGK-1A. There were
significant differences between the mean values for <24 
day PI mice and >24 day PI mice for all splenic B and T 
cells where <24 day PI mice had the higher mean %PGK-1A 
values {Table 3.17 and 3.21).
For splenic B cells of PHI mice, there was a significant 
difference between the mean % PGK-1A values for <24 day 
and >24 day with the latter group having the higher value 
(Table 3.17 and 3.22) .
Bone marrow 
Unsorted material
It was not possible to successfully obtain marrow from <15 
day mice in sufficient quantities for PGK-1 analysis 
therefore, 15-24 mice were compared with >24 day mice. 
There was no significant difference between the mean 
values for bone marrow of 15-24 day PI mice with 35% PGK- 
1A and >24 day PI mice with 40% PGK-1A. For bone marrow of 
PHI mice, there was a single value of 42% PGK-1A for 15- 
24 day mice compared with the mean value of 40% PGK-1A for 
>24 day mice (Table 3.48 and 3.50).
Sorted material
For high scattering cells of bone marrow of PI mice there 
was a single value of 62% PGK-1A for 15-24 day mice 
compared with the mean value of 44% PGK-1A for >24 day 
mice. For B cells of bone marrow of PI mice there was a 
single value for 15-24 day mice of 41% PGK-1A compared
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with the mean value for >24 day mice of 10% PGK-1A. For 
non-B (B200 ) cells of bone marrow of PI mice there was a 
single value for 15-24 day mice of 48% PGK-1A compared 




It was not possible to successfully obtain lymph node 
material from <15 day mice in sufficient quantities for 
PGK-1 analysis therefore, 15-24 day mice were compared 
with >24 day mice. For PI mice, there was no significant 
difference between the mean values of 15-24 day mice with 
21% PGK-1A and >24 day mice with 13% PGK-1A. For lymph 
node of PHI mice, there was a single value for 15-24 day
mice of 28% PGK-1A compared with the mean value for >24 
day mice of 23% PGK-1A (Table 3.39, 3.40).
Sorted material
The mean %PGK-1A value for lymph node T cells of PI mice 
aged 15-24 day was significantly higher than the mean 
%PGK-1A value for >24 day mice (Table 3.17 and 3.39).
Thymug
Unsorted material
For thytnus there was no significant difference in the mean
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values between <15 day PI mice with 29% PGK-1A and 15-24 
day PI mice with 18% PGK-1A. Hence, all mean %PGK-1A 
values for <24 day PI mice were pooled to give a mean 
value of 23% PGK-lA and compared with >24 day PI mice. The 
mean value for <24 day PI mice was 23% PGK-lA which was 
significantly greater than the mean value for >24 day PI 
mice with 13% PGK-lA (Table 3.16 and 3.30).
Sorted material
The mean %PGK-1A value for thymocytes of <24 day PI mice 
was significantly greater than the mean %PGK-1A value of 
>24 day PI mice (Table 3.17 and 3.30) .
Comparisons Of The Effect Of The ENU Mutation Between 
Neonatal Liver Lymphocytes and B and T Cells
The level of PGK-lA expression for 1-3 day neonatal liver 
lymphocytes (NLL) was compared with that for B and T cells 
of PI mice and B cells of PHI mice of age <24 day and >24 
day to identify the stage at which the ENU mutation takes 
effect. Differences in the mean %PGK-1A values between NLL 
and B and T cells were recognised as significant by 
Student's t-test. Only statistical results that were 
significant are presented in Table 3.18.
Sorted material
Neonatal liver compared with spleen
Refer to table 3.18, 3.21 and 3.49. There was a
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significant difference between the mean values for NLL 
with 44% PGK-lA and splenic T cells of <24 day PI mice 
with 33% PGK-lA and also >24 day PI mice with 2% PGK-lA.
There was a significant difference between the mean values 
for NLL with 44% PGK-lA and splenic B cells of >24 day PI 
mice with 2% PGK-lA but not between NLL and splenic B 
cells of <24 day PI mice with 35% PGK-lA.
There was no significant difference between the mean 
values for neonatal liver high scattering cells with 54% 
PGK-lA and splenic high scattering cells of <24 day PI 
mice with 46% PGK-lA and for splenic high scattering cells 
of >24 day PI mice there was a single value of 43% PGK-lA.
There was not a significant difference between the mean 
values for NLL with 44% PGK-lA and splenic B cells of <24 
day PHI mice with 25% PGK-lA and also splenic B cells of 
>24 day PHI mice with 50% PGK-lA (Table 3.22 and 3.51) .
Neonatal liver compared with bone marrow
Refer to table 3.18, 3.48 and 3.49. There was a 
significant difference between the mean values for NLL 
with 44% PGK-lA and bone marrow B cells of >24 day PI 
mice with 10% PGK-lA. For bone marrow B cells of <24 
day PI mice there was a single value of 41% PGK-lA.
There was not a significant difference between the mean 
values for neonatal liver high scattering cells with 54%
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PGK-1A and bone marrow high scattering cells of >24 day PI 
mice with 44% PGK-1A. For bone marrow high scattering 
cells of <24 day PI mice there was a single value of 62% 
PGK-1A (Table 3.18) .
For PHI mice, there was a significant difference between 
the mean values for NLL with 44% PGK-1A and bone marrow B 
cells of >24 day mice with 22% PGK-1A (Table 3.18, 3.50, 
3.51) .
Neonatal liver compared with lymph node
The mean value of NLL with 44% PGK-1A was significantly 
higher than that for lymph node B cells of >24 day PI mice 
with 3% PGK-1A and than that for lymph node T cells of <24 
day PI mice with 16% PGK-1A and also than that for lymph 
node T cells of >24 day PI mice with 2% PGK-1A (Table 
3.18, 3.39, 3.49) .
There was not a significant difference between the mean 
values for NLL with 44% PGK-1A and lymph node B cells of 
>24 day PHI mice with 32% PGK-1A (Table 3.40 and 3.51) .
Neonatal liver compared with thymus
The mean value of NLL with 44% PGK-1A was significantly 
higher than that for thymocytes of <24 day PI mice with 
33% PGK-1A and than that for thymocytes of >24 day PI mice 
with 4% PGK-1A (Table 3.18, 3.30, 3.49).
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TABLE 3.16: The Effect Of The ENU Mutation With Age For 
Unsorted Tissues
AGE COMPARISONS
<15day v 15-24day <15day v >24day <24day v >24day
PI <15%PGK-1A >15%PGK-1A
MUSCLE Mil v 19) ** * /
(31 v 1) (33 v 26)
PI *(££ v 42) ** (55 v 26) 
BLOOD /









** (51 v 26)
* (35 v 27)
/ 
** (51 v 34)
/ * (21 v 13)
The table gives for unsorted tissue the significance level 
*=P<0.05, **=P<0.01 and the mean %PGK-1A values for 
younger v older PI and PHI mice
Note there is bimodal distribution of %PGK-1A values for 
muscle of >24 day PI mice
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TABLE 3.17: The Effect Of The ENU Mutation With Age For 
Sorted Cell Populations
AGE COMPARISONS OF MICE 
PI PHI
T cells B- ** (35 v 4) / 
T+ ** (17 v 0) / 
SPLEEN--------------------------------------------------
B+ ** (16 v 2) B+ * (24 v 50) 
B cells T- ** (15 v 2) /
1C T+ ** (13 v 2) / 
THYMUS
M T+ * (26 v 3) / 
all thymocytes mean# ** (33 v 2) /
L.NODE T cells mean# ** (16 v l) /
The table gives for sorted cells the significance level 
*=P<0.05, **=P<0.01 and the mean %PGK-1A values for 
younger v older PI and PHI mice
note the age comparisons for spleen, thymus is <24 day v 
>24 day and l.node is 15-24 day v >24 day
key to cell types (see tables 3.21,3.22,3.30,3.39)
+ 
staining for antigen: for B cells (B220 ) and (Thyl.2 ) ;
+ 
for T cells (Thyl.2 ) and (B220 );
mean# refers to pooled mean %PGK-1A values: for lymph
+ - +or- 
node T cells or thymocytes (Thyl.2 ),(B220 ),(L3T4 ),
+or- 
(Lyt2 )
For thymocytes: IC=inner cortex, M=medulla
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TABLE 3.18: Con^arison Of The Effect Of The ENU Mutation 
In Neonatal Liver Lymphocytes With B and T Cells
NLL v 15-24 or <24day NLL v >24day
B cells / ** (44 v 2) 
PI SPLEEN
T cells * (44 v 33) ** (44 v 2)
PI THYMUS thymocytes * (44 v 33) ** (44 v 4)
PI B cells / ** (44 v 10)
MARROW 
PHI B cells / * (44 v 22)
B cells / ** (44 v 3) 
PI L.NODE
T cells ** (44 v 16) * 
* (44 v 2)
The table gives the significance level *=P<0.05, **=P<0.01 
and the mean %PGK-1A values for NLL v B and T cells. For 
B, T cells, mean %PGK-1A values are pooled values for 
cells defined below.
note the age comparisons are NLL v 15-24 day lymph node 
and NLL v <24 day spleen, thymus; and NLL v >24 day all 
tissues above
a significant result for PHI mice was only obtained for 
comparisons between NLL and B cells of bone marrow of >24 
day mice
key to cell types for pooled mean %PGK-1A values, staining 
for antigen:
+ + - 
Spleen: B cells=B220 , Thyl.2 ; T cells= Thyl.2 , B220 ,
+ + + 
L3T4 Lyt2 ,Lyl (table 3.22)
+ +or- +or- 
thymocytes=Thyl- ? ,L3T4 ,Lyt2 , inner, outer cortex,
medulla (table 3.30)
+ 
marrow: B cells=B220 (table 3.48, 3.50)
+ + - + 
LJ2Q&£: B cells=B220 , Thyl. 2 ; T cells=Thyl. 2 ,B220 , L3T4
+ 
Lyt2 (table 3.39)
NLL=neonatal liver lymphocytes from 1-3 day PI or PHI 
mice, unstained for antigen (table 3.49, 3.51)
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DISCUSSION
Studies of X-chromosome inactivation patterns in cells of 
AT29-ENU.556 mice that were heterozygous for the X-linked 
mutation ENU were used to characterise the phenotypic 
effect of the mutation by delineating the cell lineages 
affected by the mutation, the differential effect of the 
mutation in cell lineages and the effect of the mutation 
with age.
The presence of cells carrying the ENU mutation was 
detected by the expression of the alloenzyme PGK-1A such 
that unbalanced expression of PGK-1A in a cell lineage 
delineated the cells affected by the mutation.
X-chromosome inactivation patterns were studied in cell 
lineages of heterozygous female controls that were 
unaffected by the mutation as there is a wide variation in 
normal random patterns of X-chromosome inactivation 
(comparison tables 3.2, 3.4, 3.6, 3.8, 3.10, 3.12, 3.14) 
and X-chromosome inactivation patterns were also studied 
in brain tissue of AT29-ENU.556 heterozygous females which 
was unaffected by the mutation and was used as a control 
tissue (summary table 3.15).
As the patterns of PGK-1 expression change with age in 
AT29-ENU.556 heterozygous females where there are random 
patterns once inactivation has taken place, the success of 
cells or competition is favoured and not skewed 
inactivation as an explanation for the variations in PGK-l
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expression.
cell lineages affected by the mutation in adult mice
Unbalanced expression of the X chromosome carrying the ENU 
mutation was seen for skeletal muscle and the haemato- 
poietic tissues, blood, spleen, thymus, lymph node and 
bone marrow (comparison tables and summary table 3.15) and 
for the cell subpopulations constituting these tissues 
namely, erythrocytes and B and T cells and possibly 
platelets (table 3.19, 3.20, 3.21, 3.39).
The cells of blood, spleen and bone marrow which were 
defined as high scattering and were distinguished from 
lymphocytes by their relatively high right angle scatter 
being structurally more complex, were not affected by the 
ENU mutation having balanced X-chromosome expression 
similar to that for brain in the same mice (summary table 
3.15) and similar to that for the same cells in control 
mice (table 3.21, 3.48, 3.53, 3.56).
The differential effect of the ENU mutation in tissues and 
cell subpopulations was demonstrated. Skeletal muscle, 
thymus and lymph node were affected by the mutation to a 
greater extent than blood, spleen and bone marrow (summary 
table 3.15). This reflected the presence of cells in these 
tissues that were shown to be unaffected by the mutation 
such as high scattering cells in the spleen and bone 
marrow and also the presence of cells that were affected 
by the mutation to a lesser extent such as erythrocytes in
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whole blood and whole spleen and bone marrow B cells, 
which were predominantly pre-B cells, which tended to 
shift the patterns of PGK-1 expression towards balanced 
ratios (table 3.21, 3.19, 3.48).
It was also demonstrated that the ENU mutation had 
differential effects on cell subpopulations within a cell 
lineage. For example, the patterns of PGK-1 expression for 
bone marrow B cells, which were predominantly pre-B cells, 
showed that the pre-B cells were affected by the mutation 
to a lesser extent than the circulating B cells of the 
spleen and lymph nodes. Unbalanced expression was also 
seen for bone marrow lymphocytes that stained negatively 
for B220 implying the mutation takes effect before the 
pre-B cell stage. These results suggest the mutation has 
subtle differential effects within the B cell lineage 
(Table 3.21, 3.39, 3.48) .
+ + + 
The T cell subsets L3T4 helper, Lyt2 cytolytic, Lyl and
the thymocytes of the cortex and medulla were all 
similarly affected by the mutation (table 3.21, 3.30, 
3.39) .
studies of mice heterozygous for the ENU and xid mutations
Attempts to relate the ENU mutation to a candidate gene 
were made by assessing whether the ENU mutation was an 
allele of xid by studying the X-chromosome inactivation 
patterns in females heterozygous for ENU and xid.
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Studies of X-chromosome inactivation patterns have 
revealed that the defect in xid is intrinsic to B cells 
and that T cells, pre-B cells, other haematopoietic cells 
and non-haematopoietic cells are unaffected by the xid 
mutation (Nahm et al, 1983; Conley et al, 1986; Forrester, 
1986) .
The extent of the mutation, relative to xid which affects 
mature B lymphocytes, was assessed by comparing (AT29- 
ENU.556 x CBA/N) PHI heterozygotes with (AT29 x CBA/N) 
and non-mutant (PIV) control heterozygotes. For PHI 
females, skeletal myocytes and unsorted haematopoietic 
tissues were affected by the mutation, to the same order 
as PI samples (summary table 3.15).
Examination of the constituent populations of the 
haematopoietic tissues revealed a more complex pattern of 
PGK-1 expression in PHI females. For splenic B cells 
there was balanced PGK-1 expression and for lymph node B 
cells there was unbalanced expression of PGK-1 in favour 
of cells carrying xid and, for B cells of bone marrow 
there was unbalanced expression of PGK-1 in favour of 
cells carrying xid (table 3.22, 3.40, 3.50).
If balanced X-chromosome expression depends on whether 
both mutations affect the same population of cells and the 
penetrance of each mutation, then tendency to balanced 
expression for splenic B cells reflects simultaneous 
effects and similar penetrance of both mutations in mature
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B cells.
Discrete differences between lymph node and spleen in the 
degree of PGK-1 expression may reflect tissue differences 
in ratios of B and T cells and not differential effects of 
the mutations on B cells of these tissues because in PI 
females the ENU mutation had an equal effect on B 
lymphocytes of the spleen and lymph node. Unbalanced 
expression of PGK-1 in B cells of bone marrow was 
greater than that for B cells of the spleen and lymph 
node, which implies that the ENU mutation also acts in 
pre-B cells, unlike xid. as B cells of marrow are 
predominantly pre-B cells. These results are consistent 
with previous findings in +/xid heterozygotes which showed 
unbalanced PGK-1 expression in favour of normal B cells in 
the spleen and lymph node and slightly unbalanced PGK-1 
expression in marrow as xid acts in circulating mature B 
cells and not in pre-B cells (Witkowski et al. 1985; 
Forrester et al. 1987) .
For thymocytes, the level of PGK-1 expression was similar 
for PI and PHI females (table, 3.30, 3.31). However, in 
PHI mice, T cells of the lymph node and the spleen, in 
particular, demonstrated unbalanced PGK-1 expression but 
to a lesser degree than those of PI females (table 3.21, 
3.22 and 3.39, 3.40). This is interesting since xid does 
not affect thymocytes and the degree of unbalanced PGK-l 
expression was similar for PHI and PI females (see also 
Forrester, 1986). This suggests that ENU-mutant T cells
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compete less well with normal T cells than they do with 
xid-bearing T cells which might suggest that xid-bearing T 
cells are subtly defective. These results may relate to 
previous findings which showed defective function of a T- 
cell helper subset in CBA/N mice (Bottomly and Hosier, 
1979, Scher, 1982).
effect of the ENU mutation with age
All cells affected by the ENU mutation demonstrated 
variation in PGK-1 expression with age.
The effect of the ENU mutation with age was assessed using 
developmental profiles (Fig. 3.2-3.28) and correlation 
analysis which quantifies the degree of linear association 
between PGK-1A expression and age studied in skeletal 
muscle, blood and lymph node and compared with brain 
and control mice.
For skeletal muscle, blood and lymph node of PI mice, the 
effect of the mutation increased with age, particularly 
between 0-11 weeks for skeletal muscle and between 14-100 
weeks for lymph node. There was little difference in the 
degree of the decline in PGK-1A expression in comparisons 
between the 0-11 week period and the 14-100 week period 
for blood.
T cells and thymocytes
There was a significant difference in the mean %PGK-1A 
values between neonatal liver lymphocytes and T cells of
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the spleen, lymph node and thymocytes of PI mice (table 
3.18). There was a significant difference in the mean 
%PGK-1A values between T cells of pre-adult and adult PI 
mice for spleen, lymph node and thymocytes (table 3.17).
Developmental profiles (Fig. 3.2-3.28) showed that the 
level of PGK-1A expression for thymocytes of PI and PHI 
mice and for T cells of the spleen and lymph node of PI 
mice decreased most noticeably during the first 3 weeks 
and after 12 weeks of age. For PHI mice the level of PGK- 
1A expression of T cells in the spleen and lymph node 
remained relatively constant from 12 weeks of age, after 
decreasing during the first 3 weeks.
Results show that the effects of the mutation in T cells 
were apparent in pre-adult mice and became more pronounced 
with age, except for lymph node and splenic T cells of 
PHI mice which supports the idea that balanced PGK-1 
levels after 12 weeks of age was attributable to the 
presence of xid- and ENU-defective B cells in these 
tissues.
B cells
There was a significant difference in the mean %PGK-1A 
values between neonatal liver lymphocytes and B cells 
of the spleen, marrow and lymph node of PI adult mice and 
of the bone marrow of PHI adult mice (table 3.18)
There was a significant difference in the mean %PGK-1A
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values between B cells of pre-adult and adult mice for 
the spleen of PI and PHI mice (table 3.17) .
Developmental profiles showed that the level of PGK-1A 
expression for B cells of the spleen and lymph node in PI 
mice decreased most noticeably during the first 3 weeks 
and after 12 weeks of age. For PHI mice, the level of 
PGK-1A expression for B cells of the lymph node and the 
spleen, in particular, increased most noticeably after 12 
weeks of age. The level of PGK-1A expression for marrow 
pre-B cells of PI and PHI mice decreased most noticeably 
during the first 3 weeks of age, after which levels were 
constant.
The results demonstrate a significant difference in the 
effect of the mutation between neonatal liver lymphocytes 
and B and T cells of PI mice. In PHI mice, there was a 
shift towards balanced PGK-1 expression after 12 weeks of 
age which suggests that the effects of xid became more 
pronounced during this period. This is consistent with 
previous findings in which xid B cells of adult mice are 
at a greater competitive disadvantage than those of mice 
of age 2-6 weeks (Forrester et al, 1987).
Balanced levels of PGK-1 expression depend on the X- 
chromosome inactivation patterns in the tissue progenitors 
(McLaren, 1972; West, 1975; Fialkow, 1973; Pappaioannou et 
al, 1981; McMahon et al. 1983) and on the nature of the X- 
chromosome controlling element (Xce). Allelic variants of
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this locus and the parental source of the allele influence
a 
X inactivation such that an X chromosome carrying the Xce
allele has a greater chance of being inactivated than an X
b 
chromosome carrying the Xce which, in turn, is more
likely to be inactivated than an X chromosome carrying the
b 
Xce allele (Cattanach, 1972; Johnston and Cattanach,
1981). Moreover, in females heterozygous for Xce (b/c), a
c 
maternally-derived X chromosome bearing the Xce allele is
less likely to be inactivated than a paternally-derived X 
chromosome carrying the same allele (Forrester and Ansell, 
1985). Further evidence for parental effects on X 
chromosome expression and the possible existence of a 
fourth allele for AKR/J mice have been demonstrated 
following studies of their hybrids (Fowlis, 1988; Fowlis 
et al. 1991). In this study variation of PGK-1 expression 
may depend on parental factors where this effect may be 
specific to certain tissues and on the nature of the Xce 
allele which is discussed in Chapter 5.
Variation in PGK-1 expression between tissues within an 
individual may be due to the constituent cells arising 
from different progenitor pools such as haematopoietic 
cells compared with brain or skeletal muscle or tissues 
seeded from the same progenitor pool where sampling events 
concerning seeding of a tissue involved few cells, 
discussed in Chapter 5.
Individual variation within a strain may be reflected by 
bimodal distribution of values of %PGK-1A, such that a
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strain can be divided into separate sample groups (see 
Fig. 3.1 for skeletal muscle) where there is a reasonable 
sample number for each group. Therefore, subtle 
differential effects of the mutation may be difficult to 
recognise due to variation of PGK-1 mosaicism.
Studies of X-chromosome inactivation patterns using 
alloenzyme analysis have delineated distinct cell lineages 
in which the ENU mutation acts, namely, B and pre-B and T 
cells, erythrocytes and possibly platelets and skeletal 
myocytes and also its effect on these lineages with age. 
Variation of PGK-1 expression between affected lineages 
may reflect the differential effects of the mutation and 
variation of PGK-1 expression within a lineage may reflect 
differential effects of the mutation on cells at different 
stages of maturation.
Loci controlling the affected lineages have been mapped to 
the X chromosome. Although several loci that control 
muscle development are X-chromosome specific, it is rather 
interesting to find skeletal muscle affected by the same 
mutation as haematopoietic cells. Two murine X-chromosome 
loci can be eliminated as possibilities. These are the 
muscular mutation mdx. since its effect cannot be detected 
by unbalanced expression of PGK-1 in skeletal muscle 
(Chapman, 1990, personal communication) and the xid 
mutation as, unlike the ENU mutation, it does not 






































































































































































































































































































































































































































Key to tables for blood:
WHOLE = unsorted blood





















































































































































%PGK-1A : (AT29-ENU.556 x CBA) PI



























































































Key to tables and figures for spleen: 
WHOLE = unsorted spleen 
WBC = unsorted white blood cells
HIGH SCATTER = cells with higher right angle scatter than lymphocytes 
antibody staining B = B220, T = Thy 1.2; L4 = L3T4, L2 = Lyt2;
d,b = dull or bright staining
167
%PGK-1A:(AT29-ENU.556 x CBA/N) PHI


























































































%PGK-1A : (AT29 :: CBA)



















%PGK-1A : (CBA x AT29)



















































%PGK-1A : (CBA x AT29-ENU.556)PI 
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Table 3.28
%PGK-lA:(AT2Q-ENU.55o x CBA/N)PIV 











































































































































































































































































































































































































































































































































































%PGK-1A : (AT29-ENU.556 X CBA) Pi













































































Key to tables and figures for THYMUS:
WHOLE = unsorted thymus
I CORTEX, O.CORTEX, MEDULLA = thymocytes within thymic compartments 
antibody staining: T = Thyl.2; L4 = L3T4, L2 = Lyt2; LI = Lyl,
d,b = dull or bright staining
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%PGK-1A:(AT29-ENU.556 x CBA/N) PHI








































































































%PGK-1A : (CBA x AT29) 































%PGK-1A : (CBA x CBA-Pgk-la)



















%PGK-1A : (CBA x AT29-ENU.556) PI
































%PGK-1A : (AT29-ENU.556 X CBA) PI I































%PGK-1A : (AT29 x CBA/N)




































































































































































































































































































































































%PGK-1A : (AT29-ENU.556 X CBA) PI


















































































Key to tables and figures for LYMPH NODE: 
WHOLE = unsorted lymph node
antibody staining. B = B220, T = Thyl.2; L4 = L3T4; L2 = Lyt2, Ll=Lyl;
d,b = dull or bright staining
185
%PGK-1A:(AT29-ENU.556 X CBA/N) PHI
























































































































%PGK-1A : (AT29 x CBA)
























%PGK-1A : (CBA X AT29) 
LYMPH NODE : CELL POPULATIONS
%PGK-1A : (CBA x CBA-Pgk-la)























































1 >24d Table 3.43
1 87
%PGK-1A : (CBA x AT2C-ENU.55c)PI

























%PGK-1A : (AT29-ENU.556 X CBA) PI!






















1 >24d Table 3.45
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%PGK-1A : (AT29 x CBA/N)

































































































































































































































































































































































































































































































































































































































































































































%PGK-1A : (AT29-ENU.556 X CBA) Pi 


















































% PGK-1A : (AT29-ENU.556 x CBA) PI


























Key to tables and figures for BONE MARROW and NEONATAL LIVER: 
WHOLE = unsorted tissue
HIGH SCATTER = cells with higher right angle scatter than lymphocytes 
antibody staining: B - B220, d = dull staining
197
%PGK-1A;(AT29-ENU.556 x CBA/N) PI





































%PGK-1A:(AT29-ENU.556 x CBA/N) PI!



























%PGK-1A : (AT29 x CBA)



















%PGK-1A : (CBA X AT29)
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Phenotvpic Variation In Female Offspring From AT29- 
ENU.556 Crosses
Studies of X-chromosome inactivation patterns in female 
Offspring of (1) AT29-ENU.556 x CBA, (2) CBA x AT29- 
ENU.556 and (3) AT29-ENU.556 x CBA/N crosses revealed two 
distinct phenotypes for cross (1) and (3), defined in 
Chapter 3 as PI and PII for cross (1) and PHI and PIV for 
cross (3), respectively.
Phenotype Of AT29-ENU.556 x CBA Female Offspring (PI. 
PII) .
The phenotypes of PI and PII mice have been described in 
Chapter 3. Briefly, females with the PI phenotype had 
unbalanced patterns of PGK-1 expression in favour of CBA 
for skeletal muscle, erythrocytes and lymphocytes. In 
contrast, PII females termed non-mutant, did not show any 
selection against cells carrying the AT29-ENU.556 X 
chromosome and the patterns of PGK-1 expression for 
skeletal muscle, erythrocytes and lymphocytes were similar 
to that in control females.
Phenotype Of AT29-ENU.556 x CBA/N Female Offspring (PHI. 
£IYI.
The phenotypes of PHI and PIV mice have been described in 
Chapter 3. Briefly, females with the PHI phenotype had 
unbalanced patterns of PGK-1 expression in favour of CBA/N
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for skeletal muscle, erythrocytes and certain lymphocyte 
populations. As both the ENU and xid mutations result in 
defective lymphocytes, the patterns of PGK-1 expression 
for the females carrying both these mutations will depend 
on:
(a) whether the mutations affect the same or different 
lymphocyte populations
(b) the stage at which each mutation takes effect
(c) the selective effects of the mutations
For example, if both mutations affect the same population 
to the same degree although not necessarily in the same 
way, the cells will be equally defective and the PGK-1 
patterns of expression would be similar to those in 
control females.
In general, in PHI females there was selection against T 
cells carrying the AT29-ENU.556 X chromosome. For B cell 
populations, the patterns of PGK-1 expression tended to a 
random pattern, depending on the tissue and the age of 
the individual.
In contrast, PIV females did not show any selection 
against cells carrying the AT29-ENU.556 X chromosome for 
skeletal muscle, erythrocytes or lymphocytes; rather, B 
cell populations carrying xid were selected against.
The phenotypic distribution of the female progeny from
206
various crosses is summarised in table 4.1, where 1703, 
2261, 2199, 1998, 2115 and 2203 were homozygous AT29- 
ENU.556 mice and all female progeny of a given pair from 
each cross had the same phenotype, namely PI or PII and 
PHI or PIV.
Table 4.1 showing the phenotypes of female progeny
PHENOTYPE OF FEMALE PROGENY
CROSS OF THE PAIRS IN EACH CROSS
PI PII PHI PIV
(1703 x CBA) 1 0 / / 
(2261 x CBA) 1 0 / / 
[(2199 x 1998) x CBA] 3 1 / / 
(2203 x CBA) 0 1 / / 
(CBA x 2115) 1 0 / / 
(* x CBA) 3 0 / / 
[(2199 x 1998) x CBA/N] / / 1 3 
(* x CBA/N) / / 2 0
2 2 
* { [ (CBAx2115)x(2199xl998)]x[(CBAx2115)x(2199x1998)] }
the male parent is given first
In this discussion the alleles of Pgk-1 will be 
represented by a and b and the mutant and wildtype
allelic forms of the xid-mutation in CBA/N mice will be
+ 
represented by xid and xid, respectively.
As the ENU mutation affected both the skeletal muscle and 
the haematopoietic system and not one without the other, 
in all PI and PHI mice, it is assumed that one locus
controlling both systems is involved, represented by M
+ 
with its allele M .
Possible genotypes for the X chromosome in the homozygous 
strains studied, applying the definitions stated above,
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are presented in table 4.2.
Table 4.2 showing X-chromosome loci of the strains studied
X-CHROMOSOME 
STRAIN LOCI
AT29 M , xid ,a
AT29-ENU.556 M , xid ,a
CBA-Pgk-la M , xid , a
CBA M ,xid ,b
CBA/N M .xid ,b
The results of the patterns of PGK-1 expression for 
the females derived from the male 2203 suggest that M was 
inherited by the female offspring giving PII mice and the 
results for the females derived from the male (2199x1998) 
suggest that M was inherited by half the offspring giving 
PI and PHI mice and that M was inherited by the 
remainder giving PII and PIV mice (table 4.1).
This suggests that the male 2203 was hemi/homozygous for 
M and that the female 1998 was heterozygous for the loci 
M and M although homozygous for Pgk-la and Hprta. as 


































































































































































































































































2199 x 1998 ____> (2199 x 1998)
M M M MM
[ YX ] x [ X X ] [ YX ] or [YX ]
a a a a a
and,
(2199 x 1998) x CBA _---> [(2199 x 1998) x CBA]
M M M MM
[ YX ] x [ X X ] [XX] PI
abb a b
also,
(2199 x 1998) x CBA __--> [(2199 x 1998) x CB




(2199 x 1998) x CBA/N ---->[ (2199 x 1998) x CBA/N]
M,xid M .xid M .xid M,xid M .xid
[YX ]x[ X X ] [X X ] PHI
abb a b
also,
(2199 x 1998) x CBA/N ---->[ (2199 x 1998) x CBA/N]
+ + + + 4- + +
M ,xid M .xid M .xid M ,xid M .xid
[ YX ]x[ X X ] [ X X 1PIV
a b b a b
With reference to the pedigree (Fig. 4), males 2199, 1703 
and female 2115 were derived from line IB and male 2261 
was derived from line 2A. All were hemi/homozygous for M, 
as determined by the patterns of PGK-1 expression of their 
female progeny.
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The male 2203 and female 1998 were derived from lines 1C 
and 1A, respectively. Hence, from the progeny analysed,
some mice of line 1 and, more specifically, 1A and 1C
+ 
carried the allele M .
As the ENU-mutant mice (M) were selected on the basis of
expression of PGK-1A which is discussed in Chapter 2, the
+ 
introduction of the M allele to the pedigree, which gave
rise to PII and PIV mice, could be explained by the 
process of recombination such that the mice 2203 and 1998,
which were screened as hemi/homozygous for Pgk-la. carried
+ 
the allele M .
The process of recombination is the rearrangement of 
genetic material at crossover points or chiasmata on 
nonsister chromatids of homologous chromosomes during 
meiosis (Morgan, 1910; Tease and Jones, 1978). This 
results in the formation of different arrangements of 
alleles in the gametes such that the original arrangements 
of alleles are called the parental chromosomes and the two 
new combinations are called recombinants. Sturtevant, 1913 
suggested that the percentage of recombinants is a 
quantitative index of the linear distance between two 
genes such that the greater the distance between genes on 
a chromosome the greater the chance that nonsister 
chromatids cross over in the region between the genes and 
hence the greater the proportion of recombinants that 
would be produced.
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If a cross over had occurred between the loci M and Pgk-l 
then the recombinant X chromosome would carry M and Pgk- 
la and the X chromosome with the parental combination 
would carry M and Pgk-la as the mice were screened for 
expression of PGK-1A (Chapter 2).
The hypothesis states that the production of PII and PIV 
females results from the inheritance of the recombinant 
X chromosome through the male 2203 (line 1C) and through 
the female 1998 (line 1A) and the production of PI and 
PHI females results from the inheritance of the X 
chromosome with the parental combination of loci through 
the female 1998 (line 1A) (Fig. 4).
Recombination could have occurred in female 649 involving 
at least two gametes that affected line 1 or in females, 
1285/1286 and 1093 involving at least one gamete per 
female that affected line 1A and 1C, respectively (Fig. 
4) .
DISCUSSION
This hypothesis offers an explanation for the phenomenon 
of phenotypic variation in AT29-ENU.556 crosses. It 
depends on :
(1) the assumption that there is one locus controlling the 
haematopoietic and skeletal muscle systems as both systems 
are affected in all cases
(2) the production of at least one gamete carrying the
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recombinant X chromosome in females 1285/1286 and 1093 or 
the production of two gametes carrying the recombinant X 
chromosome in female 649 only (Fig. 4)
The question to be addressed is whether recombination 
occurred in one or several females. There is evidence of 
a high frequency of recombination on the X chromosome 
(Davies et al. 1985; Grimm et al. 1989) . The frequency of 
recombination has been shown to increase by various 
recombinagenic agents such as mutagens which affect DNA 
metabolism, repair and recombination (Kunz and Haynes, 
1981). Another possibility worth mentioning, is that the 
ENU mutation induced a meiotic-like recombination event 
during mitosis of the germ line of female 649. Inter- 
chromosomal recombination could explain the production of 
at least two gametes carrying the recombinant X chromosome 
in female 649.
Before formation of the recombinants, females 649, 
1285/1286 and 1093 carried a paternally-derived X
chromosome which was of C57BL/10 .mcix background with the
+ 
alleles Pgk-lb. M and mdx and a maternally-derived X
chromosome which was of AT29-ENU.556 background with the
+ 
alleles Pgk-la. M and mdx . To speculate further, the
recombinant X chromosome in PII and PIV mice could have
been of C57BL/10.mdx background with the alleles Pgk-la.
+
M and mdx or of AT29-ENU.566 background with the alleles
+ +
£gk-la, M and mdx (Fig. 4).
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The genotype of the recombinant X chromosome in PII and 
PIV mice might be assessed by the identification of traits 
specific to C57BL/10.mdx or AT29-ENU.556 mice. For 
example, measuring the levels of creatine phosphokinase 
(Chapman et a_l, 1989) or probing for mdx might indicate 
the presence of mdx on the recombinant X chromosome.
This hypothesis may reflect the positional relationship of 
the loci M and Pgk-1 where the greater the distance 
between loci on a chromosome the greater the chance that 
nonsister chromatids cross over in the region between the 
loci and hence the greater the proportion of recombinants 
produced.
Linkage mapping utilises the process of recombination to 
map loci in relation to each other as the percentage of 
recombinants is a quantitative index of the linear 
distance between two loci.
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CHAPTER 5
X-Chromosome Inactivation Studies In Normal Tissues Of
X-chromosome controlling elements have been shown to 
produce non-random inactivation of the X chromosome 
(Cattanach and Williams, 1972; West and Chapman, 1978). 
The murine locus (Xce) was mapped to the XD region, 
between mdx and Pgk-1 (Cattanach, 1970; Cattanach et al, 
1970). Allelic variants of this locus influence X-
chromosome inactivation such that an X chromosome
a 
expressing the Xce allele has a greater chance of being
b 
inactivated than an X chromosome carrying the Xce allele
which, in turn, is more likely to be inactivated than an X
c 
chromosome carrying the Xce allele {Cattanach, 1972;
Johnston and Cattanach, 1981). It has also been shown that 
the parental source of the Xce allele determines which X
chromosome is inactivated (Rastan and Cattanach, 1983).
M 
For example, in females heterozygous for Xce (b/c), the X
c 
chromosome bearing the Xce allele is less likely to be
P 
inactivated than the X chromosome carrying the same
allele (Forrester and Ansell, 1985). Further evidence of 
parental effects on expression of the X chromosome, in 
addition to the possible existence of a fourth Xce allele 
have been demonstrated (Fowlis, 1988; Fowlis e_£ al, 1991) .
Studies of X-chromosome inactivation patterns using PGK-1 
alloenzyme analysis were used to examine variation of PGK-
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1 expression to determine the nature of the Xce in AT29 
and AT29-ENU.556 mice and to examine the parental effects 
in the hybrids of these and CBA and CBA/N mice.
The following hybrids were considered:
Hybrid 1: AT29 x CBA
Hybrid 2: CBA x AT29
Hybrid 3: AT29-ENU.556 x CBA (PI)
Hybrid 4: CBA x AT29-ENU.556 (PI*)
Hybrid 5: AT29 x CBA/N
Hybrid 6: AT29-ENU.556 x CBA/N (PHI)
a 
CBA mice carry the Pgk-lb and Xce alleles. It is assumed
that CBA/N mice (Pgk-lb) also carry the same Xce allele as 
CBA mice as xid was originally a mutation in CBA stocks 
and it is assumed that Pgk-1 and Xce tend to cosegregate 
as they are closely linked and any recombination between 
these loci would be expected to be infrequent (Cattanach 
e_£ a_l, 1970; Franke and Taggart, 1980; Forrester and 
Ansell, 1985) . Similarly, the Xce allele of AT29 and AT29-
ENU.556 mice (both Pgk-la) is expected to be the same.
c 
This would be expected to be Xce which is associated with
b 
Pgk-la. C57BL/6 lines have been shown to carry Xce
(Cattanach et al. 1970) .
PGK-1 alloenzyme analysis was performed on tissues 
unaffected by either the xid or the ENU mutation. These 
included brain of all hybrids and skeletal muscle of 
hybrids 1, 2 and 5. Individual variation in PGK-1
216
expression may depend on whether cells seeding different 
tissues originated from the same precursor pool and 
whether the sampling events concerned with seeding the 
tissue involved few cells. For example, similar PGK-1 
levels have been noted for blood granulocytes, 
erythrocytes and lymphocytes (Gandini and Gartler, 1969). 
Similarly, Gornish et al. 1972 and Micklem et al. 1987 
showed that cells of the thymus, bone marrow, spleen and 
blood originated from the same precursor pool.
In this study, PGK-1 expression was determined for 
skeletal muscle with mesodermal origin and brain with 
ectodermal origin. Genotypes and mean %PGK-1A values of 
hybrids are presented in table 5A. Student's t-test was 
used to examine possible differences in the mean %PGK-1A 
values of the following hybrids:
reciprocal hybrids:
1 versus 2; 3 versus 4.
AT29 compared with AT29-ENU.556 hybrids:
1 versus 3
CBA compared with CBA/N hybrids:
1 versus 5; 3 versus 6.
It was expected that there would be no significant 
difference between:
(1) the AT29 and AT29-ENN.556 hybrids (1 versus 3) or the 
CBA and CBA/N hybrids (1 versus 5 and 3 versus 6) as the 
Xce allele for the respective groups is assumed to be the
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same.
(2) the reciprocal hybrids assuming AT29 and AT29-ENU.556
c 
mice carry the Xce allele. Studies in hybrids carrying
a c 
the Xce and Xce alleles showed no reciprocal cross
differences in the mean %PGK-1A values as there are no 
parental effects for this combination of alleles and 
demonstrated high mean values of %PGK-1A for both the c/a 
and the a/c hybrids (Johnston and Cattanach, 1981; 
Forrester and Ansell, 1985).































69+10 55±7 63±13 64±6 60±9 64±12 





showing mean %PGK-1A values ± standard deviation and 
sample number in brackets
P 
X = paternally-derived X chromosome
M 
X = maternally-derived X chromosome.
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Results and Discussion
There was no significant difference in the mean %PGK-1A 
values between CBA and CBA/N hybrids for brain (1 versus 5 
and 3 versus 6) and for skeletal muscle (1 versus 5). This 
is consistent with the assumption that the Xce allele for 
CBA and CBA/N is the same, as discussed above.
There was no significant difference in the mean %PGK-1A 
values between AT29 and AT29-ENU.556 hybrids for brain (1 
versus 3) which is consistent with the assumption that the 
Xce allele for AT29 and AT29-ENU.556 is the same, as 
discussed above.
There was no significant difference in the mean %PGK-1A 
values between the reciprocal hybrids 1 versus 2 which is 
(AT29xCBA) versus (CBAxAT29) for brain and skeletal muscle 
and also, 3 versus 4 which is (AT29-ENU.556xCBA) versus
(CBAxAT29-ENU.556) for brain. This is consistent with an
a/c 
Xce genotype which has no reciprocal cross differences
in the mean %PGK-1A values as there are no parental 
effects for this combination of Xce alleles with high 
levels of PGK-1A expression (60-70% PGK-1A), as discussed 
above (Johnston and Cattanach, 1981; Forrester and Ansell, 
1985) .
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Flow Cytometric Analysis Of Lymphocyte Surface Antigens 
From Homozygous Normal And AT29-ENU.556 Mice And Their Fl 
Crosses
This chapter is divided into sections:
Section I. comparisons between normal (CBA, AT29) and 
mutant (AT29-ENU.556) mice.
Section II. comparisons between (a) normal (AT29 and CBA) 
Fls and mutant (PI) Fls and (b) CBA/N (AT29 x CBA/N) and 
mutant (PHI) Fls and (c) mutant (PI, PHI) Fls and 
homozygous CBA or CBA/N, mutant (AT29-ENU.556) and AT29 
mice.
It aims to identify immunological defects associated with 
the X-chromosome inactivation patterns described in 
Chapter 3 by analysing the effect of the mutation on the 
relative proportions of B cells and their subsets, T cells 
and thymocytes and their subsets and high scattering bone 
marrow cells. The latter are defined as high scattering, 
as in Chapter 3, on the basis of their relatively high 
right angle scatter, being structurally more complex than 
lymphocytes. Fig. 1, Appendix 2 shows the FACS dot plots 
for bone marrow lymphocytes and high scattering cells 
separated by their right angle scatter properties.
The B and pre-B cell marker used in this study is a 
surface glycoprotein termed B220 (Trowbridge et al.
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1975; Coffman e_t al, 1981a, b; Kincade et al, 1981) . B 
cells were also classified according to the density of 
surface irnmunoglobulin isotype (see Table 2A, Chapter 2) . 
Population I has high IgD, low IgM; population II has 
high IgD, high IgM and population III with low IgD, high 
IgM (Hardy et al, 1982, 1984) Population III are a 
subpopulation of B cells termed B-l cells which also 
express CDS (Ly-1) , a membrane protein found on all T 
cells. These constitute 1-2% of splenic (Manohar et al. 
1982) and 25-50% of peritoneal (Hayakawa et al . 1986) B 
cells in normal CBA mice. Immunodefective strains such as 
the NZB and motheaten viable mice have elevated levels of 
B-l cells and CBA/N mice have low levels of B-l cells 
(Hayakawa et al. 1983, 1986; Sidman et al. 1986) . 
Population I B cells are also absent in CBA/N mice (Hardy 
al, 1982, 1984) .
Fig. 6.1 is a diagrammatic representation of the FACS 
analysis delineating population I -II I in CBA and CBA/N 
mice and Fig. 6i-viii shows FACS dot plots of splenic, 
lymph node and peritoneal B lymphocytes defined as region 
1 (Rl) which were separated according to the density of 
surface IgD (FL1) and IgM (FL2) . Lymphocytes (Rl) were 
distinguished from a population of cells named high 
scattering (R2) which had relatively high forward scatter 
being larger than the lymphocytes in Rl . It is believed 
that the R2 population were dividing lymphoblasts .
Murine T cell markers used in this study include Thyl . 2
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which is an alloantigen of Thyl and L3T4 and Lyt2 (see 
Table 2A, Chapter 2). Thyl.2 is present in high density 
on cortical thymocytes (80-85% of thymus) and low density 
on medullary thymocytes (15% of thymus) and peripheral T
cells (Fathman et al, 1975; Shortman et al, 1979; Mulder,
+ + 
1986). CD4 (murine L3T4 ) T cells interact with cells
+ + 
expressing class II MHC antigens and CDS (murine Lyt2 ) T
cells with cells expressing class I MHC (Swain, 1983;
+ 
Wilde et al. 1983) . Although there is evidence that CD4
+
(L3T4 ) T cells can have cytolytic activity (MacPhail et
al. 1987), it is considered that the helper subset is
+ + 
marked by the CD4 (L3T4 ) antigen and the cytolytic
+ + 
subset by the CDS (Lyt2 ) antigen (Ceredig et al. 1983;
Dialynas et al. 1983) . Thyl.2 expression should be 
studied in relation to expression of markers, L3T4 and 
Lyt2 since it can be dislodged from T cells (Scollay et 
al, 1982) and may attach to other cells.
Thymocyte subsets were classified as belonging to the 
inner cortex, the outer cortex and the medulla using a 
combination of forward light scatter measurements defining 
relative cell size and intensity of fluorescence measuring 
the density of Thyl.2 (Fig. k, Appendix 2).
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SECTION I
Comparisons Between Normal (CBA. AT29) And Mutant (AT29-
The effect of the ENU mutation on the frequency of B and T 
cells or thymocytes and T cell subsets was examined using 
FACS analysis and Student's t-test to compare the mean 
frequency (%) of cells staining positively for a cell 
marker in the mutant strain AT29-ENU.556 and normal (CBA, 
AT29) mice. Comparisons between the strains for each cell 
type, excluding B lymphocyte subsets are given in tables 
6.1-6.3 which follow an account of the results. Summary 
tables 6.6-6.15 and the FACS dot plots showing B cell 
subsets, Fig. 6i-viii are presented at the end of this 
chapter. Representative FACS dot plots for all tissues, 
Fig. a-p are given in Appendix 2.
la The Normal Phenotype: Comparison Between CBA And AT29 
Mice
It was important to characterise the phenotype of AT29 
mice in terms of the frequency of lymphocyte subsets 
constituting various haematopoietic tissues as the AT29- 
ENU.556 mutant strain was derived from the AT29 line. The 
well-characterised strain, CBA was used for comparison.
B Lymphocytes
+ 
AT29 mice had significantly less mean % of B cells (B220 )
within the spleen and bone marrow and significantly more
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in lymph node than CBA mice. The greatest difference in 
the mean % of B cells was for lymph node. There was no 
significant difference between the two strains for blood 
(table, 6.1, 6.6, 6.8, 6.13, 6.14).
T Lymphocytes or Thymocytes
AT29 mice had a significantly less mean % of T cells
+ 
(Thyl.2 ) within the lymph node than CBA mice which is
consistent with the data for B cells above. There was no 
significant difference in the mean % of T cells for 
spleen, blood or thymocytes of thymic cortex (C) or 
medulla (M). However, by splitting the cortex into inner 
(1C) and outer (OC) parts, AT29 mice had significantly 
less mean % of thymocytes within the inner cortex and 
significantly more within the outer cortex than CBA mice 
(table 6.1, 6.6, 6.8, 6.11, 6.12, 6.14).
T Lymphocyte Subsets
There was no significant difference in the means
+ 
between CBA and AT29 mice for Lyt2 cells of all tissues
+ 
and L3T4 cells of all tissues with the exception of the
lymph node for AT29 mice which had a significantly less
+ 
mean % of L3T4 cells than CBA mice. This latter result is
consistent with the data for the frequency of B and T 
cells, discussed above (table, 6.1, 6.7, 6.9, 6.10, 6.15).
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High Scattering Cells
Bone marrow high scattering cells were separated from 
lymphocytes by virtue of their relatively high right angle 
scatter, being structurally more complex. The bone marrow 
of AT29 mice had a significantly greater mean % of high 
scattering cells than CBA mice (table, 6.1, 6.13).
B Lymphocyte Subsets
The B cell subsets, population I-III were present in the 
spleen and peritoneum of AT29 and CBA mice. Populations I 
and II, but not III, were present in the lymph node of 
AT29 and CBA mice. For peritoneum of both strains, the 
high scattering compartment (R2) which was distinguished 
from lymphocytes in Rl by virtue of its relatively high 
forward scatter being larger, contained more population 
III cells than populations I or II cells (Fig. 6.1, Fig. 
6i, v, viii).
DISCUSSION
The results demonstrate several differences in the 
frequency of leukocyte populations between the CBA and 
AT29 normal strains. There was a significant difference in 
in the frequency of B cells for the spleen which was down 
15% in AT29 mice (Table 6.1, 6.6) and for lymph node which 
was up 30% in AT29 mice (Table 6.1, 6.8) and for bone 
marrow which was down 9% in AT29 mice (Table 6.1, 6.13). 
There was a significant difference in the frequency of T
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cells, particularly L3T4 cells for the lymph node which 
was down 30% in AT29 mice (Table 6.1, 6.9). Furthermore, 
within the marrow, AT29 mice had 20% more high scattering 
cells than the CBA strain (Table 6.1, 6.13). It is worth
considering whether compensatory mechanisms exist between
+ 
B and L3T4 cells within the lymph node and between B and
high scattering cells within the marrow which might 
explain the relative increases or decreases of these cell 
types. Regarding B lymphocyte subsets, there was no 
apparent difference between AT29 and CBA mice in the 
distribution of populations I-III within the three tissues 
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showing the mean frequency (%) of cells positive for the 
selected markers and the AT29 means underlined
significant differences, *=P<0.05, **=P<0.01 in bold
HS=high scattering cells defined as having a relatively 
higher right angle scatter than lymphocytes
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Ib The Mutant; Phenotype: Comparison Between Normal (AT29) 
And Mutant (AT29-KNU.556) Mice
Studies of X-chromosome inactivation patterns of 
heterozygous females, discussed in Chapter 3, placed 
homozygous AT29-ENU.556 mice into two groups:
(1) a mutant phenotype which produced PI and PHI 
heterozygous females following crosses with AT29-ENU.556 
and CBA and CBA/N mice, respectively.
(2) a non-mutant phenotype which produced PII and PIV 
heterozygous females following crosses with CBA and CBA/N 
mice, respectively.
The frequencies of leukocytes were compared between mutant 
and non-mutant homozygous AT29-ENU.556 mice to identify 
differences due to the mutation. Comparisons between 
mutant and non-mutant homozygous mice showed:
(1) a narrow range of values for the frequency of B cells 
of spleen, lymph node, bone marrow and blood (table 6.3).
(2) a narrow range of values for the frequency of T cells 
or thymocytes of spleen, lymph node, blood, thymic inner 
cortex and medulla (Table 6.3)
(3) an overlapping range of values for the frequency of
+ 
Lyt2 cells of spleen and lymph node (Table 6.3).
(4) a narrow range of values for the frequency of L3T4 
cells of spleen, lymph node and blood (Table 6.3).
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(5) a narrow range of values for the frequency of high 
scattering cells of bone marrow (Table 6.3)
Any differences that did exist between mutant and non- 
mutant mice may be explained by sampling effects or low
sample number. For example, see values for frequency of
+ + + 
blood Lyt2 ; thymus Lyt2 and L3T4 and thymus outer
+ 
cortex Thyl.2 (Table 6.3).
The results showed that the range of values for the 
frequency of leukocytes of mutant mice overlapped or 
were close (within 10%) to those of non-mutant mice which 
suggests the mutation does not affect leukocyte frequency 
Hence, for comparisons of frequency of leukocytes with 
other strains AT29-ENU.556 mutant and non-mutant mice 
shall be considered as one group.
Comparisons between AT29-ENU.556 and AT29 mice 
B Lymphocytes
There was no significant difference between AT29-ENU.556 
and AT29 mice in the mean % of B cells for spleen, lymph 
node and marrow. AT29-ENU.556 mice had significantly less 
mean % of B cells than AT29 mice for blood (Table 6.2, 
6.6, 6.8, 6.13, 6.14) .
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T Lymphocytes and Thymocytes
There was no significant difference between AT29-ENU.556 
and AT29 mice in the mean % of T cells for lymph node or 
of thymocytes for thymic cortex, inner cortex and medulla. 
AT29-ENU.556 mice had significantly less mean % of 
thymocytes than AT29 mice for outer cortex (Table 6.2, 
6.8, 6.11, 6.12).
T Lymphocyte Subsets
There was no significant difference between AT29-ENU.556
+ 
and AT29 mice in the mean % of Lyt2 cells for lymph node
+ 
and blood and in the mean % of L3T4 cells for spleen,
lymph node and blood. AT29-ENU.556 mice had significantly
+
less mean % of Lyt2 cells for spleen and thymus than
+ 
AT29 mice and significantly less mean % of L3T4 cells for
thymus than AT29 mice (Table 6.2, 6.7, 6.9, 6.10, 6.15). 
High Scattering Cells
Bone marrow high scattering cells were distinguished from 
lymphocytes by virtue of their relatively high right angle 
scatter being structurally complex. AT29-ENU.556 mice had 
significantly less mean % of high scattering bone marrow 
cells than AT29 mice (Table 6.2, 6.13).
B Lymphocyte Subsets
AT29 and AT29-ENU.556 mice had populations I-III in the 
spleen and peritoneum and population I, II but not III in
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the lymph node. For the peritoneum of both strains, the 
high scattering compartment (R2) contained more population 
III cells than population I or II cells (Fig. 6.1, 6i, 6v,
DISCUSSION
The results demonstrate that for most cell types there was
no significant difference in the frequency of leukocytes
+ 
between AT29-ENU.556 and AT29 mice. For thymus Lyt2 and
+ 
L3T4 cells, of both AT29-ENU.556 and AT29 mice there was
great variation within the sample making comparisons 
difficult. This might explain the difference observed 
between the two strains for these cell types (Table 6.2, 
6.10). Regarding B lymphocyte subsets, there was no 
obvious difference between AT29 and AT29-ENU.556 mice in 
the distribution of populations I- III within the three 
tissues studied.
It is interesting that those cell types in AT29 mice 
which differed most from those in CBA mice, differed 
least from those in AT29-ENU.556 mice. For example see 
Table 6.8 for lymph node stained for B220. This implies 
that the most obvious characteristics of the AT29 strain 









































showing the mean frequency (%) of cells positive for the 
selected markers and the AT29-ENU.556 mean underlined
significant difference, *=P<0.05, **=P<0.01
HS=high scattering cells defined as having a relatively 
higher right angle scatter than lymphocytes
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Table 6.3: Frequency of cells positive for selected 
lymphocyte markers in homozygous AT29-ENU.556 mutant (M) 
and AT29-ENU S56 non-mutant (NM) mice
mean frequency (%) of positive cells
B220 THY1.2 LYT2 L3T4
SPLEEN
M 48-52,5£ (2) 25-33,21 (3) 3-26,16 (3) 16-22,17 (3)
NM 55-73, M (4) 20-31,25 (3) 2-13, 9 (4) 7-14,12 (4)
LYMPH NODE
M 38-39,19 (2) 49-61,^7 (3) 32-43,37 (3) 16-19,17 (3)









































M 8-11,10 (2) 70-81,14 (3)
NM 16-27, 20. (4) 45-63,56 (3)
showing the range of values of the frequency (%) of cells 
staining positive for the selected markers and the mean 
underlined and sample number given in brackets
HS= high scattering cells defined as having a relatively 
higher right angle scatter than lymphocytes
overlapping or close (within 10%) ranges are given in bold
233
SECTION TT
Analysis Of Lymphocyte Subpopulations In Mutant (PI. PHI) 
Female Mice
Student's t-test was used to compare the mean frequency 
(%) of cells staining positive for selected markers in 
hybrids. Results of comparisons, excluding B lymphocyte 
subsets are given in tables 6.4 and 6.5 which follow an 
account of the results. Summary tables 6.6-6.15 and the 
FACS dot plots showing B cell subsets, Fig. 6i-viii are 
presented at the end of this chapter. Note that CBA x 
CBA-Pgk-la Fl females are included in the summary tables 
to represent a non-AT29 heterozygous group.
Ila Comparisons Between (i) Normal AT29 x CBA Fl females 
And Mutant (PI) Fl Females and (ii) These Fl Females And 
The Homozygous Lines From Which They Were Derived
The effect of the ENU mutation on the frequency of 
leukocytes in the heterozygote was studied by comparing 
PI Fl females (PIA and the reciprocal cross PI*A, in 
tables) with normal Fl females ((AT29 x CBA)A and the 
reciprocal cross). As X-chromosome inactivation studies 
(Chapter 3) revealed PII Fl females to be of normal 
phenotype, the data from these mice was pooled with that 
for the AT29 x CBA Fl females (Table 6.4). The phenotype 
of the heterozygotes were compared with the homozygous, 
CBA, AT29-ENU.556 and AT29 phenotype. PI and PII Fl males 
(PIB and PUB, respectively in tables) were used as
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sibling controls for PI and PII Fl females, as only the 
CBA X chromosome is inherited. To simplify, PIB and PUB 
mice were pooled with CBA mice for comparison with Fl 
females and the pooled group referred to as the CBA 
phenotype.
B Lymphocytes
There was no significant difference the mean % of B 
cells between normal and PI Fl females for spleen, 
lymph node and bone marrow. There was a significant 
difference between the normal and PI Fl females for 
blood. However, this is probably a false result since the 
sample number for blood was low (Table 6.4).
Compared with homozygous AT29 and AT29-ENU.556 mice 
respectively, both normal and PI Fl females had a reduced 
frequency of lymph node B cells, similar to the CBA 
phenotype. The converse was the case for bone marrow, 
in which normal and PI Fl females had an increased 
frequency of B cells, similar to the CBA phenotype. 
There was no obvious difference in the mean % of B cells 
of the spleen between both normal and PI Fl females and 
their respective homozygous counterparts (Table 6.6, 6.8, 
6.13, 6.14) .
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T Lymphocytes and Thymocytes
There was no significant difference in the mean % of T 
cells between normal and PI Fl females for spleen, lymph 
node and blood or thymocytes of thymus including medulla, 
cortex, inner cortex and outer cortex (Table 6.4).
Compared with homozygous AT29 and AT29-ENU.556 mice 
respectively, both normal and PI Fl females had an 
increased frequency of lymph node T cells, similar to the 
CBA phenotype. Conversely, compared with homozygous mice, 
there was a reduced frequency on of cortical thymocytes 
in the inner cortex of PI Fl females and in the outer 
cortex of normal Fl females. It should be noted that for 
the inner cortex and outer cortex of normal Fl females, 
the sample number was low which may have produced a false 
result. There was no obvious difference in the mean % of T 
cells of the spleen between both normal and PI Fl females 
and their homozygous counterparts (Table 6,6, 6.8, 6.11, 
6.12, 6.14) .
T Lymphocyte Subsets
There was no significant difference in the means between
+ 
the normal and PI Fl females for Lyt2 cells of spleen,
+
lymph node, thymus and blood and for L3T4 cells of the 
spleen, lymph node, thymus and blood. It should be noted 
that for blood the sample number was low, which may have 
produce a false result (Table 6.4).
Compared with homozygous AT29-ENU.556 and AT29 mice 
respectively, both PI and normal Fl females had an 
increased frequency of lymph node L3T4 cells, similar to 
the CBA phenotype. There was no difference in the 
frequency of L3T4 cells between normal and PI Fl females 
and their homozygous counterparts for spleen and thymus.
There was no notable difference in the frequency of Lyt2 
between normal and PI Fl females and their homozygous 
counterparts for spleen, lymph node and thymus (Table 6.7, 
6.9, 6.19, 6.15)
High Scattering Cells
Bone marrow high scattering cells were separated from 
lymphocytes by virtue of their relatively high right angle 
scatter, being structurally more complex.
There was no significant difference between normal and PI 
Fl females in the mean % of high scattering bone marrow 
cells (Table 6.4) .
Compared with homozygous AT29 and AT29-ENU.556 mice 
respectively, both normal and PI Fl females had a reduced 
frequency of high scattering marrow cells, similar to 
the CBA phenotype (Table 6.13) .
B Lymphocyte Subsets
There was no difference between PI Fl females and the CBA 
phenotype in the distribution of populations I-III within 
the two spleen and lymph node. For spleen there were
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populations I-III present and lymph node had populations 
I, II but not III present (Fig. 6.1, 6ii, 6vi).
DISCUSSION
The results demonstrate that for most tissues there was no 
significant difference in the frequency of leukocytes 
between normal and PI Fl females. The most obvious 
characteristics of the AT29 and AT29-ENU.556 phenotype 
differed from the normal Fl and PI Fl phenotype,
respectively. For example, see the frequency of B, T and
+ 
L3T4 cells of the lymph node and high scattering cells of
the marrow (Table 6.4, 6.8, 6.9, 6.13).
Regarding B lymphocyte subsets, there was no obvious 
difference between the CBA phenotype and PI Fl females 
in the distributions populations I-III within the spleen 
and lymph node (Fig. 6ii, 6vi).
The results of section II were consistent with section I, 
which showed that the phenotype of AT29-ENU.556 homozygous 
and (PI) heterozygous mice was very similar to that of 
AT29 mice which suggests that the ENU mutation does not 







































showing the mean frequency (%) of cells positive for the 
selected markers and the normal Fl mice underlined
normal# Fl = (AT29xCBA), (CBAxAT29), PII females pooled 
data
significant difference, *=P<0.05
HS=high scattering cells defined as having a relatively 
higher right angle scatter than lymphocytes
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lib Conparisons Between fi) CBA/N (AT29 x CBA/N) Fl 
Females And Mutant (PHI) Fl Females and (ii) These PI 
Females And The Homozygous Lines From Which They Were 
Derived
The combined effect of the ENU and xid mutation on 
leukocyte frequencies in PHI Fl females (PIIIA in tables 
6.6-6.15) was studied by comparing PHI Fl females with 
CBA/N Fl females ((AT29 x CBA/N)A in tables). The 
phenotype of PHI and AT29 x CBA/N Fl females, relative to 
the homozygous CBA/N, AT29-ENU.556 and AT29 phenotype was 
established. Note that, from X-chromosome inactivation 
studies discussed in Chapter 3, PIV Fl females were 
regarded a CBA/N phenotype, hence PIVA mice were pooled 
with AT29 x CBA/N Fl females (Table 6.5) . PHI and PIV Fl 
males (PIIIB and PIVB, respectively in tables) were used 
as sibling controls for PHI and PIV Fl females, since 
only the CBA/N X chromosome is inherited. To simplify, 
PIIIB and PIVB mice were pooled with CBA/N mice for 
comparison with Fl females and the pooled group referred 
to as the CBA/N phenotype.
B Lymphocytes
There was no significant difference in the mean % of B 
cells between AT29 x CBA/N and PHI Fl females for spleen 
and blood. There was a significant difference between the 
Fl females for lymph node and bone marrow (Table 6.5)
Compared with homozygous AT29 and AT29-ENU.556 mice
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respectively, both AT29 x CBA/N and PHI Fl females had a 
reduced frequency of lymph node B cells, tending towards 
the CBA/N phenotype. There was no obvious difference in 
the mean % of B cells of the spleen or bone marrow between 
both AT29 x CBA/N and PHI Fl females and their respective 
homozygous counterparts (Table 6.6, 6.8, 6.13, 6.14).
T Lymphocytes or Thymocytes
There was no significant difference in the mean % of T 
cells between AT29 x CBA/N and PHI Fl females for spleen, 
lymph node or thymocytes of thymic medulla, cortex, inner 
cortex and outer cortex. There were no comparisons made 
for blood (Table 6.5).
Compared with homozygous AT29 and AT29-ENU.556 mice 
respectively, both AT29 x CBA/N and PHI Fl females had an 
increased frequency of lymph node T cells, tending towards 
the CBA/N phenotype. There was no obvious difference in 
frequency of T cells of the spleen or thymocytes between 
both AT29 x CBA/N and PHI Fl females and their homozygous 
counterparts (Table 6.6, 6.8, 6.11).
T Lymphocyte Subsets
There was no significant difference in the means
+ + 
between the crosses for both Lyt2 and L3T4 cells of
spleen, lymph node and thymus. There were no comparisons 
nade for blood (Table 6.5).
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Compared with homozygous AT29 and AT29-ENU.556 mice
respectively, both AT29 x CBA/N and PHI Fl females had an
+ 
increased frequency of lymph node L3T4 cells, tending
towards the CBA/N phenotype. There was no apparent
+ 
difference in the frequency of L3T4 cells between both
AT29 x CBA/N and PHI Fl females and their homozygous 
counterparts for the spleen and thymus.
Similarly, there was no difference in the frequency of
+
Lyt2 between both AT29 x CBA/N and PHI Fl females and 
their homozygous counterparts for the spleen, lymph node 
and thymus. There were no comparisons made for blood 
(Table 6.7, 6.9. 6.10) .
High Scattering Cells
Bone marrow high scattering cells were separated from 
lymphocytes by virtue of their relatively high right angle 
scatter being structurally more complex. There was no 
significant difference between the AT29 x CBA/N and PHI 
Fl females in the mean % of high scattering bone marrow 
cells (Table 6.5) .
Compared with homozygous AT29 and AT29-ENU.556 mice 
respectively, both AT29 x CBA/N and PHI Fl females had a 
reduced frequency of high scattering marrow cells, 
tending towards the CBA/N phenotype (Table 6.13)
B Lymphocyte Subsets
There was a difference between PHI Fl females and the
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CBA/N phenotype in the distribution of populations I-III 
cells within the spleen and lymph node.
Spleen of Pill Fl females had a relatively small 
proportion of population I and II and a relatively large 
proportion of III and the CBA/N spleen had a relatively 
large population II, low III and no I.
Lymph node of PHI Fl females had a relatively small 
proportion of population I and II but no III and the CBA/N 
lymph node had a relatively large population II but no I 
or III.
DISCUSSION
The results demonstrate that for most cases there was no 
significant difference in the frequency of leukocytes 
between AT29 x CBA/N and PHI Fl females. Differences can 
be explained by sampling effects, producing false results. 
The most obvious characteristics of the AT29 and AT29- 
ENU.556 phenotype differed from the AT29 x CBA/N Fl and
PHI Fl phenotype, respectively. For example, see the
+ 
frequency of B, T and L3T4 cells of the lymph node and
high scattering cells of the marrow (Table 6.8, 6.9, 
6.13) .
These results give further evidence that the phenotype, 
in terms of the frequency of leukocytes of AT29-ENU.556 
and AT29 mice and their hybrids was very similar which 
suggests that the ENU mutation does not affect the
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frequency of leukocytes quantified by flow cytometry.
The distribution of B cell subsets for CBA/N mice were 
consistent with previous work which showed low levels of 
population III (B-l cells) (Hayakawa et al. 1983, 1986; 
Sidman et al. 1986) and an absence of population I B cells 
(Hardy e_£ al, 1982, 1984) .
There was a difference between the CBA/N phenotype and 
PHI Fl females in the distribution of populations I-III 
for spleen and lymph node.
For spleen, the small population III, large II and an 
absence of I seen in CBA/N mice tended towards a large 
population III and small II, I in PHI Fl females. For 
lymph node, the large population II and an absence of I 
tended towards a small population II and I in PHI Fl 
females (Fig. 6iii, 6iv, 6vii).
These results suggest that, despite the ENU mutation, the 
AT29-ENU.556 cells have corrective ability within the 
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showing the mean frequency (%) of cells positive for the 
selected markers and the normal Fl mice underlined
normal# Fl = (AT29xCBA/N) , PIV females pooled data 
significant differences, *=P<0.05
HS=high scattering cells defined as having a relatively 
higher right angle scatter than lymphocytes
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The table shows for spleen, the mean % of cells staining 
positive for the antigen B220=B cells and Thyl.2=T cells, 
the sample number, n and the standard deviation
where n=l, a single value of % of positive cells staining 
for B220 or Thyl.2 is given
A=female mice; B=male mice; C=female and male
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The table shows for spleen, the mean % of cells staining 
positive for the antigen Lyt2=cytolytic T cells and 
L3T4=helper T cells, the sample number, n and the standard 
deviation
where n=l, a single value of % of positive cells staining 
for Lyt2 or L3T4 is given
A=female; B=male; C=female and male mice
247




















































































































































The table shows for lymph node, the mean % of cells 
staining positive for the antigen B220=B cells and Thyl.2 
=T cells, the sample number, n and the standard deviation
where n=l, a single value of % of positive cells staining 
for B220 or Thyl.2 is given
A=female mice; B=male mice; C=female and male mice
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The table shows for lymph node, the mean % of cells 
staining positive for the antigen Lyt2=cytolytic T cells 
and L3T4=helper T cells, the sample number, n and the 
standard deviation
where n=l, a single value of % of positive cells staining 
for Lyt2 or L3T4 is given
A=female; B=male; C=female and male mice
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The table shows for thymus, the mean % of cells staining 
positive for the antigen Lyt2=cytolytic thymocytes and 
L3T4=helper thymocytes, the sample number, n and the 
standard deviation
where n=l, a single value of % of positive cells staining 
for Lyt2 or L3T4 is given
A=female; B=male; C=female and male mice
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The table shows for cortex and medulla of thymus, the mean 
% of cells staining positive for the antigen Thyl.2= 
thymocytes, the sample number, n and the standard 
deviation
where n=l, a single value of % of positive cells staining 
for Thyl.2 is given
A=female; B=male; C=female and male; PI* is the reciprocal 
PI cross
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The table shows for the inner and outer cortex of thymus, 
the mean % of cells staining positive for the antigen 
Thyl,2=thymocytes, the sample number, n and the standard 
deviation
where n=l, a single value of % of positive cells staining 
for Thyl.2 is given
A=female; B=male; C=female and male; PI*is the reciprocal 
PI cross
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The table shows for bone marrow, the mean % of cells 
staining positive for the antigen B220=B cells and the 
mean % of cells with higher right angle scatter than 
lymphocytes=HS cells, the sample number, n and the 
standard deviation; where n=l, a single value of % of 
positive cells staining for B220 or % high scattering 
cells is given; A=female; B=male; C=female and male mice; 
PI* is the reciprocal PI cross
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The table shows for blood, the mean % of cells staining 
positive for the antigen B220=B cells and Thyl.2=T cells, 
the sample number, n and the standard deviation
where n=l, a single value of % of positive cells staining 
for B220 or Thyl.2 is given
A=female; B=male; C=female and male mice
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The table shows for blood, the mean % of cells staining 
positive for the antigen Lyt2=cytolytic T cells and 
L3T4=helper T cells, the sample number, n and the standard 
deviation
where n=l, a single value of % of positive cells staining 
for Lyt2 or L3T4 is given
A=female; B=male mice; C=male and female
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Fig. 6.1
Diagrammatic representation of FACS analysis of IgD/IgM B cell subsets 
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Fig 6i
Dotplots showing lymphocyte (Rl) and high scattering cell (R2) populations of 
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Fig. 6ii
Dotplots showing lymphocyte (Rl) and high scattering cell (R2) populations of 
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Fig 6iii
Dotplots showing lymphocyte (Rl) and high scattenng cell (R2) populations o 
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Dotplots showing lymphocyte (Rl) and high scattering cell (R2) populations of 
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Fig. 6vi
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Fig. 6vii
Dotplots showing lymphocyte (Rl) and high scattering cell (R2) populations of 
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Fig 6viii
Dotplots showing lymphocyte (Rl) and high scattering cell (R2) populations of Peritoneum stained for IgD (FL1) and IgM (FL2)
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Effect Of The KNU Mutation On Immune Function: A 
.narv Stiidv With
Studies of X-chromosome inactivation patterns in mice 
heterozygous for the ENU mutation have delineated 
distinct haematopoietic cell lineages that are affected 
by the ENU mutation. These include B and T cells, 
erythrocytes and possibly platelets, discussed in 
Chapter 3.
Preliminary experiments were carried out with the aim of 
characterising the effect of the ENU mutation in 
leukocytes in functional terms by comparing the response 
of homozygous AT29-ENU.556 mice and their hybrids with 
control mice following sensitisation with the skin- 
sensitising agent, oxazolone. It was expected that the 
leukocytes affected by the ENU mutation would be 
functionally defective in their response to oxazolone.
Previous work in normal mice (Davies et al. 1969) and 
guinea pig (Oort and Turk, 1965) showed immense 
proliferation of T-lineage blasts on the 4th day and 
proliferation of B cells which reached a peak at day 8, in 
the draining lymph node, and to a lesser extent, the 
spleen, following treatment with the skin-sensitising 
agent, oxazolone (Parrott and De Sousa, 1966; Pritchard 
and Micklem, 1972; Micklem ej; al, 1972) .
The response following the administration of oxazolone was
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assessed by analysis of the cellularity of the lymph nodes 
and spleens. This involved making cell counts and 
measuring the frequency of leukocyte populations.
Studies were made of X-chromosome inactivation patterns 
using alloenzyme analysis in mice that were heterozygous 
for the ENU mutation to assess the response of cells 
carrying the ENU mutation compared with cells carrying the 
CBA allele in PI females or compared with cells carrying 
the xid mutation in PHI females.
Mice of age 12 weeks were divided into an experimental 
group treated with oxazolone and a control group treated 
with ethanol. The agent was applied to a shaved area on 
the right side of the thorax and each group caged 
separately for 3 days. Spleens and brachial lymph 
nodes from the treated area were removed for analysis 
after being examined for signs of swelling.
Cell suspensions of the spleens and lymph nodes were 
prepared for analysis of PGK-1 expression and assessment 
of cellularity using the coulter counter and FACS analysis 
to measure the frequency of leukocytes. In FACS analysis, 
lymphocytes and high scattering cells were assessed 
separately. In this study, unlike previous sections, high 
scattering cells were identified by their high forward 
scatter, being larger than lymphocytes (see Chapter 2).
Summary tables 7.1-7.8 and representative FACS dot plots 
Fig. 7i-iii are given at the end of this chapter. PIA and
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PIIIA refer to PI and PHI female mice and PIB and PI I IB 
refer to PI and PHI male mice.
Results
Cell counts and FAGS analysis of AT29-ENU.556. AT29 and 
CBA mice
The results demonstrated the ability of AT29, CBA and 
AT29-ENU.556 cells of the lymph node draining the treated 
area, but not the spleen, to respond to oxazolone (table 
7.1)
The single value for the number of cells for the lymph 
nodes of AT29 mice was x4 that of controls and the mean 
number of cells for AT29-ENU.556 mice was x3 that of 
controls and that for CBA mice was x9 that of controls. 
The results suggest that in terms of the mean number of 
cells, the response of CBA mice was greater than that of 
AT29 and AT29-ENU.556 mice and that the response of AT29 
and AT29-ENU.556 mice was similar (table 7.1).
FACS analysis revealed that there were increases in the 
frequency of B cells and high scattering cells (defined 
above), almost in equal proportions (Fig. 7i).
With regard to an increase in the frequency of B cells, 
the response of the lymph nodes in AT29 mice was xl.3 that 
of controls, that of AT29-ENU.556 mice was x2.5 that of 
controls and that of CBA mice was x4 that of controls. The 
results suggest that the increase in the frequency of B
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cells was greater in CBA mice than in AT29 and AT29- 
ENU.556 mice (table 7.2).
With regard to an increase in the frequency of high 
scattering cells, the response of the lymph nodes in AT29 
mice was x3 that of controls, that of AT29-ENU.556 mice 
was x2 that of controls and that of CBA mice was x4 that 
of controls. The results were similar to the results for B 
cells where the increase in the frequency of high 
scattering cells was greater in CBA mice than in AT29 and 
AT29-ENU.556 mice and the response for AT29 and AT29- 
ENU.556 mice was similar(table 7.3).
There was no difference between experimental and control
mice in the frequency of lymph node T cells of AT29 mice
+ 
(note that no other mice were studied) or lymph node L3T4
cells of AT29, CBA and AT29-ENU.556 mice or lymph node
+ + 
Lyt2 cells of AT29 and CBA mice. Lymph node Lyt2 cells
of AT29-ENU.556 mice appeared to respond negatively to
oxazolone whereby the experimental mice had half the
+ 
number of Lyt2 cells of the controls (table 7.4, 7.5,
7.6) .
Although sample numbers were low, results of the mean 
numbers of cells and FACS analysis were consistent and 
showed that for the lymph nodes but not the spleen of CBA, 
AT29 and AT29-ENU.556 mice there were increases in the 
frequency of B and high scattering cells following 
treatment with oxazolone and the response for AT29 and
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AT29-ENU.556 mice was similar.
Cell counts and FACS analysis of PI and PHI mice
The results showed that the cells of the lymph node 
draining the treated area but not the spleen of PI and 
PHI females and males responded to oxazolone (table 7.1) .
There was a similarity in the mean number of cells for the 
lymph nodes of the experimental PI, PHI females compared 
with AT29 and AT29-ENU.556 mice which had a mean number of 
cells that was x3 or x4 that of controls and also a 
similarity in the mean number of cells for the lymph nodes 
of the experimental PI, PHI males compared with CBA mice 
with a mean number of cells that was x6 or x9 that of 
controls. The results demonstrate that in terms of the 
mean number of cells, the response of CBA mice was greater 
than that of PI and PHI females.
FACS analysis of the experimental PI and PHI mice 
compared with controls revealed that there were increases 
in the frequency of B and high scattering cells, almost in 
equal proportions (Fig. 7ii, 7iii where A are females and 
B are males).
Furthermore, for all experimental hybrids compared with 
controls, there was no difference in the frequency of 
lymph node T cells or their subsets following treatment 
with oxazolone (table 7.4, 7.5, 7.6,).
Although sample numbers were low, the results of the mean
269
number of cells and FACS analysis for the PI and PHI mice 
and the homozygous mice were consistent and demonstrated 
that the frequency of the lymph node B and high scattering 
cells, but not T cells, increased in response to 
oxazolone.
The Effects of Oxazolone-sensitisation on the Patterns of 
Expression of PGK-1 Alloenzymes in PI and PHI females
Studies were made of the patterns of PGK-l expression in 
females that were heterozygous for the ENU mutation to 
assess the response to oxazolone of cells carrying the ENU 
mutation compared with cells carrying the CBA allele in PI 
females and with cells carrying the xid mutation in PHI 
females. Experimental mice were compared with ethanol- 
treated and untreated control PI or PHI females.
There was no difference in the mean values of %PGK-1A 
between the experimental PI females and the treated 
control PI females for splenic B or T cells (table 7.8).
Similarly, there was no difference in the mean values of
%PGK-1A between the experimental PI females and the
+
treated control PI females for lymph node B ; T, L3T4 or
+ 
Lyt2 cells. The high scattering cell population of lymph
node had a mean value of 9% PGK-1A which suggests that 
cells within this population were affected by the ENU 
mutation (table 7.7).
There was a difference in the mean %PGK-1A values between
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the splenic cells of experimental PHI females compared 
with treated control PHI females (table 7.8) . For whole 
spleen the experimental mice had a mean value of 62% PGK- 
1A compared with 25% PGK-1A for the treated PHI controls. 
For B cells the experimental mice had a mean value of 75% 
PGK-1A compared with 40% PGK-1A for the treated PHI 
controls and 53% PGK-1A for the untreated PHI controls. 
There was no difference between the experimental and 
control PII females in the mean %PGK-1A values for splenic 
T cells {table 7.8).
Similarly, for B cells of lymph nodes of experimental PHI 
controls the mean value was 60% PGK-1A compared with the 
mean value of 35% PGK-1A for the treated PHI controls.
There was no difference in the mean %PGK-1A values between
+ 
experimental mice and the controls for lymph node L3T4
+ 
cells or Lyt2 cells (table 7.7).
The patterns of PGK-1 expression for the lymph nodes of 
the experimental and control PI females were similar which 
may suggest that following treatment with oxazolone, the 
cells carrying the ENU mutation expanded at the same rate 
as the cells carrying the CBA allele.
However, there was a difference in the patterns of PGK-1 
expression for B cells, but not T cells, of the lymph 
nodes of the experimental and control PHI females where 
there was unbalanced PGK-1 expression in favour of the 
cells carrying the ENU mutation. This suggests that the B
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cells carrying the ENU mutation may have expanded at a 
faster rate than the cells carrying the xid mutation 
following treatment with oxazolone.
DISCUSSION
The development of an immune response occurs mainly in 
secondary lymphoid organs such as the spleen and lymph 
nodes.
+ + 
In general, CD4 (murine L3T4 ) cells are termed helper T
+ + 
cells and CDS (murine Lyt2 ) are termed cytolytic T cells
and the cell surface glycoproteins, CD4 and CDS have 
specificity for class II or class I MHC proteins, 
respectively. These proteins have a role in the activation 
and effector functions of mature peripheral T cells 
(Swain, 1983; Parnes, 1989) .
The activation of T cells results in clonal expansion, 
generation of memory T cells and maturation into 
regulatory or effector cells. Following stimulation, 
T cells release IL-2 initially and IL-4, 11-5, IL-6 and 
IFN Jf appear several days later (Swain et al. 1991) .
T cells interact with B cells through surface molecules.
For example, cross-linking of surface CD40 on B cells by
+ 
the CD40 ligand on activated CD4 T cells switches on
activation and differentiation and may act as a signal for 
the migration of B cells into primary follicles (Armitage 
al, 1992; Noelle et al. 1992). A massive proliferation
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of B cells initiates the germinal centre reaction (Liu et 
al. 1991) . Selected B cells are induced to differentiate 
into recirculating memory cells or plasma blasts that 
migrate from the germinal centres and form plasma cells 
that produce immunoglobulins with specific effector 
functions (Howard et al. 1992; Butch et al, 1993).
The combination and the relative concentrations of the
+ 
various cytokines released from different subsets of CD4
TH1 and TH2 cells determines the effect on B cells in 
terms of the type of Ig isotype produced (Croft and Swain, 
1991; Banchereau and Rousset, 1992).
+ 
In general, the generation of the CDS cell response
requires help from helper T cells and the various
cytokines released from TH1 and TH2 cells have different
+ 
effects on CDS cells (Chen and Zlotnik, 1991).
Previous studies of the immune response following 
treatment with the skin-sensitising agent, oxazolone have 
demonstrated immense proliferation of T-lineage blasts on 
the 4th day and proliferation of B lymphocytes which 
reaches a peak on day 8 in the draining lymph node and to 
a lesser extent, the spleen (Oort and Turk, 1965; Parrott 
and De Sousa, 1966; Davies et al, 1969; Pritchard and 
Micklem, 1972; Micklem et al, 1972).
In this study, preliminary experiments were carried out 
with the aim of characterising the effect of the ENU 
mutation in leukocytes in functional terms by comparing
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the response of homozygous AT29-ENU.556 mice and their 
hybrids with control mice following sensitisation with 
oxazolone. It was expected that the leukocytes affected by 
the ENU mutation would be functionally defective in their 
response to oxazolone.
In terms of an increase in the mean number of cells, 
leukocytes of the lymph node but not the spleen of AT29- 
ENU.556, AT29, CBA mice and their hybrids responded to 
oxazolone. The response of the leukocytes of CBA mice was 
greater than that of AT29-ENU.556, AT29 and PI and PHI 
female mice and the response of AT29 and AT29-ENU.556 
leukocytes was similar (table 7.1)
FACS analysis showed that for all mice studied there was 
an increase in the frequency of lymph node B and high 
scattering cells. High scattering cells were distinguished 
from lymphocytes by their relatively high forward scatter 
profile, being larger than lymphocytes and were assumed to 
be dividing lymphoblasts, discussed below. There were no 
increases in the frequency of lymph node T cells or T cell 
subsets in response to oxazolone (table 7.2-7.6).
These results are consistent with previous studies which 
demonstrated that following oxazolone treatment there was 
proliferation of lymph node B lymphocytes and the 
formation of lymphoblasts. It was also shown that the 
lymphoblasts were of the T-lineage using cytological 
markers (Davies et aJL, 1969) .
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In the present study it is probable that the high forward 
scattering lymphoblasts were dividing T cells which would 
be consistent with other studies (Davies et al. 1969) as 
there was unbalanced expression of PGK-l for the cells of 
this population in the lymph nodes of PI females which 
implies that they were affected by the ENU mutation.
If it is assumed that the lymphoblasts are large, dividing 
T cells, then the increase in the frequency of B cells 
probably reflected some B cell proliferation, being 
consistent with previous work {Davies et al. 1969) but may 
also reflect a reduction in the frequency of T cells as T 
cells move from the low forward scattering region to the 
high forward scattering region containing lymphoblasts. 
The B cell frequency was taken as a proportion of the 
number of lymphocytes, not as a proportion of the number 
of T-lineage cells which included lymphoblasts and T 
lymphocytes (Fig. 7i-iii) .
Hence, the response to oxazolone was similar for AT29 and 
AT29-ENU.556 mice, which suggests that either the ENU 
mutation does not affect cell responsiveness to oxazolone 
or the effects of the mutation cannot be recognised 
by assessing cell counts or leukocyte frequencies or both. 
The latter is consistent with FACS data in Chapter 6.
The results of studies of the patterns of PGK-l expression 
in the spleen and lymph nodes of PI females implied that 
the responding cells carrying the ENU mutation expanded at
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the same rate as the cells carrying the CBA allele, 
following oxazolone treatment (table 7.7).
However, the results of studies of the patterns of PGK-1 
expression for B cells of the spleen and lymph nodes of 
PHI females implied that the B cells carrying the ENU 
mutation expanded at a faster rate than the cells carrying 
the xid mutation, following treatment with oxazolone 
(table 7.7, 7.8). This suggests that B cells carrying the 
ENU mutation were more responsive to oxazolone than the B 
cells carrying the xid mutation.
Previous work noted a splenic reaction to oxazolone with 
regard to cell proliferation measured by radiolabelling 
(Asherson et al. 1971; Micklem et al. 1972). Although 
this reaction was to a lesser degree than that of the 
draining lymph node (Micklem et al. 1972), there was no 
evidence in the present study from cell counts or from the 
assessment of leukocyte frequencies of any splenic 
reaction to oxazolone (table 7.1-7.6).
However, the results of studies of the patterns of PGK-1 , 
expression in splenic B cells of PHI females suggested 
that following oxazolone treatment, the cells bearing the 
ENU mutant chromosome were more responsive than the cells 
bearing the xid mutation (table 7.8).
276















































































































































































































showing the mean number of cells (xlO ), the sample number 
and the standard deviation
for n=l a single value is given
experimental mice=oxazolone-treated 
control mice=ethanol-treated
the difference in the means between the experimental and 
control mice is given as exptl/control
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showing the mean % of cells positive for marker B220, the 
sample number (n) and the standard deviation
for n=l a single value is given
experimental mice=oxazolone-treated 
control mice=ethanol=treated
the difference in the means between the experimental and 
control mice is given as exptl/control
A=female mice, B=male mice, C=female and male mice
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showing the mean % of high scattering cells, the sample 
number (n) and the standard deviation
for n=l a single value is given for the % of cells
experimental mice=oxazolone-treated 
control mice=ethanol-treated
the difference in the means between the experimental and 
control mice is given as exptl/control
high scattering cells had a relatively high forward 
scatter, being larger than lymphocytes
A=female mice, B=male mice, C=female and male mice
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showing the mean % of cells positive for marker Thyl.2, 
the sample number (n) and the standard deviation
for n=l a single value is given
experimental mice=oxazolone-treated 
control mice=ethanol=treated
the difference in the means between the experimental and 
control mice is given as exptl/control
A=female mice, B=male mice, C=female and male mice
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one -treated and control mice
EXPERIMENTAL CONTROL 
St st 
n mean dev n mean dev exptl/ 

















































































showing the mean % of cells positive for marker Lyt2, the 
sample number (n) and the standard deviation
for n=l a single value is given
experimental mice=oxazolone-treated 
control mice=ethanol-treated
the difference in the means between the experimental and 
control mice is given as exptl/control
A=female mice, B=male mice, C=female and male mice
281
Table 7.6: Frecruencv of L3T4 T cells in the
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showing the mean % of cells positive for marker L3T4, the 
sample number (n) and the standard deviation
for n=l a single value is given
experimental mice=oxazolone-treated 
control mice=ethanol-treated
the difference in the means between the experimental and 
control mice is given as exptl/control
A=female mice, B=male mice, C=female and male mice
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nodes of oxazol one -treated and control hvbrids
L.NODE EXPERIMENTAL CONTROL ( 
PIA n mean n mean 
%PGK-1A %PGK-1A
WHOLE 2 27 (0.7) /
B+ 1 0 10
B- 1 0 10
L4+ 10 10
L2+ 10 10














Bb 1 60 1 35
B- 1 18 16
L4+ 1 17 1 17







showing the mean %PGK-1A , the sample number, n and the 
standard deviation in brackets
when n=l a single value is given
experimental=oxazolone-treated mice
control (-»-ve) =ethanol-treated; control (-ve) =untreated mice
high scatter cells have a relatively high forward scatter
+ 
B cells= B220 and Bb is bright staining for B220
+ + 
T cells= L3T4 and Lyt2 and B220
whole=unsorted lymph node
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oxazolone- treated and control hybrids
SPLEEN EXPERIMENTAL CONTROL (+ve) CONTROL (-ve) 





/ 27 27 (8.1)
10 92 (6.0)







1 25 8 34 (9.7)
/ 3 50 (8.4)
1 40 2 53 (18.4)
1 29 7 20 (10.8)
showing the mean %PGK-1A, the sample number n and the 
standard deviation in brackets
when n=l a single value is given
experimental=oxazolone-treated mice
control(+ve)=ethanol-treated; control(-ve)=untreated mice
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Animals with genetic mutations can be used to study the 
factors controlling normal development and function and as 
models for the study of genetic disease in man. 
Comparisons of human and murine genetic maps can indicate 
the chromosome regions where the genetic order is 
conserved and can identify mouse genetic loci which may be 
homologous to human mutations causing disease. In humans 
and mice, loci controlling the haematopoietic and muscular 
systems have been mapped to the X chromosome (see the 
comparative human and mouse X-chromosome map, Fig. 1).
The aim of this study was to characterise the phenotypic 
effect of a novel X-linked mutation in offspring of male 
mice treated with the mutagen N-ethylnitrosourea (ENU). It 
has been demonstrated that treatment with ENU can produce 
X-linked mutations affecting the haematopoietic and 
muscular systems (Chapman et al. 1988, 1989).
Studies of X-chromosome inactivation patterns in 
heterozygous females using electrophoretic alloenzyme 
analysis were used to characterise the phenotypic effect 
of the X-linked ENU mutation. The presence of cells 
carrying the ENU mutation was detected by the expression 
of the alloenzyme PGK-1A such that unbalanced expression 
of PGK-1A demonstrates selection against the cells 
affected by the mutation, the differential effect of the
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mutation in cell lineages and the effect of the mutation 
with age.
Unbalanced expression of the X chromosome carrying the ENU 
mutation was seen for skeletal muscle and the haemato­ 
poietic tissues blood, spleen, thymus, lymph node and bone 
marrow (summary table 3.15) and for the cell 
subpopulations constituting these tissues namely, 
erythrocytes and B and T cells and possibly platelets 
(table 3.19, 3.20, 3.20, 3.39).
The cells of blood, spleen and bone marrow which were 
defined as high scattering and were distinguished from 
lymphocytes by their relatively high right angle scatter, 
being structurally more complex, were not affected by the 
ENU mutation having balanced X-chromosome expression 
similar to that for the control tissue brain in the same 
mice (table 3.15) and similar to that for the same cells 
in control heterozygotes (table 3.21, 3.48, 3.53, 3.56).
The differential effect of the ENU mutation in tissues and 
cell subpopulations was demonstrated. Skeletal muscle, 
thymus and lymph node were affected by the mutation to a 
greater extent than blood, spleen and bone marrow (table 
3.15). This reflected the presence of cells in these 
tissues that were unaffected by the mutation such as the 
high scattering cells defined above and also the presence 
of cells that were less affected by the mutation such as 
erythrocytes in whole blood, spleen and bone marrow B
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cells, which were predominantly pre-B cells (table 3.21, 
3.19, 3.48) .
It was also shown that the ENU mutation had differential 
effects on cell subpopulations within the B cell lineage. 
Pre-B cells were affected by the mutation to a lesser 
extent than the circulating B cells of the spleen and 
lymph nodes (table 3.21, 3.39, 3.48). T cell subsets were 
similarly affected by the mutation (table 3.21, 3.30, 
3.39) .
Attempts to relate the ENU mutation to a candidate gene 
were made by assessing whether the ENU mutation was an 
allele of xid by studying the X-chromosome inactivation 
patterns in PHI females heterozygous for ENU and xid. 
Previous studies demonstrated that the defect in xid mice 
is intrinsic to B cells (Nahm et aJL,1983; Forrester, 
1986) .
Results demonstrated balanced PGK-1 expression for splenic 
B cells and unbalanced expression of PGK-1 in favour of 
cells carrying xid for B cells of the lymph node and bone 
marrow (table 3.22, 3.40, 3.50).
Balanced expression of PGK-1 for splenic B cells may 
reflect similar effects of ENU and xid in splenic B cells. 
Unbalanced expression of PGK-1 in bone marrow B cells was 
greater than that for the B cells of the spleen and lymph 
node which implies that ENU also acts in pre-B cells, 
unlike xid. These results are consistent with previous
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findings in +/xid heterozygotes which showed unbalanced 
PGK-1 expression in favour of cells carrying the CBA X 
chromosome in spleen and lymph node and slightly 
unbalanced PGK-1 expression in the bone marrow as xid acts 
in circulating mature B cells and not in pre-B cells 
(Witkowski et al. 1985; Forrester et al, 1987).
There was also unbalanced expression of PGK-1 in T cells 
of the spleen and lymph node of PHI mice although this 
was to a lesser extent than in +/ENU (PI) females (table 
3.21, 3.22 and 3.39, 3.40). This may relate to previous 
findings which showed defective function of a T cell 
helper subset in CBA/N mice (Bottomly and Mosier, 1979; 
Scher, 1982) .
All cells affected by the ENU mutation demonstrated PGK-1 
variation with age (Fig.3.2-3.28). Correlation analysis 
showed that for skeletal muscle, blood and lymph node of 
PI mice, the effect of the mutation increased with age, 
particularly between 0-11 weeks for skeletal muscle and 
between 14-100 weeks for lymph node.
Studies in PI mice showed that the effects of the ENU 
mutation in T and B cells were apparent in pre-adult mice 
and became more pronounced with age. Studies in PHI mice 
revealed balanced PGK-1 expression in B cells after 12 
weeks of age which implies that the effects of xid became 
more pronounced during this period and this relates to 
previous studies (Forrester et al. 1987) .
291
Balanced levels of PGK-l expression depend on the X- 
chromosome inactivation patterns in the tissue progenitors 
(McLaren, 1972; Fialkow, 1973; West, 1975; Pappaioannou et 
al. 1981; McMahon et al. 1983) and on the nature of the X- 
chromosome controlling element (Xce). Allelic variants of 
this locus and the parental source of the allele influence 
X inactivation (Cattanach, 1972; Johnston and Cattanach, 
1981; Forrester and Ansell, 1985; Fowlis et al. 1991).
Studies of X-chromosome inactivation patterns using PGK-l 
alloenzyme analysis were used to examine variation of PGK- 
1 expression to determine the nature of the Xce in AT29 
and AT29-ENU.556 mice and to examine the parental effects
in the hybrids of these and CBA and CBA/N mice (table 5)
a 
Results were consistent with the assumption of an Xce
allele for AT29 and AT29-ENU.556 mice and studies of the
c 
reciprocal crosses with CBA (Xce )mice were consistent
a/c 
with an Xce genotype with no parental effects for this
combination of alleles (Johnston and Cattanach, 1981; 
Forrester and Ansell, 1985).
Flow cytometric analysis of the frequency of leukocytes 
demonstrated differences between the two normal strains, 
CBA and AT29 but not between AT29 and AT29-ENU.556 mice. 
Despite the mutation, both AT29 and AT29-ENU.556 mice 
shared the same characteristics which were highly 
distinguishable from those of CBA mice. Furthermore, the 
frequency of leukocytes in AT29 and AT29-ENU.556 Fl 
females was similar (table 6.6-6.15).
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B cells were classified according to the density of 
surface immunoglobulin isotype (Fig. 6i-viii). Population 
I has high IgD, low IgM; population II has high IgD, high 
IgM and population III has low IgD, high IgM (Hardy et al. 
1982, 1984) . CBA/N mice have low levels of population III 
B cells and no population I B cells (Hardy et al. 1982, 
1984; Hayakawa et al. 1983, 1986; Sidman et al. 1986).
In this study, the distribution of the B cell subsets for 
CBA/N mice was consistent with work described above. The 
corrective ability of AT29-ENU.556 cells within the IgD/ 
IgM B cell subset of ENU/xid heterozygotes was 
demonstrated (Fig. 6iii, 6iv, 6vii).
The results of flow cytometric analysis suggested that the 
ENU mutation does not affect the frequency of leukocytes 
although studies of X-chromosome expression imply the 
mutation may control aspects of cell function that render 
ENU mutant cells unable to compete with normal cells.
Preliminary experiments were carried out to characterise 
the effect of the ENU mutation in leukocytes in functional 
terms by comparing the response of homozygous AT29-ENU.556 
mice and their hybrids with control mice following 
sensitisation with oxazolone.
In terms of an increase in the number of cells, leukocytes 
of the lymph node of AT29-ENU.556, AT29, CBA mice and 
their hybrids responded to oxazolone. The response of the
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leukocytes of CBA mice was greater than that of AT29- 
ENU.556 and AT29 mice which had a similar response (table 
7.1) .
Flow cytometric studies demonstrated an increase in the 
frequency of lymph node B and high scattering cells (table 
7.2, 7.3). High scattering cells were distinguished from 
lymphocytes by their relatively high forward scatter 
profile and were probably dividing lymphoblasts which 
would be consistent with other studies (Davies et al. 
1969). The increase in the frequency of B cells probably 
reflected some B cell proliferation being consistent with 
previous work (Davies gt al, 1969) but may also have 
reflected a reduction in the frequency of T cells as T 
cells became dividing lymphoblasts (Fig. 7i-iii).
The response was similar, in terms of cell type and 
degree for AT29 and AT29-ENU.556 mice. This suggests 
that either the mutation does not affect cell 
responsiveness to oxazolone or the effects of the mutation 
cannot be recognised by assessing cell counts or leukocyte 
frequencies.
The results of studies of the patterns of PGK-1 expression 
in the spleen and lymph nodes of PI females implied that 
the responding cells carrying the ENU mutation expanded at 
the same rate as the cells carrying the CBA allele, 
following oxazolone treatment (table 7.7).
However, the results of studies of the patterns of PGK-1
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expression for B cells of the spleen and lymph nodes of 
PHI females implied that the B cells carrying the ENU 
mutation expanded at a faster rate than the cells carrying 
the xid mutation, following treatment with oxazolone 
(table 7.8). This suggests that B cells carrying the ENU 
mutation were more responsive to oxazolone than the B 
cells carrying the xid mutation.
Loci controlling the affected lineages have been mapped to 
the X chromosome. Although several loci that control 
muscle development are X-linked, it is rather interesting 
to find skeletal muscle affected by the same mutation as 
haematopoietic cells. Two murine X-chromosome loci can 
be eliminated as possibilities. These are the muscular 
dystrophy mutation mdx as its effect cannot be detected by 
unbalanced expression of PGK-1 in skeletal muscle (Chapman 
1990, personal communication) and the xid mutation as, 
unlike the ENU mutation, it does not act in pre-B cells.
There are examples of X-linked disorders involving at 
least two of the cell types that are affected by the ENU 
mutation. Examples of these are discussed below.
XSCID is characterised by absent or depressed T 
lymphocytes, normal numbers of B cells and low to no 
levels of immunoglobulins (Rosen et al. 1966; Yount et al. 
1978) .
Studies of the X-chromosome inactivation patterns in XSCID 
delineated the cell types affected which include T and B
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cells and in some cases granulocytes and natural killer 
cells (Goodship e_£ aj,, 1991; Conley, 1992; Puck, 1993; 
Wengler et al. 1993) .
There may be several SCID loci on the X chromosome since 
it is phenotypically heterogeneous (Mensink and Schuurman, 
1987). One form of X-linked combined immunodeficiency, 
similar to but less severe than XSCID, termed thymic 
dysplasia with normogammaglobulinaemia, is characterised 
by T and B lymphocyte dysfunction with normal to slightly 
low lymphocyte levels and the presence of plasma cells and 
iiranunoglobulins (Nezelof et al, 1964; Fulginiti et al. 
1966; Lawlor et al, 1974) .
There is also evidence of human XSCID due to a membrane 
defect (Kersey et al. 1977; Yount et al. 1978). Affected 
individuals have normal levels of B cells, T cells and 
immunoglobulins but they have abnormal responses to 
concanavalin A which is characterised by an inability to 
"membrane cap" membrane glycoproteins (Gelfand et al. 
1979) .
Brooks et al. 1990 described a form of X-linked combined 
immunodeficiency which differed from XSCID in that serum 
concentrations of immunoglobulin isotypes were normal and 
the deficiencies in the number of T cells were less marked 
than in XSCID.
Another X-linked combined immunodeficiency, suggested as 
being either an attenuated form of XSCID or corresponding
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to a separate locus has been described with T and B 
dysfunction but normal numbers of T cells (de Saint-Basile 
et. al, 1992) .
XLA is characterised by low numbers of B cells and normal 
levels of T cells and immunoglobulin levels are low but 
not absent (Bruton, 1952, Winkelstein, 1985; Ochs and 
Wedgewood, 1989) .
Studies of X- chromosome inactivation patterns showed that 
the defect was intrinsic to B cells (Conley et al. 1986; 
Hendriks et al. 1989) .
Vetrie et al, 1993 identified the gene, BTK which encodes 
protein tyrosine kinases in B cells and is mutated in XLA 
patients (Tsukada et al. 1993) .
There have been conflicting results from studies of X- 
chromosome inactivation patterns to identify the defective 
cells in HIGM1 (Hendriks et al. 1990; Notarangelo et al . 
1991) .
In HIGM1, deletions or point mutations of the CD40 ligand 
gene results in the failure of T cells to interact with 
CD40 on B cells (DiSanto et al, 1993) which results in the 
defect in Ig switching in HIGM1 .
The murine gene for the I12r chain was mapped to a locus 
on the X chromosome consistent with the human IL2R o locus 
(Noguchi et al. 1993a) and it was shown that the defect in 
the gene is not responsible for the xid mutation (Cao et
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al, 1993) .
Although xid. like XLA is characterised by a B cell 
lesion, the defect is less severe than that seen in XLA 
patients. The murine Btk has been mapped to the xid locus 
and xid and XLA share a similar molecular lesion despite 
exhibiting different disease phenotypes (Rawlings et al. 
1993; Thomas et al. 1993) .
The loci, Xlr-1 and Xlr-2 are expressed in both T and B 
lymphocytes; lymphocyte membrane antigens, Lyt-X for T 
cells and, Lyb-X for B cells (Lyon and Searle, 1989).
Defective membrane protein of muscle and erythrocytes has 
been identified in patients with Duchenne muscular 
dystrophy which results from abnormal lipid composition 
and mechanical, metabolic and morphological properties 
(Dhalla et al. 1975; Percy and Miller, 1975; Niebroj- 
dobosz, 1976; Distefano and Bosmann, 1977; Howland and 
lyer, 1977; Solomons et al, 1977; Atkinson et al. 1979; 
Butterfield et al. 1976) . Interestingly, the impairment of 
membrane protein capping has also been described in B and 
T lymphocytes of Duchenne patients (Verrill et al. 1977; 
Hornstein and Emery, 1980; Sensi et al. 1984; Goldsmith 
and Greumer, 1987; Baricordi et al, 1989) as well as, 
defective erythrocyte morphology (Pickard et al, 1978). 
This example illustrates a relationship between the four 
lineages affected by the ENU mutation, although mdx. the 
murine homologue of Duchenne has been eliminated as the
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possible locus affected by ENU.
There is evidence for a common recombinase for receptors 
of B (Ig) and T (TCR) cells. Highly conserved DNA 
sequences flank V, D and J elements (Tonegawa, 1983; 
Kronenberg e_£ al, 1986) and T cell receptor V region 
gene segments have been successfully incorporated into 
pre-B cells (Yancopoulis et al,1986) . It has been 
suggested that the scid mutation in mice may adversely 
affect a component of the recombinase system resulting in 
a lack of functional B and T cells (Schuler et al, 1986) 
and abnormal J-associated deletions during D to J or V to 
J joining have been reported for these mice (Schuler et 
, 1986, 1987) .
In scid mice, differences have been shown in patterns of
V gene family expression in pre-B cells such that a
H 
chromosome position-dependent bias of V gene expression
H 
is seen in neonatal and fetal normal mice and adult
"leaky" (Bosma et al, 1983, 1988) scid (Ig+) mice and
random V gene expression is seen in normal adult mice at
H 
5-7 days postnatally, reaching the randomised pattern at
about 2 weeks of age (Yancopoulis et al. 1988; Malynn et 
, 1990) .
Analysis of PGK-1 expression in females heterozygous for 
ENU and the normal allele has shown that selection against 
B and T cells carrying the ENU mutation shows a similar 
developmental profile. One might speculate that ENU-mutant
o299
lymphocytes were selected against, in the presence of 
normal lymphocytes, because of their restricted repertoire 
of immunoglobulin and T cell receptor gene expression. 
This might also explain balanced PGK-1 expression in 
ENU/xid female hybrids.
The phenotypic effect of the ENU mutation was assessed. 
Results of analysis of X-chromosome expression indicated 
that B, pre-B and T cells, erythrocytes, possibly 
platelets and myocytes were affected by the ENU mutation. 
It was not possible to identify the effects of the ENU 
mutation in leukocytes by flow cyometric analysis or in 
functional terms following treatment with oxazolone, the 
major differences in these analyses being attributable 
to background genotype.
Future studies could involve a closer assessment of the B 
cell response in PHI hybrids as cells carrying the ENU 
mutation were more responsive than cells carrying xid 
following oxazolone treatment. This could involve studies 
of the response of population I-III B cells in PHI 
hybrids.
The effect of the mutation with age could be extended to 
studies of population I-III B cells in homozygous AT29- 
ENU.556 mice and their hybrids.
Other studies might involve functional studies of the 
muscular system in homozygous AT29-ENU.556 mice and their 
hybrids, complemented by histological and molecular
300
studies including gene mapping.
Studies of the X-linked mutation in AT29-ENU.556 mice may 
be useful as a model for X-linked disorders of the 
haematopoietic and muscular systems and in assessing the 
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sodium azide (Sigma) 0.5g 
bovine serum albumin (BDH) SOOmg 
EDTA lOOmg
added to 500ml of PBS (below). 
Phosphate-buffered saline (PBS)
Quantity (g/1)
sodium chloride (BDH) 7.848 
potassium chloride (Fisons) 0.201
disodium hydrogen 1.015 
orthophosphate (BDH)
potassium dihydrogen 0.388 
orthophosphate (BDH)
added to 1 litre distilled water; solution adjusted to pH 
7.2 using sodium hydroxide or hydrochloric acid. At this 
pH the solution should be approximately 308 mOsm, similar 
to mouse plasma tonicity.
Acridine-orange/Ethidium-bromide stain
Quantity (mg)
acridine-orange (BDH) 50.0 
ethidium-bromide (Sigma) 15.0
dissolved in 1ml 95% ethanol; add 49ml distilled water,
o 
mix; store at -20 C (1ml aliquots); dilute 1ml in 100 ml
359
o 




dithioerithritol (Sigma) 30.0 
BSA (Sigma) 50.0 
digitonin (Sigma) 200.0
added to 100ml of 50mM tri-ethanolamine hydrochloride 
(Sigma) at pH 7.6.
Electrophoresis buffer
Quantity (g/1)
EDTA (BDH) 0.744 
sodium citrate (Fisons) 2.94 
magnesium sulphate (Fisons) 1.23 
sodium barbital (Sigma) 4.12






magnesium sulphate (Fisons) 320.0
glucose (BDH) 270.0
adenosine diphosphate (Sigma) 112.5
360
NADP (Sigma) 306.0
added to 10ml distilled water; adjust pH to 7.6 using 2M
o 
sodium hydroxide; store at -20 C (lOO^il aliquots) .
14 




trisodium fructose- 650.0 
1,6-diphosphate (Sigma)
dipotassium hydrogen 279.0 
orthophosphate (BDH)
added to 40ml electrophoresis buffer (above);stored at
o 
-20 C (400jil aliquots) .
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Appendix 2
Fig. a-p are representative FACS dot-plots for Chapter 6 
showing the spleen, lymph node, thymus, bone marrow and 
blood stained for the markers B220, Thyl.2, Lyt2 and 
L3T4 for homozygous CBA, AT29 and AT29-ENU.556 mice.
Lymphocytes were identified by their right angle scatter 
profile and lymphocyte populations were defined by 
quantifying fluorescence-labelled cells to assess the 
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Immunologically Related Loci
Mosaic Analysis of the Effects of a Novel X-Chromosome 
Mutation of the Haematopoietic System
j.D. Ausell, V.M. Chapman*, L.M. Forrester, D.J. Fowlis, C. MacKenzie, and H.S. Micklem
SUMMARY
Mutations specific to the X chromosome were identified in female 
offspring, sired by mice treated with the mutagen ethyl nitrosourea 
(ENU), by alterations in the mosaic patterns of x chromosome-linked 
enzyme polymorphisms in blood and other somatic tissues. Flow 
cytometric analyses were performed on haematopoietic and lymphoid 
cells of mice homozygous for one such mutation. Similar studies 
were made on heterozygotes that were, in addition, mosaic for 
electrophoretic variants of the enzyme phosphoglycerate kinase (PGK-1) 
The PGK-1 mosaic patterns in cells of different haematopoietic 
lineages were used to investigate the nature of the primary lesion 
induced by the mutation. Preliminary results indicate that one of 
the ENU mutations has effects on differentiation of T lymphocytes and 
possibly some other haematopoietic cells.
INTRODUCTION
X chromosome-linked genes in man code for a variety of immuno­ 
deficiency syndromes and haematopoietic disorders. Three of the 
major categories of immunodeficiency diseases are inherited through 
the X chromosome: Bruton-type agammaglobulinaemia is characterised 
by an absence of plasma cells, which renders patients susceptible to 
bacterial infections (Geha et al. 1973); in Wiskott-Aldrich syndrome 
(eczema-thrombocytopenia-immunodeficiency syndrome) T lymphocytes and 
platelets are lacking and there are defects in the afferent limb of 
the immune response at the level of antigen processing (Blaese et al. 
1968); Swiss-type agammaglobulinaemia (thymic epithelial hypoplasia, 
X-linked severe combined immuno-deficiency disease) patients are 
vulnerable to viral and fungal, as well as bacterial, infections and 
suffer from lymphocytopenia and atrophy of the thymus. A profound 
immunodeficiency is seen in some cases despite high levels of 
circulating B lymphocytes, which are however incapable of terminal 
differentiation into plasma cells (Yount et al. 1978).
Several other less common X-linked haematopoietic disorders have been 
recorded. These include; immunodeficiency with increased IgM 
(dysgammaglobulinaemia Type 1), granulomatous disease, X-linked 
thrombo-cytopenia, malignant reticuloendotheliosis, acute X-linked 
leukaemia and Duncan disease (X-linked progressive combined immuno­ 
deficiency, X-linked lymphoproliferative disease, familial fatal 
Epstein-Barr infection). X-linkage has also been noted for a rare 
form of hypochromic anaemia and a proliferation defect in 
haematopoietic cells (McKusick 1986).
In summary, there may be a number of genes on the X chromosome that 
play important roles in the differentiation of immune function and
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t0 tUIUOUr deve l°P<nent. These genes may also
comnar.h H n of other haematopoietic elements. Few 
comparable disorders have been identified in mice or other 
experimental animals. The CBA/N mouse is homo- to? hemi-) zygous 
for the xid mutation and shows some similarity to the Bruton-?ype 
immunodeficiency syndrome ( Scher 1982). However, the effec? of the
mlld ' *** "^ d° ^ re°P°nd "o a class of 
antigens and at least one population of B
iSed bY Mgh concentrations of membrane ?gD 
x n rf C0ncentratlons of ™lgM f is missing from the adult! 
« *7linked 1°C1 *n mice code for high, low or absent responses 
to specific antigens (Green 1981).
STRATEGIES FOR ANALYSIS OF X CHROMOSOME MUTATIONS IN MICE
Our own work in this laboratory has concentrated on the differ­ 
entiation of B lymphocytes carrying the xid mutation in a hetero­ 
zygous environment. The experimental strategy makes use of the 
phenomenon of X chromosome inactivation, an event which occurs 
shortly after implantation in female mammals and results in one or 
other of the X chromosomes in all somatic cells being functionally 
inactive. This is a random process, and results in an individual 
being a mosaic for any allelic differences on the x chromosome. 
Mosaicism for xid is not, in itself, detectable. However, we have 
been able to make use of another X-chromosome gene, Pgk-1, which has 
a detectable product; this is used as a marker for the presence of 
xid. The two alleles of Pgk-1 code for different electrophoretic 
forms of the enzyme phosphoglycerate kinase (PGK-1), A and B. These 
alloenzymes can be separated and quantified by simple electrophoretic 
techniques (Ansell and Micklem 1986). All somatic cells in female 
mice heterozygous for xid and Pgk-1 will be either PGK-1B with the 
xid mutant allele active or PGK-1A with the normal allelic counter­ 
part of xid active. Any selection against cells carrying the xid 
mutant can be measured by looking at the relative expression of the 
Pgk alleles in that cell population. By separating subsets of B 
cells and other haematopoietic populations on a fluorescence activated 
cell sorter (FACS) we have been able to determine the cell types on 
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Fig. 1. Values of PGK-1A in cell 
lysates from a xid-heterozygous 
(+/xid Pgk-lab) and a normal 
female (+/+ Pgk-lab) mouse. 
Abbreviations : RBC, erythrocytes; 
THY, thymus; PBL, peripheral blood 
leucocytes; slg, membrane immuno- 
globulin; + -, FACS-sorted cells 
positive or negative for slg; 
14.8, monoclonal antibody 14.8 
against B220 antigen; B D, FACS- 
sorted cells staining brightly 
(B cells) or dully (pre-B cells) 
for B220. In the +/xid hetero- 
zygote, unbalanced mosaicism 
(stippled columns) is seen in 
peripheral B cells, but not in 
the bone marrow pre-B population.
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(Witkowski et al. 1985, Forrester et al. 1987). An example of the 
data acquired by this approach is shown in Fig. 1. These and other 
data have shown that although the homozygous mutant is deficient only 
in certain classes of B lymphocyte, in the heterozygote virtually all 
mature B cells carrying an active mutant X chromosome are selected 
against. Further, this selection only operates on B cells after the 
stage at which membrane Ig (mlg) is expressed: earlier B-lineage 
cells in the bone marrow are unaffected.
This strategy can be used to analyse the effects of any X chromosome 
mutation at the cellular level. it has the additional advantage that 
genetic effects of single mutations can be analysed in a relatively 
normal heterozygous environment, thus enabling the nature of the 
primary lesion to be distinguished from other secondary effects which 
may constitute major parts of the syndrome associated with the 
homozygous (hemizygous) mutant.
ANALYSIS OF AN EMU-DERIVED MUTATION
The approach described above has been used in the analysis of an X 
chromosome mutation derived by ENU mutagenesis. The techniques of 
mutagenesis and the initial identification of mutants are described 
by Chapman (this volume). A female mouse was selected which showed 
random X chromosome expression in most somatic tissues, but selective 
expression of the non-mutagenised X chromosome in erythrocytes. This 
implied that during the course of erythropoietic differentiation, 
cells in which the mutant gene was active were at a selective 
disadvantage. In addition a preliminary experiment showed that lymph 
node cells had a non-mosaic phenotype. This suggested that the 
mutation may have been inimical to T lymphocyte differentiation, since 
most peripheral lymph node cells are T cells.
A number of homozygous mice derived from this original female have 
been analysed by flow cytofluorometry to investigate the effects of 
the mutation on various haematopoietic cell lineages. Female mice 
heterozygous for the mutant and for the A and B electrophoretic 
variants of PGK-1 have also been analysed and the mosaic phenotypes 
of sorted and unsorted haematopoietic cells investigated.
Single-cell suspensions of peripheral blood lymphocytes and from lymph 
node, spleen, thymus and bone marrow were prepared for FACS analysis 
and sorting. They were stained with monoclonal antibodies against 
Thy-1, Ly-3, L3T4 and B220 (Micklem 1986), a fluoresceinated goat 
anti-rat Ig serum being used as the second step. In addition cells of 
these organs as well as erythrocytes, brain and skeletal muscle, were 
prepared from heterozygous mice for alloenzyme analysis.
A series of dot plots taken from the FACS are shown in Figs. 2, 3 and 
4, which illustrate some effects of this mutation on the haemato­ 
poietic system. Fig. 2 shows the staining of bone marrow suspensions 
from a normal 3 month old CBA/Ca female (A), a homozygous mutant 
female (B) and a heterozygous female (C), with a monoclonal antibody 
against the B220 antigen. Dully staining (pre-B) and brightly stain­ 
ing (mig-expressing) cells usually comprise about 20% and 10% of the 
nucleated marrow cells respectively. In the mutant, these were 
reduced to 10% and 1% (mean of 5 animals). Although an approximately 
1.5x increase in cellularity was seen in some mutant marrows, there 
appears to be some absolute reduction of B lymphopoiesis. Fig. 3 
shows B220 staining in, subcutaneous lymph node cells from the three 
types of animals. In a normal individual 14% of lymph node cells 
would be B cells (B220+ve). In the mutant this proportion was 47% 
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Fig. 2. FACS dot plots of 
bone marrow cells stained 
with a monoclonal antibody 
against B220 from a normal 
CBA/Ca control (A), an EMU 
homozygous mutant (B) and 
an ENU heterozygote (C). 
The diagram is of the cell 
populations in the control: 
the high-scattering 
granulopoietic and other 
cells (GRAN), a B220- 
negative population and two 
populations of B220-positive 
cells, the duller being pre- 










Fig. 3. Dot plots of lymph 
node cells stained for B220 
as in Fig. 2. A, B and C 
are from the control, 
homozygous mutant and 
heterozygous mutant respect­ 
ively. The homozygous 
mutant has a higher 
proportion of B220 +ve 
cells.










Fig. 4. Dot plots of lymph 
node cells (A and B) and 
spleen cells (C and D) 
stained with a monoclonal 
antibody against Thy-1. 
Thy-1 +ve cells are under- 
represented in the mutant 
(B and D) compared with the 





(Fig. 4, A and B). Similarly in the spleen (Fig. 4 C and D) the 
proportions of T cells in the mutant (4,D) are approximately half the 
normal value of 40%. Cells which stain for neither Thy-1 nor B220 
usually account for 10% of splenocytes; in the mutant up to 55% of 
splenocytes are in this non-B, non-T category. it is apparent that 
one of the effects of this mutation was to alter the ratio of T to B 
lymphocyte numbers in the peripheral lymphoid organs. This was 
associated with increased granulopoiesis in the bone marrow (and a 
proportionate decrease in B lymphopoiesis), an increase in the numbers 
of granulocytes in the peripheral circulation (data not shown) and 
relative increases in the numbers of B lymphocytes in the peripheral 
lymphoid organs. Other preliminary observations on the homozygous 
mutant included decreased thymus size, decreased haematocrit and white 
blood cell count, increased bone marrow cellularity and increased size 
and cellularity of peripheral lymph nodes. Platelet counts were 
normal.
The heterozygotes appeared virtually normal. However analysis of the 
patterns of mosaicism for PGK-1 alloenzymes revealed defects at the 
cellular level in a number of organs. In normal heterozygotes all 
tissues would be expected to have a similar PGK-1 phenotype (McMahon 
et al. 1983, Micklem et al. 1987). The PGK-1 data for 5 ENU hetero­ 
zygotes are summarised in Table 1. The data for skeletal muscle (SM) 
suggest that in these stocks two mutations may be segregating one of 
which has effects on the viability of muscle cells in the heterozygous 
environment. Since the original selection of these mutant stocks was 
on the basis of mosaic imbalance in blood, a double mutation would not 
have been detected. The mean ratio of PGK-1A:B in brain (BR) was 
49:51). Against this yardstick PGK mosaicism in spleen (SPL) and bone 
marrow (BM) was slightly imbalanced in favour of the non-mutant X 
chromosome (PGK-1B in this case). This would suggest that there is 
no strong selection operating against B cells, or the bulk of 
differentiating haematopoietic cells, that carry an active mutant X 
chromosome. Platelets (PL) are relatively unaffected but circulating 
erythrocytes (E) have a greater imbalance. Selection against the 
mutant X is most apparent in cell suspensions from lymph node (LN) 
and thymus (THY). In lymph nodes of heterozygotes upwards of 80% of 
cells are T-cells. In thymus most cells are of T-lineage although in 
the preparation of cell suspensions it is possible to include varying 
proportions of stromal tissue. In two thymi, PGK-1A was less than 
10%; in another, in which thymic lobes were analysed separately, one 
lobe was PGK-1B. In the one individual for which data are available 
so far FACS-sorted Thy-l+ve cells (T cells) from spleen and lymph node 
were shown to be entirely PGK-1B, i.e. devoid of cells carrying an 
active mutant X chromosome.
The data reviewed above indicate that the ENU mutation on the X 
chromosome has effects on T cell differentiation and may also have 
other effects on the haematopoietic system. Allozyme analysis of
Table 1. Percent PGK-1A in cells from ENU heterozygotes.
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FACS-sorted cell lineages as described above, coupled with 
functional studies of the immune system, will enable us to determine 
the more precise effects of the lesion on haematopoietic 
differentiation and immune function.
We are indebted to Kay Samuel, Andrew Sanderson and Helen Taylor for 
technical assistance and to Dr. Paul Kincade for a gift of 14.8 
antibody. LMF, DJF and CM were supported by Medical Research Council 
Postgraduate Studentships.
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